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Abstract 
The replication of CD4+ T cell-tropic retroviruses such as the human 
immunodeficiency virus-1 (HIV-1) and the feline immunodeficiency virus (FIV) is 
intricately linked to host cell signalling and activation status.  This intimate 
relationship between the viruses and their respective hosts plays crucial roles in 
the pathogenesis of each virus.  Focusing on FIV, this thesis examined several 
questions relating to virus replication and cell signalling.  Firstly, the possible 
cell stimulatory effect when FIV Env binds to its primary receptor CD134 was 
investigated and results suggested that FIV does not trigger CD134 signalling.  
Next the activation status of susceptible CD4+ T cells was manipulated to study 
FIV latency and it was shown that by removing exogenous supplement of the 
cytokine interleukin-2 (IL-2) from MYA-1 feline CD4+ T cells 24 hours before 
infection, productive FIV replication is down-regulated such that only a very low 
level of ongoing virus replication can be detected among the IL-2-depleted cells 
with a sensitive qPCR assay.  The phorbol esters PMA and Prostratin can 
stimulate high level of productive infection from these IL-2-depleted MYA-1 cells 
and this is mediated by a protein kinase C (PKC) dependent mechanism.  
Furthermore, productive replication of FIV in the presence of IL-2 is blocked by 
stimulation of PKC with phorbol esters, which is analogous to findings of similar 
experiments with HIV-1.  However, inhibition of viral replication is not at the 
level of viral entry, contrary to the findings of HIV-1 studies. The mechanism 
behind the Prostratin-mediated inhibition of FIV remains elusive.  It was also 
discovered that ‘early’ and ‘late’ strains of FIV responded differently to cell 
signalling manipulation and an attempt was made to map the viral genome 
region(s) responsible.  Preliminary data showed that both env and the 5’UTR 
may mediate the inter-strain differences in replication dynamics.   
Overall this thesis shows the complete dependency of FIV on host cell signalling, 
in particular optimum PKC activation to achieve productive viral replication.  
This may reflect the tropism of the virus.  The similarities between HIV-1 and FIV 
replication and latency support the notion of using FIV and the cat as a model 
for HIV-1 latency in the development of novel therapeutic measures to eradicate 
hidden HIV-1 from the host.  However, more research is required to fully 
characterise the differences between HIV-1 and FIV biology. 
 Chi Ngai Chan, 2012     3 
Table of contents 
Abstract ...................................................................................... 2 
Table of contents ........................................................................... 3 
List of Tables ................................................................................ 6 
List of Figures ............................................................................... 7 
Preface ...................................................................................... 10 
Acknowledgement ......................................................................... 11 
Author’s declaration ...................................................................... 12 
List of Abbreviations ...................................................................... 13 
1 Background ............................................................................ 15 
1.1 Discoveries and origins of the human and feline immunodeficiency 
viruses ............................................................................. 15 
1.2 The molecular biology of HIV-1 and FIV ...................................... 17 
1.2.1 Lentiviral genome structure ............................................. 18 
1.2.2 Reverse transcription ..................................................... 20 
1.2.3 Nuclear entry and integration ........................................... 23 
1.2.4 Extrachromosomal retroviral DNA ....................................... 24 
1.2.5 Virion production and egress ............................................ 24 
1.3 T cell activation .................................................................. 25 
1.3.1 CD134 – FIV primary receptor ............................................ 28 
1.3.2 NFκB ......................................................................... 30 
1.4 Lentiviral evolution within the host and disease progression ............. 31 
1.5 Pathogenesis of HIV-1 and FIV ................................................. 35 
1.5.1 Role of gp120 on lentiviral pathogenesis ............................... 37 
1.6 Antiretroviral treatments ....................................................... 38 
1.7 Lentiviral latency – obstacle to eradication ................................. 40 
1.7.1 Establishment of the latent reservoir .................................. 40 
1.7.2 Latent reservoir leads to viral persistence ............................ 43 
1.7.3 FIV latency.................................................................. 43 
1.7.4 Molecular mechanism of latency ........................................ 44 
1.7.5 Protein kinase C ........................................................... 45 
1.7.6 Phorbol esters and PKC ................................................... 46 
1.7.7 Chromatin organisation and latency .................................... 48 
1.7.8 Current models for HIV-1 latency – clues to the elusive cure ....... 49 
1.8 Scope of this thesis .............................................................. 53 
2 Materials and Methods ............................................................... 55 
2.1 Cells, reagents, buffers and viruses ........................................... 55 
2.1.1 Adherent cell lines ........................................................ 55 
2.1.2 Suspension cell line ....................................................... 55 
2.1.3 Plasmid vectors ............................................................ 56 
2.1.4 Ligands and chemicals .................................................... 57 
2.1.5 Transient transfection and stable transduction of cells ............. 58 
2.1.6 Flow cytometry ............................................................ 59 
2.2 CD134 signalling assays ......................................................... 60 
2.3 Reactivation of productive FIV infection from resting T cells ............. 61 
2.4 FIV productive infection assay ................................................. 61 
2.5 FIV syncytium formation assay ................................................. 61 
2.6 Molecular cloning techniques .................................................. 62 
2.6.1 Nucleic acid extraction from cells ...................................... 62 
2.6.2 Polymerase chain reaction (PCR) ....................................... 63 
2.6.3 DNA sequencing ............................................................ 64 
 Chi Ngai Chan, 2012     4 
2.6.4 Mutagenesis ................................................................ 64 
2.6.5 Substitution of FIV-LTR and env regions in the molecular clones .. 65 
2.6.6 Modified Hirt Protocol .................................................... 66 
2.7 Quantitative methods ........................................................... 67 
2.7.1 Human IL-8 ELISA .......................................................... 67 
2.7.2 Feline IFN-γ and IL-4 ELISA ............................................... 67 
2.7.3 FIV p24 ELISA ............................................................... 68 
2.7.4 Reverse transcriptase activity assay .................................... 68 
2.7.5 Luciferase viral entry assay .............................................. 69 
2.7.6 Quantitative PCR .......................................................... 69 
2.8 Protein visualization ............................................................. 70 
2.8.1 SDS-PAGE and Western blotting ......................................... 70 
2.9 Statistics .......................................................................... 71 
3 Investigation of virus binding and CD134 signalling ............................. 72 
3.1 Summary .......................................................................... 72 
3.2 Results ............................................................................. 72 
3.2.1 No enhancement of NFκB signalling by FIV binding to feline 
CD134 expressed on interleukin-8 (IL-8) producing cells ............ 72 
3.2.2 Effect of FIV on CD134-mediated signalling in NFκB/293/GFP 
cells ......................................................................... 83 
3.2.3 An attempt to detect cell signalling changes in MYA-1 CD4+ T 
cells by measuring cytokine released .................................. 87 
3.3 Discussion ......................................................................... 92 
4 Dual action of phorbol esters on FIV production illustrates shared principles 
in the replication of both HIV-1 and FIV .......................................... 96 
4.1 Part 1 – establishment of FIV latency in MYA-1 CD4+ T cells .............. 96 
4.2 Results ............................................................................. 97 
4.2.1 Attempts to establish latent infection in MYA-1 CD4+ T cells ....... 97 
4.2.2 Effect of phorbol esters on resting MYA-1 T cells infected with 
FIV .......................................................................... 107 
4.2.3 Effect of phorbol ester on cell growth and viability ................ 113 
4.2.4 Reactivation of productive infection from resting MYA-1 CD4+ T 
cells required PKC-mediated signalling ............................... 117 
4.2.5 Possible synergistic reactivation of productive FIV infection from 
resting MYA-1 T cells by Prostratin and the HDAC inhibitor 
valproic acid .............................................................. 119 
4.3 Part 2 – Phorbol esters inhibit productive FIV infection................... 121 
4.4 Results ............................................................................ 121 
4.4.1 Prostratin significantly blocked productive FIV infection and this 
was mediated by PKC .................................................... 121 
4.4.2 Manipulation of NFκB has no effect on productive infection with 
FIV .......................................................................... 123 
4.4.3 Pre-incubation with Prostratin did not reduce virus titre 8 days 
post infection ............................................................. 126 
4.4.4 Measuring virus entry by luciferase assay ............................. 127 
4.4.5 FIV p24 ELISA to detect intracellular gag ............................. 129 
4.4.6 Quantification of intracellular FIV DNA ............................... 130 
4.4.7 Phorbol esters and innate restriction factors ........................ 131 
4.5 Discussion ........................................................................ 135 
5 Investigation of viral growth differences between strains of FIV ............. 146 
5.1 Summary ......................................................................... 146 
5.2 Results ............................................................................ 146 
5.2.1 Experimental conditions differentially affect the replication 
kinetics of FIV GL8 and PPR ............................................. 146 
 Chi Ngai Chan, 2012     5 
5.3 Discussion ........................................................................ 160 
6 Concluding remarks ................................................................. 168 
7 Appendices ........................................................................... 172 
7.1 Appendix 1: Primers ............................................................ 172 
7.2 Appendix 2: List of buffers .................................................... 173 
Publications and posters ................................................................. 174 
References ................................................................................. 175 
 
 Chi Ngai Chan, 2012     6 
List of Tables 
  Page 
Table 1-1 A table showing the different sub-family groups of 
retroviruses which divide into simple and complex 
retroviruses 
18 
Table 1-2 Selected examples of the five classes of antiretroviral drugs 
currently in clinical uses 
39 
Table 3-1 High levels of different CD134 are expressed by transduced 
HT1080, NP-2 and HeLa cell lines 
73 
Table 3-2 CD134 expression on transduced and transfected 
NFkB/293/GFP cells 
85 
Table 3-3 Stimulation of feline CD134 transduced or transfected 
NFkB/293/GFP cells with ligand does not change NFκB 
activation status 
86 
Table 4-1 The IC50 (*) and other concentrations of the NFκB inhibitors 
tested in the viability assay of feline MYA-1 CD4+ T cells 
98 
Table 5-1 Sequence homology of different regions of the viral genome 
between FIV GL8 and PPR 
152 
   
 
 
 
 
 
 
 
 
 
 
 Chi Ngai Chan, 2012     7 
List of Figures  
  Page 
Figure 1-1 Schematic of a retrovirus particle 19 
Figure 1-2 A comparison between the genome structure of a simple 
retrovirus (MLV) and the complex retroviruses HIV-1 and 
FIV 
19 
Figure 1-3 Diagram of the reverse transcription process 22 
Figure 1-4 The lifecycle of retroviruses 25 
Figure 1-5 The CD134 signal transduction pathway 30 
Figure 1-6 Feline CD134 34 
Figure 1-7 Structure of the three main PKC isoforms 46 
Figure 1-8 Elimination of the latent lentiviral reservoir 53 
Figure 2-1 A schematic showing the sites of action for the molecules 
described in this thesis which affect cell signalling or virus 
replication 
58 
Figure 3-1 HT1080 cells transduced with CD134 exhibit species 
specificity towards ligand 
75 
Figure 3-2 The dynamics of CD134 signalling in HT1080 cells 75 
Figure 3-3 Purified FIV does not stimulate IL-8 production in HT1080 
feCD134 cells 
76 
Figure 3-4 Effect of purified FIV on the production of IL-8 by 
transduced HT1080 cells in response to feline CD134 ligand 
stimulation 
78 
Figure 3-5 Effect of purified FIV on IL-8 production from feline 
CD134- expressing NP-2 cells 
79 
Figure 3-6 HeLa cells transduced with feline CD134 do not respond to 
trigger by feline ligand 
80 
Figure 3-7 Effect of NFκB inhibitors on IL-8 production from HT1080-
feCD134 cells 
81 
Figure 3-8 Effect of the NFκB inhibitor CAPE on IL-8 production from 
HT1080-feCD134 cells treated with FIV GL8 in the 
presence or absence of feCD134L 
82 
Figure 3-9 The NFκB inhibitors CAPE and SC514 effectively inhibit 
TNF-α induced GFP production in NFkB/293/GFP cells 
83 
Figure 3-10 FIV binding does not have any effect on NFκB signalling of 
the NFkB/293/GFP cell transduced with feCD134 
87 
Figure 3-11 MYA-1 CD4+ T cells naturally express CD134 and produce 
IL-4 after stimulation 
88 
Figure 3-12 Effect of feline CD134 ligand and FIV Env SU Fc proteins on 
IL-4 production by MYA-1 CD4+ T cells 
90 
Figure 3-13 Modest reduction in cellular proliferation is caused by GL8 
Su Fc in IL-2-depleted cells.  However, feline CD134 ligand 
and FIV SU Fc protein do not induce a shift in fluorescence 
in CFSE assay of MYA-1 CD4+ T cells in the presence of IL-2 
91 
Figure 4-1 Effect of different NFκB inhibitors on the viability of MYA-
1 CD4+ T cells 
98 
 Chi Ngai Chan, 2012     8 
Figure 4-2 Productive FIV infection of MYA-1 CD4+ T cells is blocked 
by CAPE 
99 
Figure 4-3 The continuous presence of CAPE is necessary to maintain 
non-productive infection 
100 
Figure 4-4 The phorbol esters PMA and Prostratin do not rescue virus 
replication from FIV infected MYA-1 CD4+ T cells incubated 
with CAPE 
101 
Figure 4-5 Effect of exogenous IL-2 on the growth and viability of 
MYA-1 CD4+ T cells 
102 
Figure 4-6 Removing IL-2 post-infection does not establish latent 
infection 
103 
Figure 4-7 A low level of persistent FIV replication can be detected in 
IL-2 -depleted resting MYA-1 T cells 
105 
Figure 4-8 The phorbol esters PMA and Prostratin can stimulate 
productive infection from resting MYA-1 T cells 
109 
Figure 4-9 Reactivation of integrated provirus by phorbol esters 110 
Figure 4-10 Unintegrated FIV DNA contaminates genomic High 
molecular weight DNA 
112 
Figure 4-11 Improvement in DNA purification reduces contamination of 
HMW DNA by unintegrated FIV DNA 
113 
Figure 4-12 Effect of phorbol esters on cell growth and viability 115 
Figure 4-13 Reactivation of productive infection from infected resting 
MYA-1 T cells is PKC-dependent 
118 
Figure 4-14 Valproic acid enhances reactivation of productive FIV 
infection from infected resting MYA-1 T cells by Prostratin 
120 
Figure 4-15 Inhibition of productive infection with FIV by Prostratin in 
the presence of IL-2 is PKC dependent 
122 
Figure 4-16 NFκB inhibitors do not enhance productive infection 
contrary to initial findings 
124 
Figure 4-17 Effect of Prostratin and Gö6850 on the expression of 
CD134 and CXCR4 on MYA-1 CD4+ T cells 
125 
Figure 4-18 Pre-incubation of cells with Prostratin before FIV infection 
does not reduce final virus titre 
126 
Figure 4-19 Prostratin increases luciferase activity in IL-2-depleted 
MYA-1 CD4+ T cells but not the luciferase activity of IL-2 
supplemented cells 
127 
Figure 4-20 Phorbol esters increase the activity of the luciferase assay 
independent of effects on viral entry 
128 
Figure 4-21 Effect of Prostratin and Gö6850 on the amount of 
internalized FIV p24 post infection 
129 
Figure 4-22 Pre-treatment of MYA-1 CD4+ T cells with Prostratin or 
Gö6850 does not reduce intracellular FIV DNA detected 2 
hours post infection 
130 
Figure 4-23 Prostratin restricts FIV replication by means other than 
the up-regulation of tetherin 
132 
Figure 4-24 Prostratin treatment does not reduce FIV production per 
infected cell 
134 
   
 Chi Ngai Chan, 2012     9 
Figure 4-25 The potential relationship between lentiviral gene 
expression and cellular PKC and IL-2 receptor-mediated 
signalling 
140 
Figure 5-1 FIV PPR replicates at a higher rate than GL8 in MYA-1 CD4+ 
T cells 
147 
Figure 5-2 Reactivation of productive infection by phorbol esters is 
more pronounced among FIV PPR-infected cells 
148 
Figure 5-3 FIV PPR demonstrates higher rates of basal replication and 
reactivation than FIV GL8 
149 
Figure 5-4 Replication of FIV PPR from infected resting MYA-1 T cells 
stimulated with phorbol esters is less sensitive to the 
inhibitory effect of PKC inhibitor Gö6976 than FIV GL8 
150 
Figure 5-5 FIV PPR is less sensitive to phorbol ester-mediated 
inhibition of productive infection than GL8 in MYA-1 CD4+ 
T cells 
151 
Figure 5-6 Sequence variations between FIV GL8 and PPR in the U3 
region of the 5’LTR affect only one of the known 
transcription factor binding sites of the FIV LTR 
153 
Figure 5-7 Schematics of all the chimeric FIV described in this 
chapter 
154 
Figure 5-8 Substitution of the 5’ LTR in the molecular clone of GL8 
with PPR LTR results in only the partial substitution of the 
5’ LTR in the provirus 
156 
Figure 5-9 Substitution of GL8 5’LTR or env with their PPR 
counterparts increases the replication rate of the chimeric 
virus 
157 
Figure 5-10 Both the LTR and env influence viral replication efficiency 
in MYA-1 T cells 
159 
Figure 5-11 Multiple sequence polymorphisms between FIV GL8 and 
PPR are found within or near RNA secondary structures in 
the 5’ UTR 
164 
Figure 6-1 FIV replicates best at an optimum level of PKC activation 169 
 
 
 
 
 
 
 Chi Ngai Chan, 2012     10 
Preface 
The mammalian cell contains a vast network of signalling pathways which 
monitor and respond to changes in the external and internal environment.  
Essential processes such as cell division, metabolism and apoptosis are 
controlled by a delicate balance of a vast number of cellular and exogenous 
signals.  Viruses are obligate intracellular parasites which have evolved to 
manipulate the host cell to their own advantage.  However, the virus is also 
vulnerable to global changes of cellular activation.  Unravelling this intimate 
relationship between the virus and its host is essential for us to understand the 
viral life cycle and may reveal weaknesses which can be targeted 
therapeutically.   
The lentiviruses HIV-1 and FIV are global public health and veterinary concerns 
respectively.  They are similar viruses in terms of tropism, molecular biology and 
pathogenesis.  In this thesis I focused on FIV and investigated the potential 
effects of FIV on cell signalling and the potential effects of cell signalling 
changes on FIV replication and latency. 
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1 Background 
1.1 Discoveries and origins of the human and feline 
immunodeficiency viruses 
In 1983, the human immunodeficiency virus – 1 (HIV-1) was discovered to be the 
causative agent of Acquired Immunodeficiency Syndrome (AIDS) identified among 
homosexual men since the late 1970s (Gottlieb et al., 1981, Barre Sinoussi et al., 
1983, Gallo et al., 1984).  HIV is transmitted by sexual contact, infected blood or 
blood contact, and from mother to infant during pregnancy, birth or breast-
feeding (Fauci et al., 1984, De Cock et al., 2000).  The virus preferentially 
infects activated CD4+ T cells, causing a decline in their numbers which is 
associated with progression towards immunodeficiency (Lane and Fauci, 1985).  
More than two decades after the initial isolation of the virus, 25 million people 
have died from the disease and over 33 million individuals are living with the 
virus across the globe (Wainberg and Jeang, 2008).  Despite intensive public 
health campaigns and advances in antiretroviral treatments the virus continues 
to spread around the world, with 2.7 million individuals having been infected 
and 2 million AIDS-related deaths having occurred in 2007 (Wainberg and Jeang, 
2008).   In the absence of an effective vaccine to prevent the spread of infection 
the global HIV-AIDS epidemic is set to continue to be a major global public 
health concern long into the future. 
HIV-1 evolved from simian immunodeficiency virus (SIV), a primate retrovirus 
isolated from chimpanzees (Gao et al., 1999).  It was assumed that SIV does not 
increase mortality or morbidity in chimpanzees due to host or virus adaptations 
that lower viral pathogenicity (Sharp et al., 2005, Silvestri, 2009).  However, this 
is refuted in a recent study of chimpanzees in the wild, which reports ill-health 
and evidence of immunodeficiency in SIV infected individuals (Keele et al., 
2009).  Cross-species transmission is believed to have occurred during the 
hunting and butchering of chimpanzees as bushmeat by hunters in West Africa 
(Gao et al., 1999), and not as has been asserted by the contamination of oral 
polio vaccines in the 1950s (Worobey et al., 2004).  The current pandemic HIV-1 
group M viruses originated from Southern Cameroon (Keele et al., 2006).  Based 
on phylogenetic analysis of viral sequences from historical samples and field 
isolates, it has been estimated that HIV-1 has been circulating in human 
 Chi Ngai Chan, 2012                                                                   Chapter 1,   16 
populations since the 1930s (Korber et al., 2000) but was confined within the 
local area due to the lack of trade and contact with the outside world.  With the 
development of nearby Léopoldville (now Kinshasa, the Democratic Republic of 
Congo) as a major urban centre by the 1950s the movement of people in the 
region increased dramatically, allowing the virus to break out of the jungle of 
Cameroon and undergo its first expansion and diversification in the city, which 
ultimately resulted in its arrival in America by the 1970s (Worobey et al., 2008, 
Sharp and Hahn, 2008).   
Feline Immunodeficiency Virus (FIV) was first isolated in 1986 from a domestic 
cat in California (Pedersen et al., 1987).  FIV also targets activated CD4+ T cells 
in cats and causes clinical signs similar to AIDS in humans (Ackley et al., 1990, 
Novotney et al., 1990, Barlough et al., 1991).  Unlike HIV-1, FIV is mainly 
transmitted by biting (Yamamoto et al., 1989).  FIV in domestic cats evolved and 
expanded globally (Hartmann, 1998) and is divided into genetically distinct 
subtypes or clades (from A to E) (Sodora et al., 1994, Kakinuma et al., 1995, 
Pecoraro et al., 1996, Bachmann et al., 1997).   
Like HIV-1, FIV is also believed to have arisen in Africa and is believed to have 
infected the felidae family since the late Pliocene between 3.1 and 0.7 million 
years ago (Pecon-Slattery et al., 2006, Johnson et al., 2006).  Different feline 
species are infected by their own species-specific FIV strains and based on 
phylogenetic data FIV is likely to have been introduced once into each species, 
which then evolved and expand within that species (Troyer et al., 2008).  
Studies of lion and puma-specific FIV genomes have shown that they have the 
highest sequence divergence between strains, which suggest a long period of co-
evolution between host and virus (Troyer et al., 2008).  Also, it has been 
assumed that FIV infection does not reduce lifespan or increase morbidity in 
lions or pumas, which is a sign of host-pathogen co-adaptation and signifies the 
ancestral status of FIV in lions and pumas (Troyer et al., 2008).  However, 
analogous to SIV infection of chimpanzees, it is now known that lions infected 
with FIV do exhibit AIDS-related pathologies such as lymphadenopathy, gingivitis, 
tongue papillomas, dehydration, and poor coat condition (Roelke et al., 2009).  
These new findings may be significant in enhancing our understanding of 
lentiviral evolution and pathogenesis. 
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At present it is not possible to pinpoint a definite time for the introduction of 
FIV into the domestic cat population. The domestic cat (Felis catus) was 
domesticated by humans around 10,000 years ago in the Fertile Crescent region 
of the Mediterranean from the African wildcat Felis silvestris lybica (Driscoll et 
al., 2007).  The absence of FIV from nearly all of the close relatives of the 
domestic cat (Troyer et al., 2005) suggests a recent introduction of the virus into 
the species, followed by rapid dissemination (Pecon-Slattery et al., 2006).  The 
successful emergence of a virus in a new population relies on, among other 
factors, a population density high enough for efficient transmission (Troyer et 
al., 2008).  The domestication process would have increased the population 
density of the domestic cats, which would aid the establishment and spread of 
FIV among cat populations. 
 
1.2 The molecular biology of HIV-1 and FIV 
The retroviruses are a large and diverse family of enveloped RNA viruses united 
by a common genomic structure and lifecycle (Coffin, 1992).  HIV-1 and FIV are 
members of the lentivirus sub-family of retroviruses (Table 1-1).  The virion 
consists of two copies of full length viral genomic RNA packaged in the viral 
capsid, which is surrounded by matrix (MA) proteins and the viral envelope 
(Coffin et al., 1997) (Fig. 1-1).  The dimeric nature of the retroviral genome was 
first revealed by electron microscopy (Bender and Davidson, 1976, Bender et al., 
1978).  Further research revealed that the viral RNA genome not only encodes 
viral genes, but also sites that mediate the dimerization and packaging of the 
genome into nascent virions (Paillart et al., 2004, Lu et al., 2011).  The 
dimerization initiation site (DIS) and packaging signal of both HIV-1 and FIV are 
found at a region between the 5’UTR and gag of the viral RNA (Paillart et al., 
2004, Kenyon et al., 2008).  The 5’UTRs of both viruses are believed to fold into 
secondary structures which can have 2 or more conformations that either allow 
access to the dimerization and packaging signals or promote translation of viral 
genes (Lu et al., 2011, Kenyon et al., 2011). 
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1.2.1 Lentiviral genome structure 
All retroviruses contain three basic genes, gag, pol and env (Coffin et al., 1997) 
(Fig. 1-2).  The gag gene encodes the major structural proteins MA, capsid (CA) 
and nucleocapsid (NC) (Elder et al., 1993, Elder and Phillips, 1995).  The 
retroviral NC protein is a multifunctional protein vital for processes such as 
reverse transcription and viral assembly (Darlix et al., 2011).  The viral enzymes 
such as reverse transcriptase (RT), viral protease (PR) and integrase (IN) are 
encoded in the pol gene (Elder et al., 1993, Coffin et al., 1997).   The env gene 
encodes the envelope (Env) protein which mediates viral entry (Elder et al., 
1993, Coffin et al., 1997).  In addition the lentiviruses may also contain 
additional regulatory (Tat and rev) and accessory (vif, vpr, vpu, nef, Orf-A) 
genes which enhance viral replication or counteract host immune defences 
(Fig.1-2).  Retroviruses that contain only the three basic genes are called simple 
retroviruses, whereas retroviruses that contain accessory genes are known as 
complex retroviruses (Table 1-1) (Coffin et al., 1997). 
Sub-family Examples 
Simple/ 
complex 
Alpharetrovirus 
(avian) 
Avian leukemia viruses (ALV) 
Rous sarcoma virus (RSV) 
Simple 
Betaretrovrius 
(mice, primates, sheep) 
Mouse mammary tumour virus (MMTV) 
Mason-Pfizer monkey virus (MPMV) 
Simple 
Gammaretrovirus 
(mammals, reptiles, 
birds) 
Murine leukemia virus (MLV) 
Simple 
Deltaretrovirus 
(mammals) 
Human T-Lymphotropic virus (HTLVs) 
Bovine leukemia virus (BLV) 
Complex 
Epsilonretrovirus 
(fish, reptiles) 
Walleye dermal sarcoma virus 
Complex 
Lentivirus 
(mammals) 
Human immunodeficiency virus (HIV) 
Feline immunodeficiency virus (FIV) 
Complex 
Spumavirus (foamy) 
(mammals) 
Human foamy virus (HFV) 
Complex 
 
Table 1-1 – A table showing the different sub-family groups of retroviruses 
which divide into simple and complex retroviruses (Coffin, 1992).  
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Figure 1-1 – Schematic of a retrovirus particle.  vRNA = viral genomic RNA.  
Env = envelope protein.  MA = matrix protein.  CA = capsid protein.  NC = 
nucleocapsid protein.  IN = integrase.  PR = viral protease.  RT = reverse 
transcriptase. 
 
 
 
Figure 1-2 - A comparison between the genome structure of a simple 
retrovirus (MLV) and the complex retroviruses HIV-1 and FIV.  RRE is the Rev 
response element. 
HIV-1 and FIV share the accessory gene vif (which mediates the degradation of 
the host intrinsic restriction factor APOBEC3 proteins (Sheehy et al., 2002, 
Zielonka et al., 2010)) and the regulatory gene rev (which mediates the exit of 
viral RNA from the nucleus via interaction with the Rev response element (RRE) 
(Pollard and Malim, 1998)).  However, the accessory genes vpr, nef, vpu and the 
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regulatory gene tat are only found in HIV-1 and not FIV; the vpr gene product is 
associated with the nuclear import of the PIC as well as the induction of cell 
cycle arrest and apoptosis, the modulation of viral LTR activity, the suppression 
of host immune response and regulation of reverse transcription (Romani and 
Engelbrecht, 2009); nef encodes a protein with multiple functions in the host 
CD4+ T cells such as the down-regulation of cell surface CD4 and major 
histocompatibility class I (MHCI) molecules and the modulation of cell signalling 
(Foster and Garcia, 2008); Vpu protein also down-regulates CD4 expression 
(Willey et al., 1992) and more recently it is found to counteract the activity of 
tetherin, another host antiviral restriction factor (Neil et al., 2008, Van Damme 
et al., 2008);  The tat gene encodes a small protein which acts as a major 
transactivator of HIV-1 gene expression via its interaction with the Tat-
activation response element (TAR) in the 5’ LTR (Taube et al., 1999).  While FIV 
lacks these accessory genes and the Tat-TAR transactivation function, it encodes 
the gene for Orf-A (Orf-2), which may be a multi-functional protein affecting 
viral replication and host cell cycle (Gemeniano et al., 2003, Gemeniano et al., 
2004).  Recently it has been demonstrated that Orf-A can also down-regulate the 
expression of the FIV receptor CD134, mirroring a similar down-regulation of CD4 
by HIV-1 Nef and Vpu (Hong et al., 2010) 
Both viruses target activated CD4+ T cells (Zagury et al., 1986, Yamamoto et al., 
1988) but whereas the primary receptor of HIV-1 is CD4 (Dalgleish et al., 1984), 
the FIV primary receptor is CD134 (OX40) (Shimojima et al., 2004).  HIV-1 
utilizes CCR5 and CXCR4 as its secondary receptors (Choe et al., 1996, Feng et 
al., 1996, Deng et al., 1996) while FIV uses CXCR4 as its secondary receptor 
(Willett et al., 1997) (details of HIV-1 and FIV entry into host cells are discussed 
in section 1.4). 
1.2.2 Reverse transcription 
Reverse transcription (the conversion of RNA to DNA) is one of the central 
biological processes which define the retroviruses and is mediated by the 
enzyme reverse transcriptase.  The viral enzyme was discovered independently 
by Temin and Baltimore (Temin and Mizutani, 1970, Baltimore, 1970).  Before 
their discovery it had long been suspected that certain RNA viruses (which would 
go on to form the Retroviridae family) do not directly replicate their genomic 
RNA but rather go through a DNA intermediate stage.  This was deduced from 
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studies on Rous Sarcoma Virus (RSV), which had shown its dependence on DNA-
to-RNA and DNA-to-DNA synthesis (Bader, 1964, Temin, 1964).   
The mechanism of reverse transcription has been studied and reviewed 
extensively (Katz and Skalka, 1994, Coffin et al., 1997, Sarafianos et al., 2009) 
(Fig. 1-3).  Reverse transcriptase encompasses RNA-dependent DNA polymerase, 
DNA dependent DNA polymerase and ribonuclease-H activities within a single 
enzyme complex.  A host tRNA primer is required by the RT to initiate its DNA 
polymerase activity (in the case of HIV-1 and FIV the primer is tRNAlys3 (Arts et 
al., 1996)).  This tRNA primer anneals to the 5’ end of the plus-strand RNA 
genome at the Primer Binding Site (PBS) (Fig.1-3, step A).  The RT recognizes 
and binds to the viral genome to initiate minus-strand synthesis towards the 5’ 
end (Fig.1-3, step B).  At the same time the RNase H activity degrades the 5’ end 
of the plus-strand RNA from the PBS to the 5’direct repeat (R) region (Fig.1-3, 
step B), which exposes the single-stranded DNA product and allows the first 
jump (or first strand switch) to take place (Fig.1-3, step C).  The minus-strand 
DNA hybridizes to the 3’ R, which allows its synthesis from 3’ to 5’ to continue.  
Meanwhile the RNase H activity of the RT carries on degrading the positive-sense 
RNA genome except in a purine-rich sequence called the polypurine tract (PPT) 
(Fig.1-3, step D).  The PPT is relatively resistant to RNase H degradation and 
would then become the primer for the synthesis of the plus-strand DNA, usually 
mediated by another RT complex (Fig.1-3, step E).   
Plus strand DNA synthesis continues towards the 3’ end of the minus-strand DNA 
until it starts to copy the tRNA primer.  The RT then degrades the tRNA primer 
(Fig.1-3, step F), which is now on the 3’ end of the viral minus-strand DNA and 
exposes the single stranded PBS sequence of the plus-strand DNA.  This allows 
the second jump (strand switch) as the 5’ end of the minus-strand can now 
anneal to the plus-strand at the PBS to form a circular intermediate (Fig.1-3, 
step G).  DNA synthesis then continues and a process called strand displacement 
leads to the production a linear double-stranded DNA viral genome with the 
same sequences at both ends (U3, R and U5) (Fig.1-3, step H).  Failure in this 
process may lead to the formation of 1-LTR circles (Cara and Klotman, 2006). 
Despite being RNA viruses, viral DNA is detected in HIV-1 virions (Lori et al., 
1992) and it has been shown recently that reverse transcription begins at the 
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last step of replication in the virus-producing cells (Yu et al., 2009, Mougel et 
al., 2009).  Nevertheless the completion of reverse transcription only occurs 
after viral entry and is believed to initiate the process of uncoating (Arhel et al., 
2007).   
 
 
 
 
 
 
 
 
 
Figure 1-3 – Diagram of the reverse transcription process  
5’ 3’ R U5 PBS PPT U3 R 
5’ 3’ PPT U3 R 
tRNA primer 
+ strand RNA 
tRNA primer 
<RNase H 
A 
- strand DNA 
elongation 
B 
PPT U3 R C PBS 
PPT PBS 
D 
<RNase H 
PPT PBS 
E 
PPT PBS PBS 
R U5 PBS 
R U5 
PBS 
R U5 
PBS 
R U5 
F 
+ strand DNA 
elongation 
G 
PBS 
- strand 
+ strand 
H 
R U5 PBS U3 R U5 U3 PPT 
5’ LTR 3’ LTR 
 Chi Ngai Chan, 2012                                                                   Chapter 1,   23 
1.2.3 Nuclear entry and integration 
Recent experimental evidence suggest that rather than dissociating soon after 
viral entry, the HIV-1 capsid remains intact as it transfer the viral genome, 
which is undergoing reverse transcription, to the nuclear pore (Arhel, 2010).  
When reverse transcription is completed, uncoating then takes place (Arhel et 
al., 2007), allowing the direct transfer of a conglomerate of viral DNA plus viral 
and host proteins known as the viral pre-integration complex (PIC) into the 
nucleus through host nuclear pore complexes (NPCs) (Suzuki and Craigie, 2007).  
This allows lentiviruses like HIV-1 to cross the nuclear membrane of non-dividing 
cells, facilitating infection; by contrast, simple retroviruses such as murine 
leukaemia virus (MLV) have to wait until mitosis and the break-down of the 
nuclear envelope to continue their lifecycles (Harel et al., 1981, Hatziioannou 
and Goff, 2001).   
The integration of the viral DNA into the host genome is another hallmark of the 
retroviral lifecycle and is mediated by the viral integrase, which is a 288 amino 
acid protein that comprises of 3 distinct structural domains; the amino (N) – 
terminal domain, the catalytic core domain and the carboxy (C) – terminal 
domain (Coffin et al., 1997).   The active site of the HIV-1 integrase is found in 
the catalytic domain and consists of a three-amino-acids (Aspartic acid64, 
Aspartic acid116 and Glutamic acid152) motif (Coffin et al., 1997).  Indeed, this 
Asp, Asp and Glu motif of the integrase active site is conserved across all 
retroviruses (Coffin et al., 1997).  Following reverse transcription the integrase 
molecules bind to specific sequences within the long terminal repeats (LTR) at 
each end of the nascent viral DNA as part of the PIC (Coffin et al., 1997).  The 
integrase then cleaves off 2 nucleotides at a conserved region on the 3’ strand, 
generating a di-nucleotide 5’ overhang and a reactive 3’-hydroxyl group at each 
end of the DNA (Coffin et al., 1997).  Inside the nucleus the host protein 
LEDGF/p75 tethers the viral PIC and the host DNA together (Cherepanov et al., 
2003), allowing the crucial strand transfer reaction to take place.  This reaction 
utilizes the 3’-hydroxyl group to join the viral DNA strand to the host DNA but 
results in unpaired regions at the viral-host DNA junctions, which are repaired by 
the host DNA-repair mechanisms (Coffin et al., 1997).  The integrated viral DNA 
is called proviral DNA. 
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1.2.4 Extrachromosomal retroviral DNA 
For reasons still unknown, most of the reverse-transcribed retroviral DNA within 
a viral population is not integrated into the host genome and accumulates within 
the host cell (Shaw et al., 1984, Chun et al., 1997).  These unintegrated or 
extrachromosomal viral DNAs can be found in linear, 1-LTR circular or 2-LTR 
circular forms.  The 1-LTR circles can be the result of strand displacement 
failure or homologous recombination of the LTRs (Cara and Klotman, 2006, 
Telesnitsky and Goff, 1997), whereas 2-LTR circles are formed by the 
intramolecular blunt-end ligation of the linear retroviral DNA (Cara and Klotman, 
2006).  These extrachromosomal viral DNAs were initially thought to play little 
role in viral replication due to their labile nature (Pierson et al., 2002b, Zhou et 
al., 2005).  Subsequently it was discovered that circular DNA can survive for days 
in resting T cells (Pierson et al., 2002a) and longer in macrophages (Kelly et al., 
2008).  Also these extrachromosomal DNAs are transcriptionally active (Cara and 
Klotman, 2006, Kelly et al., 2008) and can still replicate during co-infections 
with integrated viruses (Gelderblom et al., 2008).  Thus these unintegrated viral 
species may contribute to viral pathogenesis and viral diversity within the host. 
1.2.5 Virion production and egress 
Viral genes are now expressed from the provirus, driven by the binding of host 
transcription factors such as NFκB, NFAT, AP-1 and AP-4 to the 5’LTR (Sparger et 
al., 1992, Thompson et al., 1994, Tang et al., 1999, Kilareski et al., 2009).  For 
HIV-1 the Tat-TAR transactivation mechanism also regulates transcription of viral 
genes; in contrast FIV does not have Tat-TAR, which may explain why the basal 
activity of the FIV 5’LTR is higher than HIV-1 5’LTR (Sparger et al., 1992).  The 
viral RNA produced can either be spliced and become templates for viral protein 
translation, or packaged into the capsids along unprocessed Gag-Pol precursors 
at the cell membrane.  Retroviral assembly is driven by Gag (Gheysen et al., 
1989) and exploits the host endosomal sorting complex required for transport 
(ESCRT) pathway for virus assembly and budding (Jouvenet et al., 2010).  After 
the emergence of the immature virion from the producer cell, the Gag-Pol 
polyprotein precursors are cleaved by the viral protease (Vogt, 1996) into their 
respective single protein species.  This maturation step of the nascent virion is 
vital for the formation of the viral capsid (Ganser-Pornillos et al., 2008) and the 
production of infectious virus particles (Kohl et al., 1988) (Fig.1-4). 
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Figure 1-4 – The lifecycle of retroviruses.  After entering the cell, the viral RNA 
genome (black) is reverse-transcribed into DNA (red) by viral reverse transcriptase 
and enters the nucleus.  The proviral DNA is then integrated into the host genome 
by viral integrase.  Viral gene expression then occurs, producing both genomic 
viral RNA and viral mRNA for the synthesis of viral proteins (Green).  The nascent 
viral genomes are packaged into virions at the cell membrane and bud off.  As part 
of the maturation process viral protease then cleaves the Gag-Pol precursor 
protein to produce Gag and Pol, allowing the formation of the viral capsid in the 
nascent virions. 
1.3 T cell activation 
The preferential target cells for both HIV-1 and FIV are activated CD4+ T cells.  
To understand how CD4+ T cells are activated and their connection with viral 
pathogenesis, we must first explore one of the fundamental questions of 
immunology: How is immune activation regulated?  This apparently simple 
question has been occupying immunologists for the last half century (Matzinger, 
2002).  Theoretically, mammals can mount an immune response against all 
antigens, including their own tissues, due to the diversity of T cell receptors 
(TCRs) generated by the random assortment of the TCR loci within the repertoire 
of naïve resting T cells of each individual (Hannet et al., 1992, Bonilla and 
Receptor 
binding 
Fusion 
and entry 
Reverse 
transcription 
Nuclear 
entry Integration 
Proviral 
DNA 
PIC 
Transcription 
Viral RNA 
Translation 
Maturation 
Assembly 
Budding 
 Chi Ngai Chan, 2012                                                                   Chapter 1,   26 
Oettgen, 2010).  However, autoimmunity does not occur in mammals most of the 
time and the theoretical models explaining how the host immune response is 
regulated have been evolving with experimental evidence.  Initially, it was 
thought that the immune system recognizes self vs. non-self entities (Burnet, 
1959) and evidence such as the clonal deletion of self-reactive thymocytes 
during T cell maturation (Kappler et al., 1987) supports this theory.  However, 
the self vs. non-self theory is not compatible with the immuno-tolerance of 
fetuses, which are antigenically distinct from their mothers, and the 
incorporation of the concept of T cell co-stimulation (Lafferty and Cunningham, 
1975), which introduced the possibility that self antigens are presented by 
antigen-presenting cells (APCs) and stimulate autoimmunity.  To address the 
inadequacies of the old self vs. non-self model, the ‘Danger’ hypothesis of 
immune activation was proposed (Matzinger, 1994). The new theory suggests 
that APCs have to be activated by ‘danger signals’ before co-stimulation of T 
cells can take place.  These ‘danger signals’ were later revealed to be both 
foreign molecules such as bacterial Lipopolysaccharide (LPS) and cellular 
molecules such as heat shock proteins (Hsps), which can be recognized by 
pattern recognition receptors (PRRs) expressed by APCs (Matzinger, 2002).    
It is now established that activation of naïve T cells requires both the TCR 
recognizing the antigenic peptide presented within the major histocompatibility 
complex (MHC) molecule of APCs as well as appropriate co-stimulatory signals 
from APCs which have been primed by the right ‘danger signals’.  The co-
stimulatory molecules CD27 and CD28 are constitutively expressed on T cells, 
while the expression of their ligands CD70, CD80 and CD86 on APCs are induced 
upon stimulation (Goronzy and Weyand, 2008).  They provide the first wave of T 
cell activation signals which lead to the rapid expression of a set of activation-
induced co-stimulatory receptors including ICOS, CD30, CD134 and CD137 (Watts, 
2005, Goronzy and Weyand, 2008).  This second wave of T cell activation signals 
serves to amplify T cell activation as well as to modulate T cell differentiation 
and memory T cell development (Coyle et al., 2000, Croft, 2003).   
According to the linear differentiation model of memory T cell development, 
after T cell activation the antigen-specific naïve T cells undergo clonal 
expansion and develop into cytokine-producing effector cells.  This is followed 
by activation induced apoptosis for the majority of the effector cells while a 
 Chi Ngai Chan, 2012                                                                   Chapter 1,   27 
small number of effector T cells remain behind as memory T cells which can be 
rapidly activated when the same antigen is encountered again (Ahmed et al., 
2009, van Leeuwen et al., 2009).   
Interleukin-2 (IL-2) is an important cytokine that regulates this process.  First 
discovered in 1976 (Morgan et al., 1976), IL-2 is a 15kDa protein synthesised by 
activated T cells after the triggering of the TCR and CD28 signalling pathways; 
the IL-2 gene promoter contains sites for the transcription factors NFAT, AP-1 
and NFκB, which are activated by the TCR signalling pathway via Protein kinase 
C (Isakov and Altman, 2002, Altman and Villalba, 2003).  The interaction 
between IL-2 and its receptor has long been associated with driving the clonal 
expansion of effector T cells, the differentiation of CD4+ T cells subsets TH1 and 
TH2 and the development of memory T cells (Malek, 2008, Hoyer et al., 2008).  
The IL-2 receptor consists of three subunits;  IL-2Rα (CD25) contributes to the 
binding affinity of the ligand but not to signal transduction, whereas IL-2Rβ and 
IL-2Rγ subunits mediate signal transduction and ligand binding (Gaffen and Liu, 
2004).   In addition, the IL-2Rβ subunit is shared with the IL-15 receptor, while 
the IL-2Rγ subunit may also form part of a receptor for IL-4, IL-7, IL-9, IL-15 and 
IL-21, thus contributing to redundancy in cytokine signalling (Lan et al., 2008).  
IL-2 receptor signalling is mediated by the Janus kinase/signal transducer and 
activator of transcription 5 (JAK/STAT5), the mitogen-activated protein kinase 
(MAPK) and the phosphoinositide 3-kinase (PI3K) pathways (Cheng et al., 2011).  
IL-2 signalling can be self-reinforcing since IL-2 receptor-mediated signalling up-
regulates the expression of the IL-2 receptor, providing a positive feedback loop 
which drives T cell proliferation (Kim et al., 2001).  Paradoxically, IL-2 is also 
vital to the growth, differentiation and survival of regulatory T cells (Treg), as 
demonstrated by the development of autoimmune disease in experimental 
animals when the IL-2 or IL-2 receptor gene is knocked-out (Sadlack et al., 1993, 
Willerford et al., 1995). 
The cell signalling network involved in T cell activation consists of a vast number 
of factors and pathways.  Those which are most relevant to this thesis are 
described below and in subsequent chapters. 
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1.3.1 CD134 – FIV primary receptor 
The primary receptor for FIV is CD134 (also known as OX40, TNFRSF4 or ACT35) 
(Shimojima et al., 2004).  It is an inducible co-stimulatory molecule and a 
member of the nerve growth factor receptor/tumour necrosis factor receptor 
(NGFR/TNFR) superfamily (MacEwan, 2002).  In the domestic cat, CD134 is 
mainly associated with activated CD4+ T cells (Shimojima et al., 2004, Joshi et 
al., 2005b, Willett et al., 2007).  The normal physiological role of CD134 is to 
regulate the clonal expansion of both CD4+ and CD8+ effector T cells.  CD134 
knock-out animals produce fewer effector CD4+ T cells following antigenic 
stimulation (Gramaglia et al., 2000, Maxwell et al., 2000).  It exerts influence 
during late proliferation and enhances T cell signalling and survival after 
encountering antigen (Croft et al., 2009).  Expression of CD134 is not 
constitutive but transient following T cell activation (Croft, 2010).  CD134 is also 
central to the development of T cell memory (Gramaglia et al., 2000, Maxwell et 
al., 2000) and mediates the interaction between T cells and other cell types 
(Croft, 2010).  Activation of the CD134 pathway also blocks the suppressive 
activity of Treg cells.  CD134 signalling inhibits the induction of regulatory 
molecules such as CTLA4, FOXP3 and IL-10 in T cells (Prell et al., 2003, So and 
Croft, 2007, Ito et al., 2006, Vu et al., 2007).  In accordance with CD134’s role 
in regulating T cell expansion, the ligand of CD134 (known as CD134 ligand or 
CD252) is expressed transiently on professional APCs such as B cells (Stuber et 
al., 1995), dendritic cells (Ohshima et al., 1997) or macrophages (Weinberg et 
al., 1999) upon stimulation by danger signals such as bacterial LPS as well as by 
the CD40 ligand, a molecule associated with activated CD4+ T cells and is 
responsible for regulating the cross-talk between CD4+ T cells and APCs 
(Gommerman and Summers deLuca, 2011).  Certain cell types associated with 
the lymphatic systems such as endothelial cells and mast cell also express 
CD134L as a mean to further augment T cell activation (Croft et al., 2009).   
CD134, like other members of the TNFR superfamily, consists of extracellular 
cysteine rich domains (CRDs) that are linked to a cytoplasmic tail (Croft et al., 
2009). Both feline and human CD134 are predicted to have three full CRDs per 
receptor molecule (Willett et al., 2006b).  The crystal structure of human and 
murine CD134 receptor – ligand complex has been solved (Compaan and 
Hymowitz, 2006) and it showed that 3 receptor molecules combine to interact 
with the trimeric ligand.  A model of the signalling events triggered by the 
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stimulation of CD134 has been constructed recently: the engagement of CD134 
by its ligand leads to the recruitment of the adapter proteins TNFR-associated 
factors (TRAF) 2, 3 and 5, mediated by a short conserved region at the CD134 
cytoplasmic tail with a QEE motif (Fig. 1-5) (Arch and Thompson, 1998, 
Kawamata et al., 1998, Ye et al., 1999, Croft et al., 2009).  Among the recruited 
TRAF proteins, TRAF2 appears to play the most important role in OX40 signalling 
as it has been shown that TRAF2 is essential to the formation of a super-
signalosome consisting of IκB kinases (IKKs), Protein Kinase C (PKC) θ (See 
section 1.7.5), CARD-MAGUK1 (Gaide et al., 2001) (CARMA1), regulation of 
phenobarbitol-inducible P450 (RIP), Mucosa-associated lymphoid tissue 1 
(MALT1), B-cell leukaemia/lymphoma 10 (BCL10), PI3K, phosphoinositide-
dependent kinase 1(PDK1) and Protein kinase B (Akt) (So et al., 2011b, So et al., 
2011a) (Fig. 1-5).  Disruption of lipid rafts (or detergent-insoluble microdomains 
– DIMs) inhibits the formation of the full signalosome and its signalling activities 
but not the association of TRAF2 and IKKs with CD134, whereas the association 
of CARMA1 with CD134 is independent of TRAF2 but is inhibited by lipid raft-
disrupting drugs, indicating that TRAF2 recruits IKKs to CD134 outside lipid rafts, 
then the complex translocates to lipid rafts to join with CARMA1 and the rest of 
the factors to form the complete signalosome (So et al., 2011b)(Fig. 1-5).   
The assembly of this signalling complex and the subsequent activation of NFκB 
and increased T cell survival are antigen independent events but the functional 
activation of the PI3K and Akt pathways is dependent on antigen specific T cell 
receptor activation.  Thus it is suggested that in the presence of antigen, CD134 
acts as a co-stimulatory receptor and supplements T cell activation via enhanced 
PI3K and Akt activity.  While in the absence of antigen only NFκB activity is 
stimulated, allowing survival of activated T cells after the withdrawal of 
antigenic stimulation and the formation of T cell memory (Croft, 2010, So et al., 
2011a, So et al., 2011b).   
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Figure 1-5 – The CD134 signal transduction pathway.  T cell activation (TCA) 
independent events: TRAF2 binds to CD134, recruits IKKs and translocates to 
lipid rafts.  The rest of the signalosome then assembles, which leads to IκB being 
phosphorylated, releasing NFκB.  TCA dependent events: PI3K is phosphorylated, 
which lead to the activation of PDK1 and the phosphorylation of downstream 
kinases such as Akt.  This augments T cell receptor-mediated activation.  Based 
on data from (So et al., 2011a, So et al., 2011b). 
1.3.2 NFκB 
The transcription factor NFκB was discovered in 1986 and was initially identified 
as a B-cell specific transcription factor, binding to a specific site in the kappa 
immunoglobulin enhancer (Sen and Baltimore, 1986b, Sen and Baltimore, 
1986a).  Since then NFκB has been found in many different cell types, mediating 
critical biological processes such as the inflammatory response, apoptosis, 
innate immunity and development.   
The molecular biology of the NFκB signalling pathway has been extensively 
reviewed (Hacker and Karin, 2006, Ghosh, 2007, Hayden and Ghosh, 2008).  In 
mammals NFκB is an evolutionary conversed family of transcription factors which 
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consists of five members, p50, p52, p65 (RelA), c-Rel and RelB.  The 5 members 
of the NFκB family form different homo/heterodimers to perform different gene 
regulatory functions.  The subunits p65, RelB and c-Rel contain a transcription 
activation domain (TAD) required for up-regulation of gene expression.  
Meanwhile the subunits p50 and p52 do not have TADs and are associated with 
down-regulation of gene expression unless dimerized with a TAD-containing 
subunit.    NFκB is normally sequestered in the cytoplasm in an inactive state by 
an Inhibitory-kappa-B (IκB) family protein, which blocks nuclear translocation.  
IκB proteins are phosphorylated by inhibitor-kappa-B kinases (IKKs) during 
activation, leading to the ubiquitination and degradation of the IκB protein and 
the nuclear translocation of the NFκB dimers.  NFκB mediates the transcription 
of genes associated with the inflammatory responses such as cytokines, 
chemokines and inhibitors of apoptosis (Bonizzi and Karin, 2004). 
The activation of NFκB is controlled by two pathways.  The classical (canonical) 
pathway presides over the degradation of most IκB family members (IκBα, IκBβ, 
IκBε) and the processing of p105, the precursor of p50.  This pathway mainly 
relies on IKK-β and IKK-γ regulatory subunit to phosphorylate IκB, leading to its 
degradation.  While the alternative (non-canonical) pathway is independent of 
IKK-β and IKK-γ, it relies on the IKK-α to initiate the processing of p100 by 
phosphorylation (Bonizzi and Karin, 2004, Dejardin, 2006).  A large number of 
other cellular signalling pathways have been discovered to trigger NFκB 
activation.  In T cell signalling these include PKC, P-I3K and MAPK (See later 
sections and chapters) 
 
1.4 Lentiviral evolution within the host and disease 
progression 
Before the identification of the HIV-1 secondary receptors, different primary 
HIV-1 strains were divided between M-tropic and T-tropic viruses.  M-tropic 
viruses are usually found during acute/early infection, do not induce syncytium 
formation and can replicate in macrophages but not in T cell lines (Schuitemaker 
et al., 1992, Zhu et al., 1993); whereas T-tropic viruses tend to appear during 
the late stages of disease, do induce syncytia formation and can replicate in T 
cell lines but not in macrophages (Tersmette et al., 1988, Tersmette et al., 
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1989).  Subsequently it was shown that M-tropic viruses use CCR5 whereas T-
tropic viruses use CXCR4 as their respective secondary receptors (Choe et al., 
1996, Feng et al., 1996).  The M-tropic, or R5 viruses as they are also called, are 
preferentially transmitted despite the availability of CXCR4-expressing 
lymphocytes in the body.  Thus it is proposed that there may be multiple 
barriers against the transmission of T-tropic (or X4) viruses such as increased 
susceptibility of X4 viruses to innate antiviral proteins, lower expression of 
CXCR4 at different sites of viral replication or increased susceptibility of X4 virus 
to neutralizing antibody (Margolis and Shattock, 2006).  Indeed, individuals with 
a rare mutation at the gene encoding CCR5 (CCR5-Δ32) are largely resistant to 
infection with HIV-1 (Dean et al., 1996b).  Nevertheless, as the infection 
progresses the more cytopathic X4 tropic viruses emerge and are associated with 
an increased loss of CD4+ T cells (Fouchier et al., 1996, Connor et al., 1997).   
The different tropisms of the R5 and X4 strains are mediated by the viral env 
gene, which encodes the viral entry glycoproteins Gp120 and Gp41 (also known 
as SU and TM domain of Env glycoprotein respectively) (Cheng-Mayer et al., 
1990, O'Brien et al., 1990).  On the virus envelope, the glycoproteins arrange 
themselves into multimeric spikes: the external Gp120 forms into trimers which 
are held in place by non-covalent interactions with Gp41 trimers, which in turn 
are inserted into the virus envelope (Wyatt and Sodroski, 1998).  The HIV-1 
Gp120 consists of four conserved domains (C1 - C4) and five variable domains (V1 
– V5), forming loop structures (Starcich et al., 1986, Modrow et al., 1987, 
Leonard et al., 1990, Coffin et al., 1997). The binding of HIV-1 Gp120 to CD4 
induces a sequential conformational change of Gp120 (Wyatt and Sodroski, 1998, 
Salzwedel et al., 2000), exposing or creating a binding site at V3 (Sattentau and 
Moore, 1991) for the secondary receptor which leads to the binding of Gp120 to 
the secondary receptor (Berger et al., 1999).  This allows the deployment of the 
Gp41 fusion protein and ultimately leads to the fusion of the viral and cellular 
membranes and the entry of the viral capsid into the cytoplasm (Sodroski, 1999).  
HIV-1 Gp120 is heavily glycosylated, masking potential antibody-binding regions 
on the glycoprotein (Wyatt and Sodroski, 1998).  The conserved CD4 and 
chemokine receptor interaction domains are hidden by the variable loops, and 
are only exposed during binding (Wyatt et al., 1995, Kwong et al., 1998).  These 
adaptations effectively render neutralizing antibody useless in suppressing viral 
replication (Wyatt and Sodroski, 1998).  However, numerous broadly neutralizing 
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anti-HIV-1 antibodies have been discovered (Wu et al., 2010, Walker et al., 
2009), which may illuminate previously unknown conserved epitopes on Gp120 
and lead to the development of an effective vaccine against the virus. 
The entry of FIV into feline cells is believed to be similar to HIV-1.  In cats the 
FIV primary receptor CD134 is mainly associated with activated CD4+ T cells 
(Shimojima et al., 2004, Joshi et al., 2005b) whereas the FIV secondary receptor 
CXCR4 is expressed on activated CD4+ and CD8+ T cells, B cells and monocytic 
cells (Richardson et al., 1999, Willett et al., 2003, Joshi et al., 2005b).  
Analogous to HIV-1 there are considerable differences in viral replication 
characteristics between strains isolated from the ‘early’ or the acute phase of 
infection and strains isolated from the ‘late’ or chronic stages of infection, 
demonstrated by the expansion of tropism of the ‘late’ stage viruses to include B 
cells, macrophages and CD8+ T cells (English et al., 1993, Dean et al., 1996a, de 
Parseval et al., 2004a, Willett and Hosie, 2008).  On-going evolution of the virus 
in vivo was also demonstrated in a study that showed the emergence of more 
pathogenic variants of a cell culture-adapted strain of FIV, PETF14, after long 
term infection in cats (Hosie et al., 2002). 
The overall structure of the FIV Env glycoprotein is believed to be similar to HIV 
Env, despite major differences in protein sequence (Pancino et al., 1995).  The 
binding of FIV Env SU domain to CD134 initiates a sequential change which 
reveals a hidden binding site for CXCR4 (de Parseval et al., 2006), indicating that 
FIV uses a similar entry mechanism to HIV-1.  Similar to the human protein, 
feline CD134 consists of three extracellular CRDs linked to a cytoplasmic tail 
(Fig. 1-6) (Willett et al., 2006b).  Using a chimeric CD134 which contains both 
human and feline CRDs, it was discovered that strains such as FIV-PPR, which is a 
‘late’ or chronic stage isolate (Phillips et al., 1990, Willett and Hosie, 2008), 
only require binding to CRD1 to mediate entry (de Parseval et al., 2005); while 
strains such as FIV-GL8, which is an ‘early’ or acute stage isolate (Hosie and 
Jarrett, 1990, Willett and Hosie, 2008), require additional determinants to enter 
cells and this was mapped to a motif at Asparagine78 – Tyrosine79 – Glutamate80 
(NYE) in CRD2 (Willett et al., 2006a) (Fig. 1-6).  Substituting the NYE motif into 
the human CRD2 restored ‘early’ strain binding to a cat-human CD134 chimera 
(FFHH) (Willett et al., 2006a).  Curiously, while ‘late’ strains have reduced 
requirement for CD134 determinants, they are also more sensitive to 
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competitive inhibition of binding with anti-CD134 antibody or trimeric soluble 
feline CD134 ligand (Willett et al., 2007, Willett et al., 2009), supporting the 
hypothesis that the emergence of the ‘late’ strains only takes place when the 
host develops immune dysregulation and deficiency (Willett and Hosie, 2008).  
Interestingly, the presence of anti-CD134 autoantibodies in FIV-infected cats is 
associated with better overall health, which is another illustration of the 
important role Env plays in pathogenesis (Grant et al., 2009). 
 
Figure 1-6 – Feline CD134 (A) Diagrammatic representation of feline CD134 
chimeras FHFH and FFHH , where F is feline and H is human, in comparison with 
wild-type CD134 (entirely feline).  The tyrosine79 (Y79) in the NYE motif is 
highlighted.  (B) Comparison of amino acid sequence between feline and human 
CD134 in the region covering CRD1 and CRD2.  The NYE motif is highlighted in 
yellow. (Willett et al., 2006a).  (Reproduced with permission from the Journal of 
Virology). 
Difference in viral entry characteristic is not the only mechanism that mediates 
variation in replicative property between strains in lentiviruses.  For example, 
mutations in the HIV-1 accessory gene nef led to the establishment of a group of 
long-term non-progressing HIV-1 positive patients known as the Sydney Blood 
Bank Cohort (Dyer et al., 1997).  Also, in a study on the pathogenic determinants 
between different clades of FIV, it was found that inter-strain variations is 
mediated by multiple parts of the viral genome rather than one single region or 
gene (de Rozieres et al., 2008) and that a mutation at residue 813 of the FIV pol 
51     CRD1_________                        CRD2                        90   
YGMESRCSGD QDTKCLQCAS GFYNEAVNYE PCKPCTQCNQ    Feline 
NGMVSRCSRS QNTVCRPCGP GFYNDVVSSK PCKPCTWCNL    Human 
 
A 
B 
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gene (which forms the FIV integrase) from arginine to histidine confers an 
enhancement to viral growth in vivo (Thompson et al., 2011). 
1.5 Pathogenesis of HIV-1 and FIV                   
During the initial phase of HIV-1 or FIV infection, the host usually experiences an 
acute syndrome characterised by non-specific symptoms such as fever, malaise, 
lymphoadenopathy and diarrhoea (Schacker et al., 1996, Yamamoto et al., 1988, 
Delfierro et al., 1995).  This is followed by an asymptomatic period when the 
host attempts to clear the virus by cell-mediated and humoral responses 
(Pantaleo and Koup, 2004).  However, without antiretroviral treatments, 
immunodeficiency may develop (Tindall and Cooper, 1991, Ishida et al., 1992), 
which would rapidly lead to fatal secondary infections or cancers.  Since the 
early days of HIV-1 research it has been noticed that depletion of CD4+ T cells 
and T-helper function is associated with the development of immunodeficiency 
(Lane and Fauci, 1985).  Thus it was proposed that the direct cytopathic effect 
of HIV-1 on CD4+ T cells was the major cause of immunodeficiency.  However, 
there was also evidence to show that peripheral blood viraemia was low and the 
number of infected T cells was small throughout most stages of infection (Shaw 
et al., 1984, Harper et al., 1986, Chun et al., 1997); in addition most activated 
CD4+ T cells undergo apoptosis soon after clonal expansion as part of the natural 
immune regulatory mechanism (Dooms and Abbas, 2006, van Leeuwen et al., 
2009), indicating that a more subtle mechanism is mediating immune 
dysfunction in the host body which cannot be explained simply by the cytopathic 
effects of HIV-1.   
From the beginnings of HIV-1 research it was also well known that productive 
virus replication requires the host CD4+ T cells to be activated (Zagury et al., 
1986, Stevenson et al., 1990).  This led some researchers to suspect that HIV-1 
pathogenesis involves the chronic activation of the immune system (Hausen et 
al., 1986, Fuchs et al., 1987, Ascher and Sheppard, 1988).  This theory was 
boosted by the discovery of the selective depletion of CD4+ T cells within the 
lymphoid tissues of the gastrointestinal tract during early infection (Brenchley et 
al., 2004b), allowing the chronic translocation of pro-inflammatory microbial 
products from the intestine to the rest of the body, causing long-term immune 
activation (it may also explain the protective effect of the antibiotic co-
trimoxazole on HIV-1 positive children reported in a trial in Zambia (Chintu et 
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al., 2004) – the antibiotic may have reduced microbial translocation and the 
subsequent immune dysregulation).  Other factors also contribute to chronic 
immune activation, for example the destruction of other lymphoid tissues such 
as the thymus (McCune, 2001, Schacker et al., 2002), the depletion of 
immunosuppressive Treg cells (Oswald-Richter et al., 2004b), the establishment 
of a latent virus reservoir which periodically seeds new infection in the body 
(See section 1.7), and the inability of the adaptive immune response to contain 
productive virus replication. This is due in part to immune evasion strategies 
such as glycosylation of the viral surface glycoprotein Env and the low fidelity of 
reverse transcriptase, promoting the generation of escape mutants (Ji and Loeb, 
1992, Bebenek et al., 1993).  In fact it has been estimated that in an untreated 
patient, every nucleotide of the HIV-1 genome would have been point-mutated 
in all possible ways every 24 hours (Siliciano and Siliciano, 2010).  All these 
factors trigger the chronic activation of CD4+ T cells, providing more target cells 
in which HIV-1 can grow and in turn stimulating the immune system even more, 
setting up a positive feedback cycle which eventually results in the exhaustion 
and dysfunction of the host immune response (Douek et al., 2008).  Indeed it 
was found that there is an increased expression of the molecule Programmed 
Death-1 (PD-1), which is a negative regulator of T cell function, among HIV-1 
specific CD4+ and CD8+ T cells in patients (Day et al., 2006, Trautmann et al., 
2006).  
FIV has the same cell tropism as HIV-1, thus it is expected that the host response 
to FIV and its pathogenesis is similar to the human virus.  Cats mount both 
humoral and cytotoxic T cell responses to FIV infection (Egberink et al., 1992, 
Beatty et al., 1996, Flynn et al., 2002).  However, the hosts usually fail to clear 
the infection and eventually succumb to immunodeficiency.  Several mechanisms 
have been proposed to explain the dysfunction of the feline immune response 
during FIV infection (Tompkins and Tompkins, 2008); firstly, chronic 
hyperactivation of the immune system is believed to cause the dysregulation of 
cytokine release (Levy et al., 1998, Dean et al., 1998) and induction of apoptosis 
among T cell populations (Tompkins et al., 2002, Vahlenkamp et al., 2004a).  As 
the disease progresses the activation of Treg cells has also been reported 
(Vahlenkamp et al., 2004b).  These Treg cells suppress the antiviral functions of 
activated CD4+ T cells.  In contrast, FIV has been shown to target feline Treg 
cells (Joshi et al., 2005b), which may contribute to host immune dysregulation.  
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It has also been reported that FIV infection induces significant reduction of 
intestinal CD4+ T cells, mirroring the results from studies on HIV-1 (Howard et 
al., 2010).  Finally, the low fidelity of the FIV reverse transcriptase results in the 
generation of a diverse pool of viral variants within the host (Kraase et al., 
2010), encouraging immune escape and chronic infection (Hosie et al., 2011). 
1.5.1 Role of gp120 on lentiviral pathogenesis 
The attachment between the HIV-1 glycoproteins Gp120 and Gp41 is not 
covalent, thus Gp120 can be released from virus particles or infected cells and 
they interact with host CD4, CCR5 or CXCR4 (Gelderblom et al., 1985).  These 
cellular molecules are important receptors for cell signalling and the possibility 
of Gp120 contributing to HIV-1 pathogenesis by triggering intracellular signalling 
pathways have been investigated extensively (Santoro et al., 2003, Jones et al., 
2011).  HIV-1 Gp120 protein has been shown to activate NFκB via interaction 
with CD4, which signals down the Ras/Raf/MEK/ERK cascade or the PI3K – Akt 
pathway, stimulating the host T cell (Popik and Pitha, 1996, Briand et al., 1997, 
Flory et al., 1998).  The binding of HIV-1 Gp120 to CCR5 stimulates focal 
adhesion kinase (FAK) and the cellular GTPase Rac-1, which promotes the re-
organisation of cytoskeleton, allowing viral entry (Cicala et al., 1999) (Harmon 
and Ratner, 2008).  HIV-1 Gp120 and FIV Gp120 can both interact with CXCR4 
and may either induce or impair cell signal transduction (Hesselgesser et al., 
1997, Hesselgesser et al., 1998, Hosie et al., 1998).  The HIV-1 Gp120 interaction 
with CXCR4 also triggers intracellular actin re-organisation in resting T cells by 
activating the actin-depolymerizing factor cofilin (Yoder et al., 2008).  This 
enables the direct infection of resting T cells by HIV-1 and contributes to the 
establishment of the latent virus reservoir (See section 1.7).  In addition it has 
also been reported that HIV-1 Gp120 induces apoptosis of uninfected CD4+ T cells 
(Jekle et al., 2003) and many studies have found that both HIV-1 and FIV Gp120 
have neurotoxic effects in their respective hosts (Hesselgesser et al., 1998, Kaul 
et al., 2001, Meeker, 2007).  It has also been reported that HIV-1 Gp120 could 
induce virus production from infected resting T cells (Kinter et al., 2003).   
While it was believed initially that the interaction between HIV-1 Gp120 and the 
receptors CD4, CCR5 and CXCR4 results in the stimulation of the host cell,  
subsequent studies on transformed cell lines have shown that inhibiting HIV-1 co-
receptor signalling has minimal effects on productive infection with HIV-1 
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(Cocchi et al., 1996, Farzan et al., 1997).  This is corroborated by studies on 
primary T cells and macrophages (Amara et al., 2003, Yoder et al., 2008).  The 
use of non-physiological experimental conditions and high amounts of HIV-1 
Gp120 may also exaggerate the effects of the protein (Klasse and Moore, 2004).  
Moreover blocking CXCR4 signalling with the application of pertussis toxin only 
inhibits subsequent HIV-1 replication in resting T cells, whereas the toxin does 
not block HIV-1 replication in activated or transformed T cells (Yoder et al., 
2008), demonstrating the relative insignificance of HIV-1 Gp120 induced 
signalling during the productive infection of activated T cells.  Therefore, based 
on all the available evidence, it is reasonable to conclude that the binding of 
HIV-1 Gp120 to its cellular receptors induces a negligible effect on productive 
infection.  Instead this binding is likely to contribute to the neuropathology 
associated with lentiviral infection (cells of the nervous system maybe more 
sensitive to the effects of Gp120 than T cells) and may enhance the 
establishment and maintenance of the reservoir of latently infected resting T 
cells. 
In terms of FIV Env, it has been associated with the neuropathology of FIV 
infection (Meeker, 2007) and there has been a report of FIV Env inducing 
apoptosis in feline peripheral blood mononuclear cells (PBMCs) (Garg et al., 
2004).  Since FIV Env binds to the T cell co-stimulatory factor CD134 and 
chemokine receptor CXCR4, it is reasonable to hypothesise that FIV binding to 
these receptors could trigger activation of the host T cells.  This may be 
advantageous to virus replication as only a low percentage of T cells are 
activated and conducive to infection at any given time. 
1.6 Antiretroviral treatments 
In the beginning of the AIDS outbreak, no effective treatments were available 
for physicians to stop the progression of the disease in the patients (Masur et al., 
1981, Gottlieb et al., 1981).  Attempts to stimulate the immune system, 
including the use of the then newly-discovered T cell growth factor interleukin-
2, failed to reverse the immunodeficiency (Lane et al., 1984, Lane, 1989).  It 
was not until the drug zidovudine (AZT) was licensed in 1986 that there was a 
successful treatment against HIV-AIDS (Rachlis, 1990).  However, drug-resistant 
strains of HIV-1 soon emerged, which is an indication of the future problems that 
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lay ahead in the development and use of antiretroviral drugs (Larder et al., 
1989). 
Currently there are five classes of antiretroviral drugs in general clinical use 
(Table 1-2).  These drugs are classified by their mode of action and their 
chemical structures.  The nucleoside and nucleotide reverse transcriptase 
inhibitors (NRTIs) are the first class of drugs used for the treatment of HIV-AIDS.  
These include AZT, lamivudine and tenofovir and are the structural analogues of 
natural deoxynucleotides used for the synthesis of viral DNA.  However, the 
NRTIs do not have a 3’hydroxyl group on the deoxyribose moiety, thus causing 
the termination of DNA synthesis when incorporated into a nascent viral DNA 
molecule by a DNA polymerase (Vivet-Boudou et al., 2006).  The NRTIs used in 
antiretroviral treatment are highly selective for viral reverse transcriptase 
rather than human DNA polymerase so in theory host DNA synthesis should not be 
affected (Mitsuya et al., 1990).  The non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) are non-competitive inhibitors which bind to a site away from 
the active site of the enzyme (de Bethune, 2010).  The viral protease is targeted 
by inhibitors such as lopinavir, which prevents the maturation of the virion 
(Hurst and Faulds, 2000, Wlodawer and Erickson, 1993).  More recently, drugs 
targeting the viral integrase such as Raltegravir (Cahn and Sued, 2007) or viral 
entry such as the fusion blocker Enfuvirtide (Qian et al., 2009) have been added 
to the growing arsenal of antiretroviral treatments.  Many of these antiretroviral 
drugs have also been shown to be effective against FIV (North et al., 1989, Elder 
et al., 2006, Savarino et al., 2007). 
Nucleoside and nucleotide reverse 
transcriptase inhibitors (NRTIs) 
Zidovudine (AZT)                             
Lamivudine (3TC)                              
Tenofovir (TDF) 
Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) 
Efavirenz (EFV)                         
Nevirapine                            
Rilpivirine 
Protease inhibitors 
Lopinavir  
Saquinavir  
Tipranavir 
Integrase inhibitors Raltegravir (RGV) 
Entry blockers 
Enfuvirtide (INN)                 
Maraviroc 
 
Table 1-2 – Selected examples of the five classes of antiretroviral drugs 
currently in clinical uses. 
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A major problem with antiretroviral treatment is that HIV-1 can rapidly develop 
resistance against all the current classes of drugs (Johnson et al., 2011) and will 
do so against any future treatments due to its high mutation rate (Mansky and 
Temin, 1995).  The use of a combination of three or more antiretroviral drugs, 
otherwise known as highly active antiretroviral therapy (HAART) makes it much 
more difficult for the virus to evolve resistance and has improved the prognosis 
of patients who can afford the treatment (Shafer and Vuitton, 1999).  
Antiretroviral drugs are expensive and the majority of the sufferers, who reside 
in the developing world still do not have access to them (Volberding and Deeks, 
2010), although in a recent study it has been shown that starting HAART early 
rather than waiting for symptoms of AIDS to appear is a cost effective way to 
reduce mortality and morbidity, even in resource-poor settings (Severe et al., 
2010, Koenig et al., 2011).  Early treatment also prevents further transmission 
(Cohen et al., 2011), indirectly reducing medical cost in the future.  HAART does 
not fully restore the health of an infected patient.  For reasons which may be a 
consequence of drug toxicity or the chronic inflammation caused by persistent 
HIV-1 infection, long-term treated HIV-1 patients have reduced lifespan and 
increased susceptibility to non-AIDS related conditions such as cardiovascular 
disease, cancer, liver and kidney dysfunctions as well as neurological decline 
(Monforte et al., 2004, Deeks, 2011).    However, the most significant drawback 
of HAART is that it cannot completely eradicate the virus from the body. 
1.7 Lentiviral latency – obstacle to eradication 
1.7.1 Establishment of the latent reservoir 
Although HAART is very effective at blocking HIV-1 spread within the body, it is 
not a cure, as viral loads readily rebound when treatment is interrupted (Chun et 
al., 1999, Davey et al., 1999).  Furthermore, ultrasensitive detection assays have 
shown that in most HAART-treated patients, a low-level viraemia of less than 5 
copies per ml persists even after years of therapy (Chun et al., 2005, Tobin et 
al., 2005, Palmer et al., 2008).  Since the half-life of the HIV-1 virion in the 
plasma is very short (Ho et al., 1995) (Ramratnam et al., 2000), it is believed 
that the persistent viraemia is either the result of the reactivation of latently 
infected resting T cells or on-going virus replication in ‘sanctuary’ sites within 
the body such as the central nervous system (Gonzalez-Scarano and Martin-
Garcia, 2005, Churchill et al., 2006, Canestri et al., 2010), the gastrointestinal 
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tract (Chun et al., 2008) and the male and female genital tract (Halfon et al., 
2010, Launay et al., 2011).  Although improvements in drug penetration or 
HAART intensification may be able to eliminate persistent virus replication 
within these sanctuary sites in the future, it will not affect the latent viruses 
hiding within resting CD4+ T cell populations in the body. 
The first indirect evidence for HIV-1 infection of resting T cells was the discovery 
that the number of cells expressing HIV-1 mRNA in vivo, as detected by in situ 
hybridisation, is lower than the number of cells carrying viral DNA (Schnittman 
et al., 1989).  Then it was shown that a small number of the resting T cells in 
HIV-1 infected individuals, even those who are receiving anti-retroviral 
treatments, harbour latent virus (Chun et al., 1997).  Latent infection of HIV is 
defined as the lack of full virus gene expression as a consequence of the 
quiescent status of the host CD4+ T cell, leading to the absence of virus 
production.  HIV-latency is thought to be an unintended consequence of the 
tropism of the virus, unlike viruses such as the herpesviruses HIV-1 does not 
encode latency induction genes  (Han et al., 2007).  Most of the circulating CD4+ 
T cells in the body at any given time are in a resting state (Berard and Tough, 
2002).  These can be broadly divided into cells that have not undergone antigen-
stimulated expansion (naïve T cells) and the cells that have remained behind 
after the end of an immune response (memory T cells) (Berard and Tough, 
2002).  Since most of these latently infected resting CD4+ T cells are CD45RO+ 
memory cells (Chun et al., 1997, Pierson et al., 2000, Brenchley et al., 2004a, 
Chomont et al., 2009), it is hypothesised that the majority of the latently 
infected T cells come from activated CD4+ T cells that were infected and then 
reverted back to a resting memory state before the start of virus replication 
(Han et al., 2007).  It is also possible that resting T cells are directly infected by 
the virus.  Direct infection of resting T cells is very inefficient (Stevenson et al., 
1990, Pierson et al., 2000) due to defects in reverse transcription and delays in 
integration in comparison with infection of activated CD4+ T cells (Vatakis et al., 
2007, Vatakis et al., 2009).  No method to date has been able to distinguish 
between latently infected memory T cells which were infected during activation 
or quiescence (Vatakis et al., 2010).  However, latent infection of naïve T cells 
has been observed in patients, albeit at a lower frequency than memory T cells 
(Pierson et al., 2000, Chomont et al., 2009).  In a recent clinical study, it has 
been shown that among patients receiving antiretroviral treatment, the total 
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amount of HIV DNA in memory T cells declined over time while the amount of 
HIV DNA in naïve cells remained constant, suggesting that direct infection of 
resting T cells may be replenishing the latent viral reservoir as the disease 
progresses (Wightman et al., 2010).  This ties in with the observation that R5 
tropic viruses (which are associated with acute infection (Zhu et al., 1993)) 
preferentially infect CCR5 expressing memory T cells whereas X4 tropic viruses 
(which are associated with late disease progression (Connor et al., 1997)) exhibit 
a preference for CCR5- CXCR4+ naïve T cells (Bleul et al., 1997, Ostrowski et al., 
1999, Wu et al., 1997). The stimulatory effects of HIV-1 Gp120 may enable the 
direct infection of resting T cells in the following ways:  Incubation of resting T 
cells with HIV-1 Gp120 stimulates calcium flux and NFAT signalling down the 
CCR5 signalling pathway, while at the same time increases inosital triphosphate 
(IP3) signalling and IL-2 receptor expression (Kornfeld et al., 1988, Weissman et 
al., 1997, Cicala et al., 2006).  Stimulation of CXCR4 signalling by HIV-1 Gp120 
induces cytoskeleton-remodelling activity in resting T cells, increasing the 
efficiency of subsequent infection with HIV-1 but at a far lower rate than in an 
activated cell (Yoder et al., 2008).     
CD4+ T cells are not the only cell type that can become reservoirs of latent 
infection.  Dendritic cells can trap HIV-1 virions on the cell surface for long 
periods and unintegrated viral DNA can persist and maintain its biological 
activity in macrophages (Coiras et al., 2009, Kelly et al., 2008).  Virus 
replication in privileged sites such as the CNS where drug penetration is poor 
may also prevent full suppression by HAART (Varatharajan and Thomas, 2009).  
In addition it has been proposed that infection of immature CD4+/CD8+ “double 
positive” thymocytes during thymopoiesis may generate a population of latently 
infected naïve T cells (Brooks et al., 2001).  In contrast, in a recent case of an 
HIV positive leukaemia patient receiving a bone marrow transplant from a CCR5-
negative donor, CCR5 positive macrophages remained after the transplant, but 
re-infection by HIV-1 was not detected (Hutter et al., 2009).  This suggests that 
latent infection in cell types other than CD4+ T cells may not be important in 
maintaining a persistent infection, at least in this one case, and that it is enough 
to achieve a cure by targeting the CD4+ T cells alone (Allers et al., 2011, Pace et 
al., 2011).  However, the HIV-1-resistant nature of the donor CCR5-negative 
CD4+ T cells may mask any low-level on-going infection which would seed a new 
wave of infection if autologous stem cells were transplanted instead. 
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1.7.2 Latent reservoir leads to viral persistence 
The long-term survival of memory CD4+ T cell populations and their rapid 
expansion following re-exposure to a previously encountered antigen are 
cornerstones of adaptive immunity (Dooms and Abbas, 2006, van Leeuwen et al., 
2009).  However, in an HIV-1 infection these vital components of the immune 
system become its biggest liability.  Latent proviruses are not affected by 
antiretroviral drugs and are hidden from the body’s immune response until they 
are reactivated by stimuli such as exposure to antigens or cytokines (Coiras et 
al., 2009).  The reactivation of the latently infected T cells is unpredictable 
(Siliciano and Siliciano, 2010) and in theory reactivation of even one cell 
carrying a replication-competent virus may lead to a new wave of infection.  
Even in patients who are responsive to HAART there may be intermittent 
episodes of detectable viraemia (Ramratnam et al., 2000) which may be caused 
by reactivation of latently infected cells.  The size of the latent HIV-1 reservoir 
is very small, estimated to consist of approximately 106 cells (Chun et al., 1997), 
but due to the lifespan of these cells and the fact that latent provirus can be 
maintained within the memory T cell population by the homeostatic 
proliferation of the infected host cells, driven by IL-7 (Chomont et al., 2009, 
Bosque et al., 2011), it has been calculated that it would take 73.4 years of 
current anti-retroviral therapy to completely eliminate all the latently infected 
cells (Siliciano et al., 2003).  For these reasons HIV-1 remains incurable in the 
absence of new therapeutic interventions that can eliminate the latent 
reservoir.   
1.7.3 FIV latency 
The role of viral latency in the pathogenesis of FIV-related AIDS in cats is less 
well understood.  Experiments using feline PBMCs identified two CD4+ T cells 
subsets which can be infected latently in the absence of exogenous IL-2: CD4+ 
CD25+ and CD4+ CD25- T cells (Joshi et al., 2004, Joshi et al., 2005a).  In these 
studies stimulation by the mitogen ConA and the addition of exogenous IL-2 was 
required to induce p24 production, and to increase CD25 expression (a sign of 
cellular activation) from CD4+ CD25- cells.  In contrast, latently infected CD4+ 
CD25+ T cells only required the addition of exogenous IL-2 to initiate productive 
infections, mirroring the crucial role of IL-2 in the productive infection with HIV-
1 (Oswald-Richter et al., 2004a).  An in vivo study showed that at a low 
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infectious dose, cats appeared to be infected asymptomatically at 12 weeks post 
infection, with a low level of FIV Gp120 expressed in multiple tissues, the 
production of which could be stimulated by PMA (Assogba et al., 2007).  More 
recently, it was shown that FIV can establish a latent infection within CD4+ 
CD25+ and CD4+ CD25- T cells in chronically infected cats, analogous to the latent 
infection of the resting T cell population by HIV-1 in humans (Murphy et al., 
2012). 
1.7.4 Molecular mechanism of latency 
The mechanism of latency in HIV-1 infection has been extensively reviewed 
(Coiras et al., 2009, Marsden and Zack, 2009, Richman et al., 2009, Marcello, 
2006, Colin and Van Lint, 2009).  In general, HIV-1 latency can be divided into 
pre-integration or post-integration latency.  Pre-integration latency refers to the 
partial or complete inhibition of the viral life cycle before the integration of the 
virus into the host genome due to due to defects in reverse transcription and 
delays in integration (Vatakis et al., 2007, Vatakis et al., 2009).  Similar 
observations have been made in feline CD4+ T cells where FIV entered resting 
CD25- cells but was unable to complete replication (Joshi et al., 2004).  Although 
linear unintegrated DNA (See section 1.2.4) is able to complete integration after 
the activation of the host T cell (Bukrinsky et al., 1991), and while HIV-1 DNA 
has been detected in resting T cells for 2 weeks post infection (Stevenson et al., 
1990), pre-integration latency is not thought to be relevant to the establishment 
of the latently infected T cell reservoir.  This is because of the labile nature of 
viral DNA in the cytoplasm of the cell (Pierson et al., 2002b), which means that 
the unintegrated viral DNA may not be replication competent after a protracted 
period inside the host cell (Zhou et al., 2005, Han et al., 2007).  Post-integration 
latency is the failure of full expression of viral genes after the integration of the 
provirus into the host genome.  Most of the HIV-1 DNA found in resting T cells is 
in the linear, unintegrated form, while less than 0.05%, or approximately 106 to 
107 cells, carry integrated provirus and this is the form of latency which 
constitutes the latent viral reservoir (Chun et al., 1997).   
A variety of mechanisms are thought to contribute to the establishment and 
maintenance of the latent provirus.  These include the low activity of the 
various cellular signalling pathways, thus reducing the availability of 
transcription factors such as NFkB, AP-1 and NFAT (Williams and Greene, 2007); 
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the restrictive host chromatin organisation caused by epigenetic silencing (See 
section 1.7.7); the insufficient expression of the viral transcription promoter 
Tat, causing inefficient elongation of the viral transcript (Weinberger et al., 
2005); the presence of cellular transcriptional repressors, for example YY1 and 
LSF, which recruit suppressive histone deacetylases to the HIV-1 LTR (Coull et 
al., 2000);  In addition, it has been demonstrated that HIV Tat and Rev 
transcripts are retained in the nuclei of resting CD4+ T cells (Lassen et al., 2006) 
and that numerous host microRNAs can directly or indirectly down-regulate HIV-
1 gene expression, contributing to the maintenance of proviral latency (Chiang 
and Rice, 2012) It is important to look at these mechanisms not as isolated 
entities but as part of the broad signalling and regulatory network with cross-
talk, redundancy and feedback loops between different factors. 
Lentiviral replication is highly integrated with the cellular signalling network 
that controls T cell activation.  The 5’LTR of lentiviruses contains DNA-binding 
sites for a number of cellular transcription factors that are triggered during T 
cell activation, such as NFκB, NFAT, AP-1 and ATF (Tang et al., 1999, Colin and 
Van Lint, 2009, Sparger et al., 1992, Thompson et al., 1994).  The activities of 
these factors are controlled by a network of signalling pathways and the 
triggering of one or more of these pathways would be sufficient to trigger 
productive viral replication (Williams and Greene, 2007).  Among the plethora of 
pathways available, Protein Kinase C signalling has attracted much attention 
because of its central role in T-cell activation, culminating in the modulation of 
transcription factors such as NFκB, NFAT and AP-1. 
1.7.5 Protein kinase C 
The family of cyclic nucleotide independent serine/threonine kinases known as 
Protein kinase C (PKC) was discovered by Nishizuka and co-workers in 1977 
(Inoue et al., 1977, Nakamura and Yamamura, 2010) and consists of three major 
groups or isoforms: conventional PKC (cPKC), novel PKC (nPKC) and atypical PKC 
(aPKC) (Fig. 1-7).  The cPKC isoforms (α, β and γ) require calcium and 
diacylglycerol (DAG) for activation; nPKC isoforms (δ, ε, η, θ and μ) require only 
DAG; aPKC isoforms (ζ and iota) require neither calcium nor DAG for activation.   
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Figure 1-7 - Structure of the three main PKC isoforms.  A representation of the 
three major PKC isoforms, showing the arrangement of the different catalytic and 
regulatory domains within each isoform.  PS = pseudo-substrate. 
All PKC isoforms consist of a catalytic and a regulatory domain, which are sub-
divided into four conserved regions C1 to C4 (Fig. 1-7).  C1 is the regulatory 
domain, with C2, C3 and C4 folded together to form the substrate binding 
domain (Tan and Parker, 2003).  The pseudo-substrate from the regulatory 
domain blocks substrate access to the catalytic domain when the enzyme is 
unstimulated.  Before activation PKC resides in the cytoplasm.  In response to 
activation the enzyme moves to the cell membrane, its catalytic domain changes 
conformation, displacing the pseudo-substrate, enabling protein phosphorylation 
to take place. 
1.7.6 Phorbol esters and PKC 
The C1 DAG binding domain of the novel and conventional PKC isoform is also 
the binding site for a class of compounds known as phorbol esters (Ono et al., 
1989, Burns and Bell, 1991).  The C1 domain contains a hydrophobic surface 
which mediates the insertion of the enzyme into lipid membranes.  In the centre 
of this hydrophobic surface there is a polar groove that disrupts the interaction 
between the protein and the membranes (Zhang et al., 1995).  DAG and phorbol 
esters cap this groove and complete the hydrophobic surface, allowing PKC 
translocation and catalytic activity to take place (Zhang et al., 1995).   
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The first phorbol ester was isolated from the seeds of Croton tiglium, a member 
of the Euphorbiaceae (Spurge) family of plants which was used in traditional 
Chinese medicine (Hecker et al., 1964, Li, 1578); croton oil was well known for 
its ability to enhance carcinogenesis and the phorbol ester extracted from 
croton oil, phorbol myristate acetate (PMA or TPA) was shown to be a potent co-
carcinogen (Paul and Hecker, 1969).  Later Nishizuka and others demonstrated 
that PMA activates PKC by binding directly to its C1 domain (Castagna et al., 
1982, Kikkawa et al., 1983, Niedel et al., 1983).  PMA was shown to have anti-
HIV-1 effects (Rullas et al., 2004, Warrilow et al., 2006) but its tumour 
promoting properties make it unsuitable for clinical use.  However, PMA remains 
a major experimental tool for cell signalling and T cell activation studies.  
Prostratin (12-deoxyphorbol 13-acetate) is a phorbol ester that stimulates PKC 
(Gustafson et al., 1992).  It was first isolated as the toxic component of the 
shrub Pimelea prostrata, which was blamed for the poisoning of livestock in New 
Zealand (Cashmore et al., 1976).  The anti-HIV-1 effect of Prostratin was 
discovered after a screening programme by the U.S. National Cancer Institute 
(NCI) looking for therapeutic compounds in a number of Samoan plant extracts.  
Substantial cytoprotective and HIV-1 inhibitory effects were detected in the 
extract of the Samoan medical plant Homalanthus nutans, another member of 
the Spurge family of plants (Gustafson et al., 1992).  Prostratin has also been 
isolated from the traditional Chinese medicine plant “lang-du” (Euphorbia 
fischeriana) (Wang et al., 2006).  From its discovery it was shown that Prostratin 
is different to other phorbol esters such as PMA due to its lack of tumour 
promoting ability (Szallasi and Blumberg, 1991, Gustafson et al., 1992).  
However, it was the latency reversing effect of Prostratin that attracted the 
attention of HIV researchers.  Prostratin has been shown by various laboratories 
to inhibit HIV replication and to reactivate latent HIV (Kulkosky et al., 2001, 
Korin et al., 2002, Brooks et al., 2003b, Biancotto et al., 2004, Rullas et al., 
2004, Warrilow et al., 2006).  HIV-1 reactivation by Prostratin is dependent on 
PKC and NFκB activation, although the role of NFAT and AP-1 may be redundant, 
depending on the cell type used (Brooks et al., 2003a, Williams et al., 2004).  
Prostratin down-regulates expression of the HIV-1 receptors CD4, CCR5 and 
CXCR4 (Kulkosky et al., 2001, Biancotto et al., 2004, Rullas et al., 2004, 
Warrilow et al., 2006) and this has been proposed as the primary mechanism for 
the inhibitory effects of Prostratin on HIV-1 replication. Although phorbol esters 
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are primarily known for their PKC-stimulating activities, non-PKC receptors for 
phorbol esters have been discovered.  These include PKD, chimaerins and 
RasGRPs and they were shown to mediate key proliferation and transformation 
processes of the cell (Yang and Kazanietz, 2003).   
1.7.7 Chromatin organisation and latency  
As the lentiviral provirus is integrated into the host genome, cellular histone 
proteins interact with the proviral DNA, forming nucleosomes.  The position of 
the nucleosomes is vital to the modulation of latency.  Studies on the HIV-1 LTR 
have revealed that two nucleosomes, nuc-0 and nuc-1, are positioned over key 
transcriptional regulatory sites of the provirus and that nuc-1 is remodelled in 
response to PMA, thus linking chromatin re-modelling to T cell activation (Verdin 
et al., 1993, Vanlint et al., 1994).  Acetylation of the various histone and non-
histone chromatin associated proteins is modulated by histone deacetylases 
(HDACs) and histone acetyltransferases (HATs) (Yang and Seto, 2007).  HDAC has 
been shown to directly affect HIV LTR expression levels (He and Margolis, 2002).  
In addition, HDAC inhibitors such as valproic acid and SAHA has been shown to 
reactivate latent HIV-1 infection in in vitro models, further illustrating the role 
of nucleosomes and chromatin re-organisation in the maintenance of latency 
(Jordan et al., 2003, Reuse et al., 2009, Bosque and Planelles, 2009, Burnett et 
al., 2010).  Methylation of DNA has also been shown to affect both HIV-1 and FIV 
LTR activity (Schulzeforster et al., 1990, Ikeda et al., 1996) and may play a role 
in the establishment of latency.   
Based on the current understanding of lentiviral latency, it has been proposed 
that to deplete the HIV-1 latent reservoir in the body, latently infected resting T 
cells would be stimulated to reactivate the dormant provirus by phorbol esters 
or HDAC inhibitors.  It is assumed that the cytopathic effects of productive 
infection would lead to the death of the host cell. Alternatively the synthesis of 
viral proteins by the reactivated infected cells would reveal it to the host 
immune system for cell-mediated killing.  Meanwhile HAART would protect 
uninfected T cells in the body from any nascent virus (Fig. 1-8) (Richman et al., 
2009). 
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1.7.8 Current models for HIV-1 latency – clues to the elusive cure 
The use of stem cell transplantation to clear HIV-1 from the body has been 
successfully demonstrated in one patient (Hutter et al., 2009, Allers et al., 
2011), but it is unlikely to be a practical or affordable cure for most patients in 
the near future, particularly in the developing world.  A more probable strategy 
for the elimination of latent viral reservoirs would be to treat the patient with 
drugs that reactivate virus production under intensive HAART without causing 
global activation of uninfected T cells (Fig. 1-9) (Marsden and Zack, 2009, 
Richman et al., 2009).  However, as viral replication is intricately tied to the 
cellular activation state (Stevenson et al., 1990), inducing reactivation of latent 
virus while avoiding T cell activation has proved challenging (Prins et al., 1999).  
Reversing HIV-1 latency would require a better understanding of the mechanism 
of lentiviral latency at both the cellular and the whole animal level.  Due to the 
rarity of latently infected CD4+ T cells in the host and the lack of surface 
markers to distinguish latently infected cells from the rest of the T cell 
population (Chun et al., 1995, Han et al., 2007), it has been difficult to use 
primary cells from patients in molecular biology research and almost impossible 
to use them in the high-throughput screening of drugs.  Thus in vitro and in vivo 
model systems are vital to illuminate the molecular mechanisms of latency and 
to discover new means to reverse it.  Early studies of lentiviral latency using cell 
lines such as ACH-2, U1 and J-Lat showed the involvement of host cytokine 
signalling pathways and chromatin re-organisation in modulating latency (Folks 
et al., 1987, Folks et al., 1989, Jordan et al., 2003), but their transformed 
nature means that their responses to treatments may not mimic the 
physiological response of primary cells.  For example in the latently infected J-
LAT cell line, HIV-1 preferentially integrates near the heterochromatin where 
transcriptional activity is low (Jordan et al., 2003).  However, this preference is 
not observed within the latently infected resting CD4+ T cells from HAART-
treated HIV-1 patients. Instead, the provirus overwhelmingly favours integration 
into active transcriptional regions (Han et al., 2004).   
Thus primary T cells form the basis of most of the in vitro models described.  In 
one model naïve T cells are activated using dendritic cells grown from PBMCs 
and with staphylococcal enterotoxin B (SEB), and then infected with HIV-1 at a 
low multiplicity of infection (M.O.I) (Marini et al., 2008).  After an initial cell 
expansion period (which also saw peak HIV-1 p24 production) the cells were 
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rested and were cultured with a low dose (1 ng/ml) of IL-7.  Il-7 is an essential 
cytokine for the maintenance of memory T cells (Marrack and Kappler, 2004) and 
protects T cells against cell death that is induced by the withdrawal of growth 
factors like IL-2.  These resting cells were able to be reactivated by secondary 
stimulation from SEB loaded dendritic cells or anti CD3/CD28 antibodies.  The 
whole process from isolation of T cells to secondary stimulation took 68 days and 
involved multiple complicated steps, in which the authors tried to simulate 
faithfully a real immune response.   However this technique leads to the loss of 
cell viability and an increase in the scope for error.  Furthermore the use of IL-7 
to maintain resting cells, albeit at a very low dose, carries the risk of 
reactivating the virus prematurely. 
A separate model aimed to prolong T cell survival by transducing primary CD4+ T 
cells with Bcl-2 (Yang et al., 2009).  Bcl-2 is an anti-apoptotic or “survival” 
factor in T cells (Marrack and Kappler, 2004) which functions downstream of the 
cytokine IL-7.  Its over-expression has been shown to restore the pro-survival 
effects of IL-7 in IL-7 receptor deficient mice (Akashi et al., 1997).  This 
abolishes the need for exogenous IL-7 and may avoid accidental reactivation.  
Transduced T cells were cultured without T cell receptor or cytokine stimulation 
for 4 weeks before expansion of the remaining viable cells (which have been 
successfully transduced) and infection with a GFP reporter virus.  The cells were 
then kept without stimulation for 4 weeks and GFP negative cells (which contain 
uninfected and latently infected cells) were sorted by FACS.  These were then 
stimulated with various agents known to reactivate HIV-1 such as anti-CD3/CD28 
antibodies, phorbol esters such as PMA and cytokines such as IL-2 and IL-7.  The 
whole procedure took more than 8 weeks and gave a modest increase in GFP 
count when stimulated (from 0.15% to 2.89% using anti CD3 and CD28 
antibodies).  This reflects the rarity of latently infected cells in vivo and the 
authors claimed to be able to generate enough of these transduced cells for 
high-throughput studies, which they have demonstrated by using the model 
system to identify a new compound, 5-hydroxynaphthalene-1, 4-dione (5HN), 
that can reactivate latent HIV-1.  There are two potential problems with this 
model: Firstly, the transduction of a survival factor into the T cells may alter the 
basic physiology of the cells. Secondly, the use of a highly mutated reporter 
virus may not reflect infections in real life since it does not demonstrate 
whether the system can support infection with a replication competent virus. 
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Direct infection of resting CD4+ T cells with virus has also been investigated as a 
potential model for HIV-1 latency.  HIV-1 engagement of CXCR4 activates cofilin, 
a cellular actin-depolymerizing factor, which aids the natural infection of resting 
T cells by the virus (Yoder et al., 2008).  Furthermore, latent infection of resting 
T cells is more efficient when the dynamics of cytoskeleton re-organisation is 
stimulated artificially (Yoder et al., 2008).  Other methods to increase the 
efficiency of direct infection of resting T cells exist; a technique known as 
spinoculation has been shown to assist viral entry without activation of the cells 
and could be useful in deducing the mechanism of latency maintenance 
(O'Doherty et al., 2000) (Swiggard et al., 2005, Agosto et al., 2007).  Stimulation 
of CCR7 with the ligands CCL19 and CCL21 also increased infection efficiency 
and the infected resting T cells responds to post-infection stimulation with 
phorbol esters in a similar fashion to other T cell preparations (Saleh et al., 
2011, Saleh et al., 2007). 
In addition to activated and resting CD4+ T cells, infected immature CD4+ CD8+ 
thymocytes may also become a latent viral reservoir after their maturation into 
naïve T cells.  This hypothesis was developed using a SCID mouse model (Brooks 
et al., 2001) and from this basis an in vitro model of latently infected 
thymocytes has also be generated (Burke et al., 2007). 
Animal models are essential if we are to achieve a better understanding of HIV 
latency and test potential therapeutic regimes that may overcome latent 
infection.  Non-human primates, in particular rhesus macaques infected with the 
simian immunodeficiency virus (SIV) or a chimeric SIV containing HIV-1 reverse 
transcriptase have been used to model HIV-1 latency in HAART-treated patients 
(Shen et al., 2003, Dinoso et al., 2009, North et al., 2010).  The major 
advantages of using non-human primates are that the persistent viral reservoirs 
are found in the same locations in both humans and primates (North et al., 
2010), which allows comparative in vivo studies.  Also the progression of SIV in 
macaques resembles HIV-1 infection in humans, with distinctive acute and 
chronic phases of infection that may lead to immunodeficiency (Hirsch et al., 
1996).  However, there are significant differences between SIV infection of non-
human primates and HIV-1 infection in humans. For example, the residual 
viraemia for SIV in rhesus macaques during chronic infection is higher than the 
levels seen in humans (Brenchley and Paiardini, 2011).  The progression of to 
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AIDS appears to be more rapid in rhesus macaques than in humans (North et al., 
2010).  In African green monkeys or sooty mangabeys, although high levels of 
virus replication are observed during the chronic phase of infection, this is not 
accompanied by the destructive chronic immune activation seen in rhesus 
macaques or humans (Brenchley and Paiardini, 2011, Chahroudi et al., 2012).  
Also different strains of SIV can produce different pathologies in the same host 
(Hirsch et al., 2000).  The complexity of finding the right host and SIV strains 
that best mimic HIV-1 latent infection, together with issues such as ethical 
concerns and high cost have led to the development of other, non-primate 
animal models for HIV-1 infection such as the humanized severe combined 
immunodeficiency (SCID) mouse models (Boberg et al., 2008, Van Duyne et al., 
2009, Brooks et al., 2001).  These are created by transplanting human foetal 
thymus and liver tissues or peripheral blood lymphocytes into SCID mice to form 
SCID-hu Thy/Liv and SCID-hu PBL mice systems respectively (Van Duyne et al., 
2009).  A major drawback of using SCID-mice-based models is the failure to fully 
reconstitute the human immune system within transplanted animals (Rossi et 
al., 2001, Van Duyne et al., 2009).  Further improvement to the efficiency of 
engraftment was achieved with the generation of the non-obese diabetic 
(NOD)/SCID mouse model (Hesselton et al., 1995) and later with the double 
knock-out of the common cytokine receptor γC and the recombinase activating 
gene 2 (Rag2) (Goldman et al., 1998).  The transplantation of human CD34+ stem 
cells into Rag2-/-γC-/- mice leads to the development of a functional human 
immune system in the body of the mouse (Traggiai et al., 2004) and forms the 
basis of a recent murine model of HIV-1 latency that contains infected resting T 
cells in the peripheral blood and lymphoid tissues (Choudhary et al., 2009, 
Choudhary et al., 2012).   A small animal model of HIV-1 where a natural host 
species interacts with an immunodeficiency-causing lentivirus would offer a 
valuable insight into potential strategies to overcome lentiviral latency.  
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Figure 1-8 – Elimination of the latent lentiviral reservoir.  Virus replication in 
latently infected resting T cells can be reactivated by phorbol esters (e.g. 
Prostratin), HDAC inhibitors or other therapeutic means.  The infected cell, 
previously invisible to the immune system, would now be detectable and targeted 
by the cytotoxic T cell response.  The process of virus replication may also induce 
cell death.  Intensive HAART prevents de novo infection of uninfected T cells.   
 
1.8 Scope of this thesis 
The pathology of lentivirus-induced AIDS has a complex aetiology and to fully 
comprehend the disease process many aspects of the biology of the host have to 
be incorporated.  The many intricate host-pathogen interactions mentioned 
above contribute to a state of chronic immune activation that is controlled by T 
cell signalling pathways.  Even lentiviral latency, which is characterised by a 
state of low T cell signalling activity also contributes indirectly to chronic 
immune activation by allowing viral persistence.  In this thesis I investigate 
different aspects of T cell signalling and their relationships with viral replication 
and pathology: 
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 In Chapter 3, the hypothesis that FIV Env binding to CD134 may trigger 
cell signalling is tested on in vitro model systems. 
 In Chapter 4, the concept that FIV-infected cats can be a model for HIV-
latency, as well as the hypothesis that Prostratin has both stimulatory and 
inhibitory effect on FIV replication similar to its effect on HIV-1 
replication were tested in vitro.   
 In Chapter 5, the hypothesis that an ‘early’ strain of FIV, GL8, has 
different replicative properties to that of a ‘late’ strain, PPR, in 
experiments that manipulate cellular signalling pathways as documented 
in Chapter 4 was tested in vitro. 
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2 Materials and Methods 
2.1 Cells, reagents, buffers and viruses 
2.1.1 Adherent cell lines 
HEK-293T, NFkB/293/GFP (System Biosciences, Mountain View, CA, USA), 
HT1080 (Rasheed et al., 1974), NP-2 (Yamazaki, 1982), HeLa, Chinese Hamster 
Ovary (CHO) cells and Crandall Rees Feline Kidney (CrFK) cells (clone ID10) were 
cultured in Dulbecco’s modification of Eagle’s Medium (DMEM) with high glucose 
(4.5g/ml) and 110 mg/L sodium pyruvate and supplemented with 10% foetal 
bovine serum (FBS), 100 IU/ml penicillin and 100μg/ml streptomycin.  This 
supplemented media will be referred to as ‘complete DMEM’.  All media and 
supplements were obtained from Invitrogen Life Technologies Ltd. (Paisley, 
United Kingdom) except for the foetal bovine serum, which was supplied by 
Thermo Fisher Scientific (Loughborough, UK).  Where appropriate, culture 
medium was supplemented with the antibiotics G418 (400 μg/ml; Invitrogen) or 
puromycin (1.25 μg/ml; Sigma Aldrich, Gillingham, UK) for transgene selection.  
Cells were grown at 37°C until confluent and then passaged by washing with 
phosphate buffered saline (PBS), digested with 0.05% Trypsin for less than 5 
minutes at 37°C, mixed with complete DMEM to halt trypsin activity, pelleted by 
centrifugation at 1000 rpm in a bench-top centrifuge, resuspended in fresh 
complete DMEM and re-seeded into new flasks at the appropriate density.   
2.1.2 Suspension cell line 
The majority of experiments described in chapter 4 and 5 were performed using 
the IL-2 dependent feline CD4+ T cell line MYA-1, which has been cultured from a 
FIV-infected cats in 1989 (Miyazawa et al., 1989) and has been cultured 
continuously since.  These cells are not considered to be primary CD4+ T cells, 
but retain some primary cell characteristics as they remain dependent on 
exogenous IL-2 for growth (Joshi et al., 2005a) and undergoes phases of blasting, 
rapid expansion and rest unlike the continuous rapid growth often associated 
with transformed cell lines.  The MYA-1 and canine lymphocytic leukaemia (CLL) 
(Willett et al., 2006b) cell lines were cultured in RPMI 1640 medium 
supplemented with 10% foetal bovine serum (FBS), 2mM glutamine, 100 IU/ml 
penicillin and 100μg/ml streptomycin.  This will be referred to as ‘complete 
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RPMI’.  For growing MYA-1 cells complete RPMI was further supplemented with 
conditioned medium from a murine cell line (L2.3) transfected with a human IL-2 
expression construct (equivalent to 100 U/ml of recombinant human IL-2) and 50 
μM 2-mercaptoethanol.  Cells were grown at 37°C until confluent and then 
pelleted by centrifugation at 800 – 1000 rpm with a bench-top centrifuge, 
resuspended in fresh complete RPMI and re-seeded into new flasks at the 
appropriate density.  Selection antibiotic was also used where appropriate (See 
Adherent cell lines).   
2.1.3 Plasmid vectors 
The retroviral expression vector pDONAI (Takara, Tokyo, Japan) and pRetroQ-
DSRed Monomer N1 (Clontech, CA, USA) were used to transduce and transfect 
cells with CD134 constructs FFF (feline wild-type CD134 (Willett et al., 2006b), 
HHH (human wild-type CD134 (de Parseval et al., 2005), FFHH (feline-human 
chimeric CD134 (Willett et al., 2006b).  Constructs expressing FIV GL8 or PPR Env 
SU Fc (de Parseval et al., 2004a) peptides were cloned into the vector pTorsten 
(Spiller et al., 2006).  The plasmids CMVi, which is a cytomegalovirus promoter-
driven MLV gag-pol expression vector (Bock et al., 2000), and pMDG, which 
contains the vesicular stomatitis virus (VSV) G-glycoprotein (Naldini et al., 
1996), were used to produce pseudotypes for transduction (See below).  FIV GL8 
or PPR env gene was cloned into the vector VR1012 (Vical Inc., San Diego, USA).  
The plasmid pNL4-3-Luc-E-R- (N. Landau, Aaron Diamond AIDS Research Center, 
the Rockefeller University) contains a defective HIV-1 NL4 provirus as well as the 
firefly luciferase gene.  Both of these vectors were used to produce pseudotypes 
for luciferase assays. 
FIV strains GL8 (Hosie and Jarrett, 1990) and PPR (Phillips et al., 1990) were 
grown in either CLL-CD134 or MYA-1 cell-lines.  Productive infection was 
confirmed by FIV p24 ELISA (see below) approximately one week after 
inoculation.  Cells were centrifuged at 3000 rpm for 3 minutes to break open 
cells and pellet cell debris.  The virus containing supernatant was then purified 
and concentrated by a double sucrose gradient centrifuged at 28,000 rpm for 2 
hours at 4°C (Beckman L8-70M Ultracentrifuge) and the virus pellets were 
resuspended in PBS and stored at -80°C.  Fresh virus aliquots were used in each 
experiment.   
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Chimeric viruses derived from GL8 and PPR-Mlu molecular clones (See below) 
were produced by transfection of the molecular clone into HEK 293T cells.  The 
0.45 μm filtered transfection supernatant was then incubated with MYA-1 cells 
for 2 hours.  The MYA-1 cells were then washed and cultured in complete RPMI 
plus IL-2 until productive infection was confirmed by FIV ELISA and the virus 
containing supernatant was processed in the same manner as described above. 
2.1.4 Ligands and chemicals 
Soluble CD134 ligand containing the trimerisation domain tenascin (TNC) and the 
human IgG Fc domain (Willett et al., 2007, Willett et al., 2009) was produced as 
described previously from the vectors pDONAI and pRetroQ-DSRed Monomer N1. 
Briefly, constructs were stably transduced into HEK 293T cells and the cells were 
grown in medium supplemented with low-IgG serum (Integra Biosciences, 
Hudson, NH, USA).  Ligand was purified from the culture medium by affinity 
chromatography using HiTrapTM Protein-A Sepharose columns (GE Healthcare, 
Little Chalfont, UK).  FIV Env SU Fc (de Parseval et al., 2004a) peptides from FIV 
GL8 or PPR were produced from the vector pTorsten. Constructs were stably 
expressed in CHO cells and the peptides were purified from culture supernatant 
with Protein-A Sepharose columns as above. 
The NFκB inhibitors CAPE (caffeic acid phenethyl ester), BOT64, SC514, JSH23 
and BAY 11-7082 were obtained from Merck Chemicals UK (Nottingham, UK).  
The phorbol ester Phorbol-12-myristate-13-acetate (PMA) was supplied by Merck 
Chemicals UK and Prostratin was supplied by Sigma Aldrich.  PKC inhibitor 
Gö6976 was supplied by Merck Chemicals UK and Gö6850 was supplied by Tocris 
(Bristol, United Kingdom).  The histone deacetylase inhibitors valproic acid and 
sodium butyrate were supplied by Sigma-Aldrich.  The HIV-1 integrase inhibitor 
Raltegravir (RGV) was obtained from Selleck Chemicals (Houston, TX, USA) while 
the nucleoside reverse transcriptase inhibitor Zidovudine (AZT) was supplied by 
Sigma Aldrich.  The activities of the aforementioned activators and inhibitors 
(including the feline CD134 ligand) are summarised below (Fig. 2-1). 
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Figure 2-1 – A schematic showing the sites of action for the molecules 
described in this thesis which affect cell signalling or virus replication.  fe 
stands for feline.  HDAC stands for histone deacetylase.  AZT stands for 
Zidovudine and RGV stands for Raltegravir. 
The cellular stain carboxyfluorescein diacetate succinimidyl ester (CFSE) was 
purchased from Invitrogen.  The non-ionic detergent Tween® (full name 
polyethylene glycol sorbitan monolaurate polyoxyethylenesorbitan monolaurate) 
was supplied by Sigma-Aldrich.  The dyes methylene blue and basic fuchsin were 
also supplied by Sigma-Aldrich.  The solvents methanol, ethanol and isopropanol 
were supplied by Fisher Scientific (Loughborough, UK).  Phenol and chloroform 
were obtained from Sigma-Aldrich. 
2.1.5 Transient transfection and stable transduction of cells 
Transfection of adherent cells was performed using SuperFect® transfection 
system (Qiagen, Crawley, UK) as per manufacturer’s protocol.  Briefly 1.5x106 
cells were seeded onto 10cm2 cell culture dishes and cultured overnight at 37°C.  
Up to 12 μg of vector DNA was added to 300 μl of serum free, antibiotic free 
DMEM medium.  60 μl of the SuperFect reagent was added and mixed thoroughly 
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and incubated at room temperature for 15 minutes.  Cells in culture dishes were 
washed with PBS.  At the end of the incubation, 3 ml of Complete DMEM was 
added to the mixture, which was then transferred to the washed cells.  The cells 
were incubated at 37°C for 3 hours and medium was changed.  The cells were 
then further incubated for 72 hours before downstream processes such as 
antibiotic selection took place.   
Stable transduction of cells involved the use of HEK 293T cells as producer of 
retroviral pseudotypes.  HEK 293T cells were transfected with the retroviral 
vector pDONAI containing the gene of interest (for example, feCD134), as well as 
the plasmids CMVi and pMDG to produce pseudotypes.  The pseudotypes-
containing supernatants from the transfected HEK 293T cells were then 
collected and filtered with a 0.45 μm filter and added to target cells (which had 
been seeded 1x105 cells per well in a 6-well plate the previous day and had been 
incubated at 37°C overnight).  After 6-hour incubation the target cells were 
transferred to 25cm2 flasks to be grown to confluency and selected with suitable 
antibiotic.   
2.1.6 Flow cytometry 
Flow cytometry was used to quantify cell growth using the CFSE (Invitrogen) 
staining method and to measure expression of FIV receptors CD134 and CXCR4 
over time (in separate experiments).  CFSE enters the cytoplasm of cells and 
binds to intracellular molecules.  During cell division the dye is transferred to 
daughter cells equally, which results in a reduction of fluorescence.  CFSE 
staining was performed as per manufacturer’s protocol but briefly: MYA-1 cells 
were resuspended in PBS with 0.1% w/v BSA that was warmed to 37°C at a 
concentration of 5x105 cells/ml. Then 1 μl of the 5 mM stock CFSE dye was added 
to each ml of cells to achieve a final dye concentration of 5 μM.  The cells and 
dye were incubated at 37°C for 10 minutes, followed by a quenching step in 
which five volumes of ice-cold complete RPMI was added to the cells.  After a 
further incubation of 5 minutes on ice the cells were washed three times using 
fresh complete RPMI and transferred to a suitable container in preparation for 
treatments with IL-2 or drugs. 
For the labelling of FIV receptors: 0.5 μg of primary antibodies (7D6, a mouse 
anti-feline CD134 monoclonal antibody (Willett et al., 2007) or the murine anti-
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feline CXCR4 monoclonal antibody from R&D Systems, Minneapolis, USA) were 
incubated with >1x104 cells for 30 minutes at 4°C.  Cells were washed with 1 ml 
of the PBAz wash buffer (1% w/v BSA (Sigma Aldrich) and 0.1% w/v of sodium 
azide (BDH Laboratory Supplies, Poole, UK) in PBS).  Secondary staining of the 
receptors was performed using 0.5 μg of rabbit anti-mouse IgG R-phycoerythrin 
(RPE) secondary antibody (AbD Serotec, Oxford, UK) for 30 minutes at 4°C.  Cells 
were then washed and resuspended in appropriate volumes of PBAz.    
Alternatively a fluorescein isothiocyanate (FITC) conjugated mouse anti-feline 
CD134 monoclonal antibody (AbD Serotec) was used as the primary antibody, 
removing the need for secondary staining.  Processed cells were analysed by 
flow cytometry using an EPICS MCS-XL flow cytometer (Beckman Coulter, High 
Wycombe, UK), with 10,000 events being collected for each sample in LIST 
mode.  Data was analysed using EXPO 32 ADC Analysis software (Beckman 
Coulter).   
2.2 CD134 signalling assays 
Before each assay, adherent cell lines HT1080, NP-2 and HeLa stably transduced 
with various CD134 constructs in the pDONAI retroviral vector were analysed 
using flow cytometry to ensure more than 90% of the cells expressed CD134.  
Cells were then seeded onto a 96-well plate at a density of 2x105 cells/ml and 
incubated overnight for cell adherence.  To determine the length of time for 
stimulated cells to reach maximum IL-8 production level, feline CD134L (0.5 
μg/ml) was added to the cells and supernatant was harvested after 5, 10, 20, 40, 
60, 90, 120, 180, 240, 360 minutes and IL-8 concentrations of the samples were 
measured by IL-8 ELISA.  To discover the minimum length of ligand stimulation 
that would induce maximum IL-8 production, cells were stimulated by CD134L 
for 0, 10, 20, 30, 40, 60 and 120 minutes before being washed and supernatant 
replaced with fresh complete DMEM.  IL-8 levels in the replaced medium were 
measured after a further incubation of six hours.  To determine the level of IL-8 
production from HT1080, NP-2 and HeLa cells transduced with CD134 and 
stimulated with CD134 ligands, FIV virions and/or the NFκB inhibitors CAPE and 
SC514, supernatant was harvested 6 hours after stimulation and IL-8 
concentrations measured by ELISA. 
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2.3 Reactivation of productive FIV infection from resting 
T cells 
IL-2 dependent MYA-1 feline CD4+ T cells were seeded at a density of 5x105 
cells/ml in the absence of IL-2 and 24 hours post-seeding they were infected 
with FIV GL8 or PPR at multiplicity of infection (M.O.I.) of 0.01.  Cells were then 
washed twice and incubated at 37°C in fresh complete RPMI without IL-2 
supplement.  The IL-2-depleted cells were stimulated with DMSO (control), PMA 
(0.08 µM), Prostratin (1 µM), sodium butyrate (1.5 mM), valproic acid (1.25 mM), 
and/or the PKC inhibitors Gö6976 (2.5 µM) or Gö6850 (2.5 µM) 2 days post-
infection (unless otherwise stated).  Samples were collected at indicated time 
points and the removed volume was replaced with a matched volume of 
complete RPMI containing the appropriate compounds.  Samples were stored at  
-80°C until the end of the experiment at which time virus levels in the culture 
supernatants were measured by either an enzyme-linked immunosorbent assay 
(ELISA) for FIV capsid antigen (CA, p24) (IDEXX PetCheck anti FIV antigen, IDEXX 
Laboratories, Maine, USA), or by non-isotopic reverse transcriptase assay (Lenti 
RT kit, Cavidi AB, Sweden) as per manufacturer’s instructions (see below). 
2.4 FIV productive infection assay 
Actively growing MYA-1 CD4+ T cells were seeded at a density of 5x105 cells/ml 
in the presence of IL-2 and infected with FIV GL8 or PPR (MOI = 0.01) for 2 hours 
at 37°C.  Cells were then washed and resuspended in complete RPMI 
supplemented with IL-2 and stimulated with DMSO (control), PMA (0.08 µM), 
Prostratin (1 µM), the NFκB inhibitors SC514 or JSH23 (Between 5 and 20 µM) 
and/or the PKC inhibitors Gö6976 (2.5 µM) or Gö6850 (2.5 µM) at 2 days post-
infection.  Samples of the culture supernatant were taken at day 8 post-
infection and the virus levels in the culture supernatants were measured by FIV 
p24 ELISA or by assaying reverse transcriptase activity.  Cell growth and viability 
was measured by Trypan Blue exclusion assay at day 8 post-infection. 
2.5 FIV syncytium formation assay 
To investigate the effect of phorbol esters on feline tetherin expression and 
virus spread, 3x105 CRFK ID10 cells were plated onto 6-well plates and allowed 
to settle overnight.  Cells were infected with equal doses of the cell-culture 
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adapted strain FIV-F14 for two hours before wash.   24 hours post infection PMA 
(0.08 μM), Prostratin (1 μM), feline IFN-ω (1000U/ml; Virbac Limited, Bury St 
Edmonds, UK) and DMSO (control) were added to the cells.  Each treatment was 
performed in duplicate.  Experiments were terminated 3 days post infection, the 
virus titre in the supernatant was measured by reverse transcriptase activity 
assay and the cells were stained with methylene blue/basic fuchsin (1% 
methylene blue, 0.2% basic fuchsin in 100% methanol) to visualise the formation 
of syncytia. 
2.6 Molecular cloning techniques 
2.6.1 Nucleic acid extraction from cells 
To extract both the total cellular DNA and RNA from infected MYA-1 CD4+ T cells 
for quantitative PCR, the Qiagen AllPrep DNA/RNA Mini kit was used.  Cells were 
homogenised using the QIAShredder spin columns (Qiagen).  RNA was treated 
with Qiagen RNase-Free DNase set on column as part of the AllPrep kit protocol 
to remove contaminating viral DNA.  DNA was eluted in the buffer EB and RNA in 
RNase-free water.  The Qiagen DNA Mini kit was used to extract total cellular 
DNA for confirmation of infection by PCR and in the viral entry quantitative PCR 
assay where RNA extraction was not needed. DNA was eluted in buffer AE.  
Supernatant FIV RNA was purified from 1 ml of culture supernatant using the 
Qiagen UltraSens Virus kit, as this kit is more suitable for extracting viral RNA 
from millilitre volumes of supernatant.  An internal control in the form of total 
cellular RNA from uninfected MYA-1 CD4+ T cells was added to all samples during 
the extraction process.  This was to provide a way to measure the efficiency of 
extraction in order to adjust the estimated FIV RNA copy number per ml of 
supernatant.   Extracted RNA was further processed by the Qiagen RNeasy Mini 
kit to remove contaminating FIV DNA.  Contamination of the extracted RNA were 
not detected by qPCR in most sample at all the time points, the exceptions 
being samples from IL-2 supplemented, productively infected cells at day 7 and 
day 10 post infection.  The quantities of the contaminated DNA were less in 
0.01% of the quantity of FIV cDNA detected.  To extract total RNA from 
uninfected cells, samples were homogenised using the QIAShredder spin columns 
(Qiagen) and RNA extracted using the RNeasy spin column kit (Qiagen).  RNA was 
eluted in RNase-free water.  Nucleic acids were quantified by a Nanodrop 2000 
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spectrophotometer (Thermo Fisher Scientific).  Eluted DNA was stored at -20°C 
and eluted RNA was stored at -80°C. 
Phenol chloroform extraction was also performed to extract DNA from high and 
low molecular weight DNA as part of the Hirt protocol.  Resuspended DNA was 
added to equal volumes of phenol: chloroform: isopentyl alcohol mixture in a 1.5 
ml Eppendorff tube.  The sample was shaken vigorously for 20 seconds and 
centrifuged at 13,000 rpm for 5 minutes at room temperature to separate the 
aqueous and organic phases.  The DNA-containing aqueous phase was removed 
by pipette and added to equal volume of chloroform: isopentyl alcohol.  This 
was shaken vigorously for 20 seconds and centrifuged at 13,000 rpm for 5 
minutes at room temperature.  The DNA from the aqueous phase of the 
chloroform extraction was then purified using ethanol precipitation.  DNA was 
made up to 100 µl in dH2O and 200 µl of 100% ethanol was added, followed by 1 
µl of 3M sodium acetate.  The mixture was incubated at -80 °C for at least 30 
minutes and then centrifuged at room temperature in a table top 
microcentrifuge for 15 minutes at full speed.  The supernatant was removed 
carefully and 200 µl of 70% ethanol was added.  Samples were centrifuged at top 
speed for a further 10 minutes.  The supernatant was then removed and the DNA 
pellets were air-dried.   
2.6.2 Polymerase chain reaction (PCR) 
The presence of FIV viral DNA in infected MYA-1 CD4+ T cells was confirmed by 
using polymerase chain reaction (PCR) and the primers (manufactured by Eurofin 
MWG, Germany) LTR Forward 3 (5’-GCTTAACCGCAAAACCACAT-3’) and Gag 
Reverse 3 (5’-CAAATCTCCTGGCTTGAAGG-3’) amplifying a 466bp region between 
the 5’ LTR and gag of the FIV provirus.  To detect FIV LTR circles, the primers 
Env sense 1 (5’-GGCAATGTGGCATGTCTGAAAAAGAGGAGGAATGATG-3’) and Gag 
Reverse 3 were used.  They produce two products which are approximately 1kb 
(1-LTR) and 1.3 kb (2-LTR) in size.  The aforementioned primers are specific for 
FIV GL8 and PPR strains.  Primers that bind to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) gene were used as controls for equal DNA loading 
(GAPDH Forward: 5’-CCTTCATTGACCTCAACTACAT-3’; GAPDH Reverse: 5’-
CCAAAGTTGTCATGGATGACC-3’).  All reactions used GoTaq® Flexi DNA 
Polymerase kit (Promega, Madison, WI, USA) as per manufacturer’s protocol but 
with the following cycling parameters: An initial denaturation step of 3 minutes 
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at 95°C was followed by 35 cycles of denaturation at 95°C for 45 seconds; 
annealing at 57°C for 45 seconds and extension at 72°C for 1 minute.  The 
amplification was completed with a final extension step at 72°C for 10 minutes.  
In certain experiments the cycle number was lowered to 27 to make the PCR 
more sensitive to small differences in template quantity. 
Roche (Mannheim, Germany) High Fidelity PCR Master reaction mix was used to 
amplify specific regions of FIV genome for the construction of chimeric viruses.  
Between 50 - 100 ng per DNA template was used.  Reactions were set up 
according to the manufacturer’s protocol and performed as followed: An initial 
denaturation step of 5 minutes at 94°C was followed by 35 cycles of 
denaturation at 94°C for 30 seconds; annealing at 55°C for 30 seconds and 
extension at 72°C for between 1 to 5 minutes.  The amplification was completed 
with a final extension step at 72°C for 10 minutes.    All PCR products were 
visualised by 2% agarose gel electrophoresis followed by ethidium bromide 
staining. 
2.6.3 DNA sequencing 
DNA sequencing was carried out using the BigDye v1.1 system (Applied 
Biosystems) as per manufacturer’s protocol.  Between 150 – 300 ng of DNA 
template was used per reaction.  Reactions were purified by ethanol 
precipitation (see the section Nucleic acid extraction from cells) and 
resuspended in 20 μl of HiDi Formamide (Applied Biosystems) and sequenced 
using an ABI 7000 genetic analyser (Applied Biosystems).  Output sequence 
traces were analysed in DNA Dynamo (Blue Tractor Software). 
2.6.4 Mutagenesis 
In-vitro mutagenesis of FIV molecular clones was carried out using the 
QuikChange® II XL Site-Directed Mutagenesis Kit (Agilent Technologies, 
Stockport, UK) according to the manufacturer’s protocol.  Mutagenic primers 
(Appendix 4) containing the desired point mutation and complementary to both 
strands of the vector were designed using the online QuikChange® Primer Design 
Program (http://www.genomics.agilent.com/homepage.aspx).  Primers were 
synthesised by MWG Eurofins.  Mutant strand synthesis reaction was then carried 
out using plasmid DNA template isolated from a dam+ E.coli strain, which 
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produces methylated plasmid DNA (DH5α and XL-1 Blue strains are appropriate).  
Reactions were set up using 5 µl of 10x reaction buffer, 125 ng of each 
mutagenic primer, 1 µl of dNTP mix, 3 µl of QuikSolution, 50 ng of template 
plasmid dsDNA, 1 µl of PfuUltra HF DNA polymerase (2.5U/μl) and dH2O up to 50 
µl.  Thermal cycling was performed with an initial denaturing step at 95°C for 1 
minute, followed by 18 cycles of denaturation at 95°C for 50 seconds; annealing 
at 60°C for 50 seconds and extension at 68°C for 14 minutes.  The amplification 
was completed with a final extension step at 68°C for 7 minutes.  Reactions 
were cooled on ice and 1 µl of Dpn I restriction enzyme (10U/μl), which digests 
methylated and hemimethylated parental DNA template, was added directly to 
each reaction.  Digestion was carried out at 37°C for 1 hour.  The remaining 
mutated DNA was purified up by ethanol precipitation (see DNA sequencing) and 
resuspended in 5µl TE buffer.  The entire volume of the mutagenesis was used in 
the transformation of XL-10 Gold® Ultracompetent cells (Agilent Technologies).  
After ampicillin selection, clones were grown up in lysogeny broth (LB) overnight 
and their plasmids were extracted using the Qiaprep Spin Miniprep kit (Qiagen).  
The nucleic acid sequence of each mutated construct was confirmed as above. 
2.6.5 Substitution of FIV-LTR and env regions in the molecular 
clones 
The molecular clone of FIV GL8 or PPR consists of the full proviral DNA sequence 
of each virus cloned into the vector backbones pBR328 and pUC119 respectively.  
The substitution of the 5’ LTR and env was performed separately.  Separations of 
restriction digest fragments were performed by electrophoresis on a 0.8-2% 
agarose gel, stained with ethidium bromide.  DNA was visualised by UV-
transillumination and bands of the expected sizes were excised using a scalpel.  
Gel extraction was carried out using the Qiaquick Gel Extraction kit (Qiagen).  
FIV 5’ LTR: The first 509 nucleotides of the 5’LTR was excised using the 
restriction enzymes EcoRI (which was originally used to clone each provirus into 
its respective vector) and SacI (at nucleotide 509).  However, the existence of 
downstream SacI (for GL8) and EcoRI (for PPR) sites meant that the initial digest 
had to be performed with another restriction enzyme that cut once downstream 
of the SacI site.  NcoI, which has a unique site at nucleotide position 2500 was 
chosen.  This fragment was digested again with SacI and the original 5’LTR was 
replaced with one from a different virus.  A double ligation was then performed 
to reconnect the 5’LTR to the remainder of the NcoI restriction fragment and 
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subsequently to join the fragment with the molecular clone.  FIV env: the env 
sequence from each molecular clone was exchanged by restriction digest with 
MluI and NdeI and subsequent re-ligation of the replacement env fragments; the 
GL8 mya molecular clone contains an engineered MluI site 256 nucleotides into 
the env gene at the L-SU junction.  The PPR molecular clone does not contain a 
MluI cut site in the env gene.  Mutagenesis of the vector was required to 
generate a MluI site at the same location as GL8 molecular clone.  In total 3 
mutations were performed at nucleotides 6515, 6517 and 6519 in 3 steps, 
resulting in an amino acid substitution A86V. The restriction enzyme NdeI cuts at 
a site downstream of the env gene in the RRE.  For the GL8-LTR-env-(PPR) 
double chimeric molecular clone, the GL8 env was exchanged before the LTR.  
See Figure 5-7 for a schematic of all the chimeric viruses. 
After an overnight ligation reaction with T4 ligase (Invitrogen), the molecular 
clones were transformed into competent cells and plated onto LB agar with 100 
μg/ml ampicillin.  Various strains of competent cells were investigated, 
including DH5α (Invitrogen), XL-1 Blue and XL-10 Gold (Agilent Technology); the 
best results were obtained when transformations were performed with XL-10 
Gold.  X-Gal IPTG blue/white colony screening was used when appropriate.  
Colonies were picked and grown in 3 – 5 ml of LB broth at 30°C in an orbital 
shaker set at 200 rpm overnight (a temperature lower than 37°C was used to 
ensure plasmid stability).  Extraction of plasmid DNA was carried out using the 
Qiaprep Spin Miniprep kit.  Large scale DNA prep was made by inoculating 300- 
500ml LB broth with bacterial clones and grown overnight.  Plasmid DNA was 
extracted using PureLink HiPure Filter Plasmid Maxiprep Kit (Invitrogen).  
Pelleted DNA was resuspended in TE buffer, the DNA concentration was 
measured using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific).  
Cultures of clones were diluted with glycerol to make 50% glycerol stock for long 
term storage. 
2.6.6 Modified Hirt Protocol 
The Hirt protocol (Hirt, 1967) was originally used to separate out low molecular 
weight (LMW) DNA from contaminating genomic DNA, which is much larger in 
size.  This protocol was modified in order to isolate only the genomic DNA from 
infected cells and not unintegrated viral DNA.  The Hirt lysis buffer for the Hirt 
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method consisted of 0.6% sodium dodecyl sulphate (SDS) and 10 mM EDTA pH 
7.5.  See chapter 4 for full description. 
2.7 Quantitative methods 
2.7.1 Human IL-8 ELISA  
The OptEIATM Human IL-8 kit (BD Biosciences – cat. No. 555244) was used to 
detect IL-8 produced by the HT1080 cells as per manufacturer’s protocol.  
Briefly, stock capture antibody was diluted 1 in 250 with coating buffer (8.40g 
NaHCO3, 3.56g Na2CO3 to 1.0 L; pH to 9.5) and 100 μl of the diluted antibody was 
used to coat the wells of high binding ELISA strips (Immulon® 2 HB 2x8 strip 
assemblies from Thermo Fisher Scientific).  The strip assemblies were incubated 
overnight at 4°C.  The strips were then washed with phosphate-buffered saline –
Tween® (PBS-T) and blocked with assay diluent (PBS with 10% FBS) for 1 hour at 
room temperature.  The strips were then washed with PBS-T and 100 µl of each 
sample was then pipetted into the appropriate wells and incubated at room 
temperature for 2 hours.  Bound IL-8 was detected using the working detector 
prep (detection antibody and streptavidin-horseradish peroxidase (HRP) 
conjugate diluted 1 in 250 in assay diluent) and strips were developed using 
tetramethylbenzidine (TMB) substrate (Sigma-Aldrich).  HRP-TMB reactions were 
stopped using 1M hydrochloric acid the absorbance of each well was read at 
450nm using the Multiskan Ascent plate reader (Labsystems). 
2.7.2 Feline IFN-γ and IL-4 ELISA 
The concentrations of feline IFN-γ or IL-4 in the supernatant of MYA-1 CD4+ T 
cells were measured using the DuoSet® ELISA Development System (R&D 
Systems) as per manufacturer’s protocol with the following minor modifications: 
Capture antibodies against IFN-γ or IL-4 were diluted in serum-free, antibiotic-
free DMEM to working concentrations of 1.5 µg/ml and 4.0 µg/ml respectively 
and were used to coat the wells of high binding ELISA strips (Immulon® 2 HB 2x8 
strip assemblies from Thermo Fisher Scientific).  After washing with PBS-T, the 
coated wells were blocked with 200 µl of 0.2% skimmed milk powder dissolved in 
PBS-T overnight at 4°C.  100 µl of samples were then added to appropriate wells 
and incubated at room temperature for 2 hours.  Bound cytokines were detected 
using biotinlyated detection antibody against the appropriate cytokine (anti-IFN-
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γ antibody - 200 ng/ml; anti-IL-4 antibody - 300 ng/ml) and streptavidin-HRP and 
visualized by the addition of TMB substrate.  HRP-TMB reactions were stopped 
using 1M hydrochloric acid and the absorbance of each well was read at 450nm 
using the Multiskan Ascent plate reader. 
2.7.3 FIV p24 ELISA 
The presence of FIV capsid antigen (CA, p24) in tissue culture medium or whole 
cell lysate was measured by ELISA.  Anti FIV p24 specific monoclonal antibody 
VPG62 stock was diluted to a concentration of 2 ng/ml with serum-free, 
antibiotic-free DMEM.  100 µl of the diluted antibody was pipetted into each well 
of high binding ELISA strips (Immulon® 2 HB 2x8 strip assemblies from Thermo 
Fisher Scientific).  The strip assemblies were incubated at room temperature for 
1 hour and then washed three times with PBS-T and blocked overnight with 200 
μl of 0.2% skimmed milk powder dissolved in PBS-T at 4°C.  The strips were 
washed once with PBS-T and 10 μl of sample treatment solution (100mM Tris, 
1.5M NaCl, 5% Triton, 5% deoxycholale, 1% SDS, 50mM EDTA and 0.1% azide for 
10X solution) were added, followed by 100 μl of each sample.  After an 
incubation period of 1 hour at room temperature the wells were washed five 
times with PBS-T and 2 drops of the anti-FIV HRP conjugate (IDEXX PetCheck anti 
FIV antigen, IDEXX Laboratories, Maine, USA) were added.  The strips were 
incubated for 1 hour at room temperature and then washed five times with PBS-
T.  100 μl of TMB solution were added to each well and 50 μl of 1M hydrochloric 
acid was used to stop the HRP-TMB reaction and the absorbance of each well 
was read at 450nm using a Multiskan Ascent plate reader. 
2.7.4 Reverse transcriptase activity assay 
Reverse transcriptase (RT) activity of the supernatant samples was measured 
using Lenti RT Activity kit (Cavidi AB, Sweden).  This technique quantifies RT 
activity by its ability to reverse transcribe a polyriboadenosine template 
attached to the wells of a 96-well plate.  Between 150 and 200 µl of reaction 
mixture containing a primer and the nucleotide analogue 5-bromo-deoxyuridine-
5’-triphosphate (BrdUTP) was added to each well of the kit poly-A plate.  
Depending on the level of sensitivity required, 10 to 40 µl of sample was then 
added to appropriate well up to a final volume of 210 μl.  The plate was sealed 
with adhesive cover tape and incubated overnight at 33°C.  The wells were then 
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washed 5 times with RT wash buffer to stop reverse transcription.  100 μl of RT 
Product Tracer containing an alkaline phosphatase (AP) conjugated anti-BrdU 
antibody was added to quantify the amount of BrdU, which is directly 
proportional to the reverse transcriptase activity and visualized by the reaction 
of the AP with a  colourimetric substrate.   Absorbance at 405nm of each well 
was read by Multiskan Ascent plate reader.   
2.7.5 Luciferase viral entry assay 
FIV strain GL8 env gene was expressed from the vector VR1012 (Shimojima et 
al., 2004, Willett et al., 2006b).  5 μg of the FIV env expression constructs plus 
7.5 μg of pNL4-3-Luc-E-R- were co-transfected into HEK 293T cells (See above).  
Culture supernatant from transfected cells containing the HIV (FIV) pseudotypes 
were collected 48 hours post transfection, filtered at 0.45 μm and stored at -
80°C till required. 
5x104 MYA-1 CD4+ T cells were then seeded into each well of a CulturePlateTM 96 
assay plate (Perkin Elmer) and cultured with 50 μl of the thawed HIV (FIV) 
pseudotype-containing supernatant for 72 hours.  Luciferase activity was 
quantified by the addition of 100 μl of Steadylite HTSTM (Perkin Elmer) luciferase 
substrate prior to measurement by single photon counting on a MicroBetaTriLux 
luminometer (Perkin Elmer). 
2.7.6 Quantitative PCR 
Quantitative PCR was used to accurately determine the amount of FIV DNA and 
cDNA.  Purified RNA was reverse transcribed into cDNA using the Roche 
Transcriptor High Fidelity cDNA synthesis kit.  Manufacturer’s protocol was 
followed and RNA was reverse transcribed using the random hexamer primer.  
The FIV GL8-specific primers FIV1360F (5’-GCA GAA GCA AGA TTT GCA CCA-3’) 
and FIV1437R (5’-TAT GGC GGC CAA TTT TCC T3’) plus the Taqman probe 
FIV1416P (5’-FAM-TGC CTC AAG ATA CCA TGC TCT ACA CTG CA-TAMRA-3’) were 
used to amplify a 78bp section of the FIV GL8 gag gene.  Primers and probes 
which amplify feline 18S rRNA (343-Fwd: 5'-CCA TTC GAA CGT CTG CCC TA-3'; 
409-Rev: 5'-TCA CCC GTG GTC ACC ATG-3', and probe: 5'-FAM-CGA TGG TAG TCG 
CCG TGC CTA-TAMRA-3') were used as internal control.  The final concentrations 
of primers and probes were 900 nM and 225 nM respectively.  The primers, 
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probes and templates were combined with TaqMan Universal Master Mix (Applied 
Biosystems) to a final volume of 20 μl per reaction in MicroAmp Optical 96-well 
reaction plates (Applied Biosystems).  Thermo cycling was performed with an 
initial denaturing step at 95°C for 5 minutes, followed by 40 cycles of 
denaturation at 95°C 15 seconds; annealing and detection at 55°C for 60 seconds 
and measurements were taken using an ABI 7500 thermal cycler (Applied 
Biosystems).  Results were analysed using the Sequence Detection Software v1.4 
(Applied Biosystems). Relative quantities of nucleic acid were calculated using 
the ΔΔCt method: ΔCt values (Ct = threshold cycles) were calculated by 
subtracting the FIV gag Ct value of each replicate from its 18S Ct value.  Each 
ΔCt value was subtracted from the average ΔCt of the mock-treated cells at Day 
0 post infection to obtain ΔΔ Ct. which was then converted to relative quantity 
using the formula: 2(-ΔΔ Ct).   The mean and standard deviation of the triplicates 
of each condition at each time point was plotted on graph.  This assay can 
detect a minimum of 10 copies of spiked FIV plasmid per reaction, equivalent of 
a theoretical minimum of 350 copies per ml of supernatant. 
2.8 Protein visualization 
2.8.1 SDS-PAGE and Western blotting 
To estimate the amount of FIV p24 in the virus stocks, they were processed by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
visualised by western blotting along with samples of recombinant FIV p24 of 
known concentrations.  Protein samples were boiled at 100°C for 5 minutes in 
SDS-PAGE protein loading buffer.  PAGE was performed in NuPAGE® 4-12% Bis-
Tris gels (Invitrogen) and the transfer of protein to nitrocellulose membrane was 
carried out using the iblot rapid dry blotting system (Invitrogen).  The 
nitrocellulose membrane was blocked overnight in blocking solution consisted of 
5% Marvel skimmed milk powder dissolved in PBS-T.  The anti-FIV p24 primary 
antibody VPG50 was incubated with the membrane at a dilution of 1 in 1000 for 
30 minutes, followed by 5 washes with PBS-T and incubation with the horse-anti-
mouse IgG biotinylated secondary antibody (Vector Laboratories) for 30 minutes.  
Protein bands were visualised using the Vectorstain® ABC (avidin-biotinylated 
enzyme complex) system and 5-bromo-4-chloro-3-indolyl phosphate/nitroblue 
tetrazolium (BCIP/NBT) substrates. 
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2.9 Statistics 
Data was analysed for statistical significance using the One Way Analysis of 
variance (ANOVA) test with the Bonferroni and the Tukey post-hoc means 
comparison tests from OriginPro 8.6 (OriginLab Corp. USA) where indicated.
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3 Investigation of virus binding and CD134 
signalling 
3.1 Summary 
The primary receptor for FIV is CD134 (OX40) (Shimojima et al., 2004).  CD134 is 
an important co-stimulatory molecule involved in T cell activation and the 
establishment of memory T cells (Croft, 2003, Sabbagh et al., 2007, Croft et al., 
2009).  The binding of CD134 to its ligand activates the NFκB and PI3K/Akt 
signalling pathways, which promote T cell function, expansion and survival (Song 
et al., 2004, Croft, 2010).  FIV preferentially infects activated CD4+ T cells; 
however, most of the T cells in the body are at a resting state (Dean et al., 
1996a, Berard and Tough, 2002, Joshi et al., 2005b).  Thus, hypothetically, it 
would be advantageous for the virus to trigger CD134 signalling by the binding of 
the virus or Env protein to its primary receptor, making the cell more conducive 
to productive infection or extending the lifespan of infected cells.  Indeed it has 
been shown that HIV-1 Gp120 Env protein stimulates T cell signalling (Kornfeld 
et al., 1988, Wu and Yoder, 2009).  To investigate whether FIV exploits its host 
cell this way, an attempt was made to detect any changes to CD134 signalling 
during virus binding using the following strategies: 
1. To transiently or stably express feline CD134 in non-T cell lines and 
measure activation of CD134 by quantifying release of cytokine (IL-8) or 
the expression of a reporter gene under the control of NFκB. 
2. To detect changes in signalling in feline CD4+ T cells (MYA-1) caused by 
the addition of CD134L or FIV. 
3.2 Results 
3.2.1 No enhancement of NFκB signalling by FIV binding to feline 
CD134 expressed on interleukin-8 (IL-8) producing cells  
IL-8 is produced by many different cell types and its expression is regulated by 
NFκB (Hoffmann et al., 2002).  The production of IL-8 has been used as an 
indicator for cell signalling activity, including the activity of the human CD134 
signalling pathway (Muller et al., 2008).  Thus I attempted to detect changes in 
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cell signalling induced by FIV binding to CD134 by quantifying IL-8 release from 
cells.  HT1080, NP-2, and HeLa cells were stably transduced with a feline CD134 
construct, a human CD134 construct, a feline-human chimera construct and 
vector only control.  After the expression of CD134 was confirmed on these cells 
by flow cytometry (Table 3-1), experiments were performed to measure IL-8 
production from these cells in response to stimulation of CD134. 
  
 
Table 3-1 – High levels of different CD134 are expressed by transduced 
HT1080, NP-2 and HeLa cell lines.  Cells were transduced with expression 
constructs in the pDON-AI retroviral vector expressing feline (FFF), human (HHH) 
or feline-human chimeric (FFHH) CD134.  PE = phycoerythrin. 
IL-8 production by HT1080 cells has been used to measure human CD134 
signalling (Muller et al., 2008), thus it was the first cell line to be tested as to 
whether it can be used to measure signalling from feline CD134.  HT1080 cells 
stably transduced with feline, human, feline-human chimera CD134 or vector 
control were seeded onto 96-well plates and stimulated with either recombinant 
soluble human, feline or murine trimeric CD134 ligands (Willett et al., 2007, 
Willett et al., 2009).  A concentration of 0.5 μg/ml for each ligand was tested 
initially based on the activity of the ligands in previous studies (Willett et al., 
2007, Willett et al., 2009).  HT1080 cells expressing feline CD134 produced IL-8 
in response to the addition of feline and murine ligands (Fig. 3-1A), the latter 
Cell line Construct Primary Antibody 
% cells 
gated (PE) 
Mean 
fluorescence 
HT1080 FFF anti-CD134 (7D6) 96.45 68.5 
  no antibody 0.5 13.1 
 HHH anti-CD134 (7D6) 59.8 21.2 
  no antibody 0.4 4.4 
 FFHH anti-CD134 (7D6) 79.14 43.6 
  no antibody 0.04 5.6 
 Vector only anti-CD134 (7D6) 1 10.8 
  no antibody 0.9 5.9 
NP-2 FFF anti-CD134 (7D6) 93.8 11.4 
  no antibody 0.6 0.3 
 Vector only anti-CD134 (7D6) 0.6 0.3 
  no antibody 0.7 0.3 
HeLa FFF anti-CD134 (7D6) 98.64 78.7 
  no antibody 3.94 1.9 
 HHH anti-CD134 (7D6) 90.7 40.8 
  no antibody 4.5 1.8 
 Vector only anti-CD134 (7D6) 5.16 1.6 
  no antibody 6.46 1.5 
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has been shown to bind promiscuously to both human and feline CD134 (Willett 
et al., 2007) and in this experiment murine ligand induced higher IL-8 
production.  As expected, human CD134 ligand did not trigger IL-8 production 
from HT1080 cells expressing feCD134, and feline CD134 ligand did not trigger IL-
8 production from HT1080 cells expressing huCD34 (Fig. 3-1A and B).    Murine 
and human ligands triggered IL-8 production in cells expressing the feline human 
chimera, consistent with the fact that the chimeric receptor contains human 
CD134 residues at amino acid positions 78 to 80, which are crucial for CD134L 
binding (Fig. 3-1C) (Compaan and Hymowitz, 2006, Willett et al., 2007). 
Next the dynamics of CD134 signalling were investigated.  To deduce the 
minimum period of time for stimulated cells to reach maximum production of IL-
8, feline CD134L was added to the feline CD134-expressing HT1080 cells and 
supernatant was collected after 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 
minutes.  Results showed that after stimulation, IL-8 production remained low 
during the first 100 minutes, then increased rapidly between 100 to 200 minutes 
post-stimulation before reaching a plateau after 240 minutes (4 hours).  
However it is unknown whether this plateau reflected a physiological negative 
feedback mechanism or rather represented the saturation of the ELISA (Fig. 3-
2A).  To discover the minimum length of ligand stimulation that would induce 
maximum IL-8 production, the cells were stimulated by CD134L for 0, 10, 20, 30, 
40, 60 and 120 minutes before being washed and supernatant replaced with 
fresh medium.  IL-8 levels in the replaced medium were measured after a 
further incubation of six hours.  Results demonstrated that the final supernatant 
IL-8 concentration depended upon the length of the contact between the cells 
and the ligand.  Efficiency of stimulation initially rose quickly, with stimulation 
for just 10 minutes achieving a final IL-8 concentration that was 70% of the 
maximum.  With longer stimulation the rate of increase in final IL-8 production 
slowed down and eventually peaked at 60 minutes (Fig. 3-2A).  Based on these 
results it was decided that the ligand should be applied to the cells for at least 
60 minutes and supernatant from cells collected after an incubation of at least 6 
hours.  
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Figure 3-1 – HT1080 cells transduced with CD134 exhibit species specificity 
towards ligand.  HT1080 cells stably expressing (A) feline, (B) human, (C) 
chimeric feline/human CD134 (FFHH) or (D) empty vector were stimulated with 
feline, murine or human CD134 ligands (0.5 μg/ml).  Supernatant IL-8 
concentration was measured by ELISA.  Each bar represents the mean +/- 
standard error (n= 3).  
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Figure 3-2 – The dynamics of CD134 signalling in HT1080 cells.  (A) Cells 
were stimulated with feline CD134L and supernatant collected at specified times 
post-stimulation to be measured by IL-8 ELISA.  (B) Cells were stimulated for 
specified times by feline CD134L and then replaced with fresh medium without 
A B 
C D 
A B 
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ligand.  Replacement media was collected after 6 hours and processed by IL-8 
ELISA.  Each point represents the mean +/- standard error (n= 3). 
The ‘early’ strain of FIV GL8 and the ‘late’ strain PPR were grown in MYA-1 CD4+ 
T cells and virions were purified by double sucrose gradient to minimise 
contamination with cellular debris.  Different concentrations of the purified 
virus were then added to feline CD134 HT1080 cells to investigate whether 
CD134 signalling is triggered by the presence of the virus.  Application of FIV 
particles, even at high doses, did not induce an increase in IL-8 production 
(Fig.3-3). 
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Figure 3-3 – Purified FIV does not stimulate IL-8 production in HT1080 
feCD134 cells.  (A) The concentrations of purified viruses were estimated by 
comparing with recombinant GST-tagged FIV p24 protein of known concentrations 
on an immunoblot. (B) FeCD134L (0.5 μg/ml) or purified FIV GL8 or PPR were 
incubated with the feline CD134-expressing HT1080 cells for 6 hours and IL-8 
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production were measured by ELISA.  Each bar represents the mean +/- standard 
error (n= 4).   
If FIV and feline CD134L bind to the same site on CD134, the virus may interfere 
with CD134L binding and reduce downstream signalling.  Alternatively, if FIV and 
feline CD134L bind to distinct sites on CD134, Env-binding may augment 
signalling.  To investigate, HT1080 cells expressing feline CD134 were pre-
incubated with purified FIV prior to the addition of feline CD134L and IL-8 
production measured.  In 6 out of 8 repeat experiments, neither strain of virus 
affected ligand-induced IL-8 production (Fig. 3-4A).  The same result was 
observed when the order of application was reversed and the cells were pre-
incubated with ligand before the addition of FIV (Fig. 3-4B).  However, in 2 of 
the repeats FIV reduced IL-8 production in a dose-dependent manner when 
added before ligand, with FIV PPR causing a more intense reduction of IL-8 
production than FIV GL8 (Fig. 3-4C).  When feline CD134L was added first, FIV 
GL8 increased IL-8 production by the same amount regardless of virus 
concentration (Fig. 3-4D).  In contrast, the titre of FIV PPR was negatively 
correlated with enhancement of IL-8 production, with the lowest virus titre 
producing the largest enhancement (Fig. 3-4D).   
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Figure 3-4 – Effect of purified FIV on the production of IL-8 by transduced 
HT1080 cells in response to feline CD134 ligand stimulation.  Various 
concentrations of FIV particles were added to feline CD134-expressing HT1080 
cells 1 hour before (A and C) or after (B and D) the application of feline CD134 
ligand (at 0.5 µg/ml).  The cells were further incubated with the virus and ligand for 
another 6 hours before supernatant was harvested.  (A and B) are representative 
of 6 independent experiments while (C and D) are representative of 2 independent 
experiments.  Each point represents the mean +/- standard error (n= 3). 
 
Given the inconsistent observations with the feline CD134-expressing HT1080 
cells, the effects of FIV on IL-8 production for two additional cell lines were 
investigated.  The human glioma cell line NP-2 (Yamazaki, 1982) and epithelial 
adenocarcinoma cell line HeLa were stably transduced with CD134 as previous 
(Table 3-1) and their responses to CD134 ligand examined.  Background IL-8 
production from the transduced NP-2 cells was 7 times higher than transduced 
HT1080 cells (Fig 3-5A).  Application of feline CD134 ligand to NP-2-feCD134 cells 
A B 
C D 
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induced a large increase in IL-8 production from the cells.  The presence of FIV 
virions enhanced IL-8 production from NP-2 cells in one independent experiment 
(Fig. 3-5B).  However, this trend was not replicated in two further independent 
experiments (Fig. 3-5C). 
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Figure 3-5 – Effect of purified FIV on IL-8 production from feline CD134-
expressing NP-2 cells (A) NP-2 and HT1080 cells transduced with feline CD134 
or the vector pDON-AI alone (control) were left unstimulated for 6 hours before 
supernatant was collected for measurement.  Each bar represents the mean +/- 
standard error (n= 3).  (B) NP-2 CD134 cells were pre-incubated with feCD134L 
(0.5 μg/ml) for 1 hour before the addition of purified FIV GL8 or PPR and the cells 
were further incubated for 6 hours post virus addition before supernatant was 
harvested.  Dotted lines represent the background levels of IL-8 production.  Each 
point represents the mean +/- standard error (n=3) 
The response of HeLa cells to stimulation with CD134 ligand was different to the 
responses of HT1080 or NP-2 cells.  HeLa cells transduced with feline CD134 
produced very little IL-8 when stimulated with feline CD134 ligand compared 
with the stimulation of human CD134-transduced cells with human CD134 ligand 
A 
B C 
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(Fig. 3-6).  The lack of a strong response to stimulation with feCD134L by HeLa 
cells suggested that they were not a suitable cell line for the purpose of 
investigating the signalling of feline CD134. 
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Figure 3-6 – HeLa cells transduced with feline CD134 do not respond to 
trigger by feline ligand.  HeLa cells transduced with feline or human CD134 were 
stimulated with feline CD134 ligand (A) or human CD134 ligand (B).  The ligands 
were added at a concentration of 0.5 µg/ml.  Control = cells transduced with 
pDON-AI vector.  Each bar represents the mean +/- standard error (n= 3). 
The major downstream effector of CD134 signalling is NFκB (Croft, 2010).  This 
transcription factor is also an important driver of IL-8 production (Hoffmann et 
al., 2002) and human CD134 activation has been shown to induce IL-8 production 
(Muller et al., 2008).  To investigate the role of NFκB in IL-8 production by 
HT1080 CD134 cells, NFκB inhibitors SC514 and CAPE were added to feCD134 
ligand-stimulated cells.  Unexpectedly CAPE increased ligand-induced IL-8 
production by 25% as well as background IL-8 production by 55% (Fig 3-7A).  In 
contrast, addition of SC514 reduced ligand mediated IL-8 production by 50% (Fig. 
3-7B), consistent with the involvement of NFκB-dependent signalling in CD134-
driven IL-8 production.  To demonstrate the NFκB inhibiting properties of CAPE 
and SC514, they were added to NFkB/293/GFP reporter cells.  Results showed 
that the two NFκB inhibitors blocked TNF-α induced, NFκB-driven GFP 
production in (Fig. 3-9).  The surprising effect of CAPE on HT1080 cells may be 
explained by the fact that in addition to affecting NFκB, CAPE also affects other 
factors such as the mitogen activated protein kinase p38 (Natarajan et al., 1996, 
Wei et al., 2008) and has both pro and anti-apoptotic effects on a range of cells 
A B 
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(Fitzpatrick et al., 2001, Chen et al., 2008, Wei et al., 2008).  Thus it may not 
be appropriate to characterize it as a specific inhibitor of NFκB. 
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Figure 3-7 – Effect of NFκB inhibitors on IL-8 production from HT1080-
feCD134 cells.  Cells were pre-incubated with complete DMEM containing (A) 
CAPE (88 μM) or (B) SC514 (10 μM) and then stimulated by feCD134L (0.5 
μg/ml).  Cells were also mock-treated with DMSO for comparison.  Results are 
representative of 2 independent experiments.  Each bar represents the mean +/- 
standard error (n= 3). 
The preceding experiments on IL-8-producing adherent cells (HT1080, NP-2, 
HeLa) transduced with feline CD134 did not suggest that FIV binding to CD134 
triggered signalling through NFkB.  However, it was possible that the effect of 
the virus was subtle and could be masked by the signal mediated by the CD134 
ligand.  Given that CAPE increased ligand-induced IL-8 production it could 
potentially amplify any effect mediated by virus binding.  To test this 
hypothesis, HT1080-feCD134 cells were pre-incubated with CAPE for 1 hour 
before the addition of feline CD134L, followed by FIV a further hour later.  
Adding ligand before virus was considered more likely to demonstrate an 
enhancement of IL-8 production.  The addition of CAPE doubled IL-8 production 
induced by ligand, consistent with earlier findings.  However, the presence of 
FIV did not increase IL-8 levels further (Fig. 3-8A).  In the absence of the ligand 
FIV did not induce extra IL-8 production from CAPE incubated cells except at the 
highest virus concentration (Fig 3-8B).  However, this increase was very small 
compared with the IL-8 production induced by stimulation with feCD134L.  Thus 
it was decided to explore other in vitro systems to see if they will provide a 
more conclusive answer. 
A B 
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Figure 3-8 – Effect of the NFκB inhibitor CAPE on IL-8 production from 
HT1080-feCD134 cells treated with FIV GL8 in the presence or absence of 
feCD134L.  (A) Cells were pre-incubated with CAPE and stimulated with 
feCD134L before FIV was added.  Dotted lines indicate the levels of background 
IL-8 production in the presence or absence of CAPE.  (B) Cells were pre-
incubated with CAPE and then virus was added.  Each point represents the mean 
+/- standard error (n= 3).   
A 
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Figure 3-9 – The NFκB inhibitors CAPE and SC514 effectively inhibit TNF-α 
induced GFP production in NFkB/293/GFP cells.   Cells were seeded in 6-well 
plate and were (A) mock-stimulated with DMSO, (B) stimulated with TNF-α (10 
ng/ml) and DMSO, (C) stimulated with TNF-α and CAPE (88 µM) and (D) 
stimulated with TNF-α + SC514 (10 µM).  Pictures were taken with bright-field 
microscopy. 
3.2.2 Effect of FIV on CD134-mediated signalling in NFκB/293/GFP 
cells 
The NFkB/293/GFP reporter cell line contains an expression vector encoding the 
GFP reporter gene driven by 4 copies of the NFκB consensus transcriptional 
response element along with a downstream minimal cytomegalovirus (mCMV) 
promoter (System Biosciences Cat. #TR800A-1).  These reporter cells may be 
more sensitive to small changes in cell signalling induced by FIV binding to CD134 
than measuring IL-8 production from non-human cell-lines because NFκB is 
further upstream of the signalling pathway and any signal generated from the 
A B 
C D 
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receptor has fewer obstacles to overcome to reach NFκB than to stimulate IL-8 
production.  First, both transient transfection and stable transduction of feline 
CD134 into NFkB/293/GFP cells using the pRetroQ-DSRed vector (Clontech) was 
successful (Table 3-2).  Next, the reporter cells were stimulated overnight with 
feline CD134 ligand to explore whether feline CD134 engagement could trigger 
the GFP reporter gene.  Flow cytometry revealed that transduction or 
transfection of feline CD134 induced a higher level of background NFκB 
activation compared to the transduction or transfection of the empty vector 
(Table 3-3).  This indicated that feline CD134 may be able to interact with the 
intracellular signalling of NFkB/293/GFP cells.  A  large increase in green 
fluorescence was observed when TNF-α was added as a positive control (Table 3-
3 and Fig. 3-10), indicating that the reporter gene was functional and responsive 
to stimulation of NFκB pathway by TNF-α.   
Addition of CD134 ligand to the CD134-expressing NFkB/293/GFP cells did not 
induce NFκB activity.  On the contrary, as more ligand was added to the cells, 
less fluorescence was generated (table 3-3).  Background fluorescence was 
higher in feCD134 transduced cells compared to feCD134 transfected cells, 
perhaps a reflection of the fact that transfection is a transient method of DNA 
expression.  More importantly, in a separate experiment the addition of FIV to 
the transduced cells did not induce an increase in NFκB activity (Fig. 3-10).  
Cells were incubated with virus alone or in conjunction with feCD134L at 0.5 and 
1 μg/ml but none of the treatments increased NFκB activity above the level of 
the no treatment control.  Since the feCD134L failed to stimulate GFP 
production, this model system was deemed inappropriate for this project.  It was 
possible that NFkB/293/GFP cells display a similar species specificity in 
signalling to HeLa cells. 
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antibody 
% cell 
FITC gated 
Mean 
fluorescence 
% cell 
PE gated 
Mean 
fluorescence 
CD134 Transduced 
anti-CD134 
FITC 
80.56 51.6 0.01 1 
  no antibody 2.9 5.8 2.55 1.7 
Vector 
only 
Transduced 
anti-CD134 
FITC 
6.5 3.7 95.87 12.7 
  no antibody 5.8 4 94.81 12.2 
       
CD134 Transfected 
anti-CD134 
FITC 
74.9 28.5 2.18 2.7 
  no antibody 3.4 5 12.05 2.1 
Vector 
only 
Transfected 
anti-CD134 
FITC 
2.7 13.4 91.8 9.7 
  no antibody 3.4 7.6 92.3 11.1 
 
Table 3-2 – CD134 expression on transduced and transfected NFkB/293/GFP 
cells.  PE = phycoerythrin.  Expression of feline CD134 on NFkB/293/GFP cells 
transduced or transfected with feline CD134 in pDSRed were analysed by flow 
cytometry.  Primary antibody was a FITC-conjugated mouse anti-feline CD134 
antibody.  High PE in empty vector control was attributed to DSRed monomer 
expression that was not disrupted due to the absence of the CD134 gene.  % 
gated relative to the untreated, untransduced/untransfected NFkB/293/GFP cells. 
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 DSRed transduced    
 293T-NFκB-GFP feCD134 293T-NFκB-GFP vector only 
Treatment % gated 
mean 
fluorescence 
% gated 
mean 
fluorescence 
NTC 13.7 4.1  0.3 11.7 
TNF-α 51.8 38.2  18.5 26.6 
feCD134L 1.0 μg/ml 12.5 5  0.2 15.3 
feCD134L 0.5 μg/ml 16 3.6  0.2 11 
feCD134L 1.0 μg/ml 
+ TNF-α 
49 35.3  17.3 24.9 
feCD134L 0.5 μg/ml 
+ TNF-α 
50.2 33.2  12.4 21.9 
      
 DSRed transfected    
 293T-NFκB-GFP feCD134 293T-NFκB-GFP vector only 
Treatment % gated 
mean 
fluorescence 
% gated 
mean 
fluorescence 
NTC 6.6 9.4  1.16 14.3 
TNF-α 18.9 16.5  24.3 21.9 
feCD134L 1.0 μg/ml 4.25 8.1  0.8 7.9 
feCD134L 0.5 μg/ml 5.9 6.4  0.9 7.3 
feCD134L 1.0 μg/ml 
+ TNF-α 
26.9 17.8  27.29 27.6 
feCD134L 0.5 μg/ml 
+ TNF-α 
22.45 14.3  28.38 26.6 
          
Table 3-3 – Stimulation of feline CD134 transduced or transfected 
NFkB/293/GFP cells with ligand does not change NFκB activation status.  
Cells were stimulated overnight by TNF-α (10 ng/ml) alone or in conjunction with 
feCD134L (1.0 or 0.5 μg/ml).  The green fluorescence level of the cells, which 
correlates to NFκB expression level, was measured by flow cytometry the next 
day.  NTC = no treatment control.  % gated relative to the untreated, 
untransduced/untransfected NFkB/293/GFP cells. 
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Figure 3-10 – FIV binding does not have any effect on NFκB signalling of the 
NFkB/293/GFP cell transduced with feCD134.  Cells were stimulated overnight 
by TNF-α (10 ng/ml) alone or in conjunction with feCD134L (=L; at 1.0 or 0.5 
μg/ml) and FIV GL8 or PPR (at 6 or 60 μg/ml). The green fluorescence level of the 
cells, which correlates to NFκB expression level, was measured by flow cytometry 
the next day.   
3.2.3 An attempt to detect cell signalling changes in MYA-1 CD4+ 
T cells by measuring cytokine released 
Activated CD4+ T cells can be divided into TH1, TH2 and TH17 subsets, based on 
the expression of subset specific transcription factors and cytokines (Hirahara et 
al., 2011, Romagnani, 1994).  TH1 cells are known to produce IFN-γ (Abbas et 
al., 1996) while IL-4 is the signature cytokine for TH2 cells (Mowen and Glimcher, 
2004).  Signalling via CD134 can influence the expression of both IFN-γ and IL-4 
(Flynn et al., 1998, Ohshima et al., 1998, Vosskuhl et al., 2010).  Thus it may be 
possible to detect changes in T cell CD134 signalling by measuring the amount of 
cytokine released after stimulation with ligand and/or virus.   
The IL-2 dependent feline CD4+ T cell line MYA-1 naturally expresses a high level 
of CD134 (fluctuating at ~50% positive over seven days) (Fig. 3-11A).  To 
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determine the TH subtype of MYA-1, supernatant of the T cells stimulated with 
the phorbol ester PMA were analysed by ELISA for feline IFN-γ and IL-4 
production.  Stimulation with PMA did not induce IFN-γ production from MYA-1 
CD4+ T cells (Figure 3-11C).  In contrast a background level of IL-4 production 
was detected which was more than doubled after PMA stimulation (Fig.3-11B), 
indicating that MYA-1 CD4+ T cells belong to the TH2 subtype. 
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Figure 3-11 – MYA-1 CD4+ T cells naturally express CD134 and produce IL-4 
after stimulation.  MYA-1 CD4+ T cells were cultured in IL-2 supplemented 
medium and (A) the expression of CD134 over a 7 day period was quantified by 
flow cytometry of the sequential samples.  Each point represents the mean +/- 
standard error (n= 3).  Unstimulated cells (No treatment) or cells stimulated with 
PMA (0.08 μM) were incubated for 48 hours and the supernatant IL-4 (B) or IFN-γ 
(C) concentrations were measured by ELISA.  Recombinant cytokines were used 
A 
B C 
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as positive control for the ELISA.  Data is representative of 2 independent 
experiments.  Each bar represents the mean +/- range (n= 2).   
MYA-1 CD4+ T cells were then stimulated with feCD134L and supernatant IL-4 
levels measured after 48 hours.  The result from one experiment showed that IL-
4 production by the MYA-1 CD4+ T cells was reduced by ~50% by feline CD134 
ligand when IL-2 was present, and more than doubled when IL-2 was absent (Fig. 
3-12A and B).  However, this trend could not be repeated in 3 subsequent 
independent experiments (Fig. 3-12C and D).  Recombinant FIV Env SU-Fc 
proteins were added to the cells in substitute for live FIV particles and these, 
particularly FIV PPR, had less pronounced but similar effect on IL-4 production as 
the ligand in the first experiment (Fig. 3-12A and B).  Again, this trend was also 
not found in subsequent experiments (Fig. 3-12C and D).  When the MYA-1 CD4+ 
T cells were loaded with carboxyfluorescein (CFSE) as a means of tracking cell 
division, none of the treatments, including the addition of PMA, produced a shift 
in fluorescence when IL-2 was present (Fig. 3-13A).  In the absence of IL-2, PMA 
increased the rate of cell division while GL8 Env SU Fc incubated cells showed a 
drop in rate of division compared to no treatment (Fig. 3-13B).  These trends 
suggested that in the absence of IL-2 virus or viral components may have an 
observable effect on cell signalling. 
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Figure 3-12 – Effect of feline CD134 ligand and FIV Env SU Fc proteins on IL-
4 production by MYA-1 CD4+ T cells.  Cells with (A and C) or without IL-2 
supplement (B and D) were subjected to incubation with PMA, feline CD134 
ligand, FIV GL8 or PPR SU Fc proteins (1 μg/ml), DMSO or PBS for 48 hours 
before supernatant IL-4 was measured by ELISA.  (A and B) are representative of 
1 out of 4 experiments while (C and D) are representative of 3 out of 4 
experiments.  Each bar represents the mean +/- standard error (n= 3).   
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Figure 3-13 – Modest reduction in cellular proliferation is caused by GL8 Su 
Fc in IL-2-depleted cells.  However, feline CD134 ligand and FIV SU Fc 
protein do not induce a shift in fluorescence in CFSE assay of MYA-1 CD4+ T 
cells in the presence of IL-2.  Feline CD134 ligand (FL), PMA, FIV Env SU Fc 
proteins were added to CFSE loaded cells in the presence (A) or absence (B) of 
IL-2 and sequential samples were taken over 6 days to monitor cell proliferation 
rates.  Percentage of proliferating cells was estimated as the percentage of cells 
with fluorescence values lower in the gated region designated in (C), arbitrarily set 
at a value of 50%.  Each point represents the mean +/- range (n= 2).   
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3.3 Discussion 
In order to ensure successful infection, viruses have evolved to manipulate the 
host at every step of the viral lifecycle.  The primary receptor for FIV is CD134 
(Shimojima et al., 2004), a CD4+ T cell co-stimulating molecule that is vital to 
the proliferation, survival and function of activated T cells (Croft, 2010).  In 
theory FIV may benefit from an enhancement in CD134 signalling in activated T 
cells as it would increase the number of target cells susceptible to infection or 
promote the survival of infected cells.  This chapter investigated the hypothesis 
that FIV binding to CD134 induced changes in signalling within the target cell.   
To achieve the initial aims of the project three potential in vitro models of 
signalling were constructed and their abilities to detect signalling induced by 
feline CD134 ligand examined.  Subsequently, they were subjected to 
stimulation with either FIV virions or recombinant FIV Env SU Fc proteins.  
Firstly, IL-8 producing adherent cells HT1080, NP-2 and HeLa cells were stably 
transduced with CD134 expression vectors.  When HT1080-feCD134 and NP-2-
feCD134 cells were stimulated by soluble feline CD134 ligand, IL-8 was produced 
in response. In contrast HeLa-feCD134 cells failed to respond to stimulation with 
feCD134L.  The reason behind this incompatibility between feline CD134 and 
HeLa cells is unknown.  More importantly, stimulation of these cells with virus 
particles, even at high titre, did not induce IL-8 production.  When FIV and 
feCD134L were added to the cells simultaneously, an enhancement of IL-8 
production was noted on some experiments but this observation was not 
reproducible.  When HT1080-feCD134 cells were stimulated by the NFκB 
inhibitor CAPE and incubated with FIV GL8, a small increase in IL-8 production 
could be detected.  This result was not thought to be reliable because it is still 
unclear as to why CAPE can induce IL-8 production, and because of the small 
magnitude of the increase.  Other experimental approaches to examine the cell 
signalling events potentially induced by FIV were examined.  The reporter cell 
line NFkB/293/GFP was transduced or transfected with feline CD134.  However, 
while efficient surface expression of the molecule was detected, ligand binding 
or incubation with FIV virions did not result in the activation of NFκB.  Finally, 
the production of cytokines from the feline CD4+ T cell line MYA-1 was studied.  
Direct stimulation of the MYA-1 CD4+ T cells with feCD134L or FIV Env SU Fc did 
not affect IL-4 production of the cell line. 
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Several studies in the past have provided evidence suggesting that HIV-1 Gp120 
Env binding to CD4, CCR5 and CXCR4 triggers cell signalling and that this may 
promote viral replication (Kornfeld et al., 1988, Popik and Pitha, 1996, 
Weissman et al., 1997, Yoder et al., 2008).  However, contradictory studies have 
concluded that HIV-1 receptor-mediated signalling has little effect on replication 
(Cocchi et al., 1996, Farzan et al., 1997, Amara et al., 2003, Yoder et al., 2008).  
Interestingly, studies which used activated or transformed cells are more likely 
to report that HIV-1 Gp120-induced signalling is unnecessary for virus production 
(Wu and Yoder, 2009).  In addition, studies which claim that HIV-1 Gp120 can 
induce significant cell signalling activity may be undermined by the observation 
that cell signalling required a supra-physiological level of HIV-1 Gp120 (Klasse 
and Moore, 2004).  The concentration of free HIV-1 Gp120 in vivo is difficult to 
measure because of interference from plasma antibody (Klasse and Moore, 
2004).   The concentration of Gp120 in different tissues may vary and it is 
difficult to quantify HIV-1 Gp120 expressed on the cell surface during cell-to-cell 
transmission (Klasse and Moore, 2004).  A small increase in IL-8 production was 
recorded when CAPE-stimulated HT1080-CD134 cells were incubated with virus 
equivalent to 6 μg/ml of FIV p24.  Is this concentration of virus physiological?  It 
is also important to consider the binding efficiency and receptor occupancy of 
the viral protein in relation to the level of receptor expression (Klasse and 
Moore, 2004).  Taken together, these data cast doubt on the hypothesis that 
HIV-1 Gp120 initiates cell signalling to a level that significantly enhances virus 
production.  It is more likely that other viral proteins such as Nef and Tat may 
contribute to the increase in T cell activation prior to viral gene expression (Ott 
et al., 1997, Wang et al., 2000a, Wu and Marsh, 2001).  
Based on the available data, there is no indication that FIV binding to feline 
CD134 triggers signalling through the NFκB cascade.  If FIV Env-induced signalling 
is confirmed by future studies, the expected level of stimulation is expected to 
be small compare to the virus-promoting signals generated by activated T cells.  
However, it is important to acknowledge that the methods described in this 
chapter have potential flaws.  Firstly, although it has been shown that using IL-8 
production as a measure for CD134 signalling is sensitive enough to detect the 
effect of soluble CD134 ligand binding, is it enough to detect a potentially more 
subtle stimulation of CD134 by FIV virions?  The stimulation threshold to 
generate IL-8 may be greater than the threshold to produce observable 
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activation of NFκB.  Secondly, the physiological level of CD134 stimulation in 
feline cells is not known, thus if stimulation of cell signalling was detected, it 
would be hard to assess its biological significance.  Thirdly, the behaviour of the 
cells has not been uniform, giving occasional positive results that were not 
repeatable.  Lastly, there is a lack of reagents available that can be used in 
feline cells.  It means that traditional methods to monitor NFκB stimulation such 
as detecting IκB phosphorylation using immunobloting are not possible.  Recent 
discoveries have demonstrated the involvement of pathways other than NFκB in 
CD134 signalling such as PKC, PI3K, PDK-1 and Akt/PKB pathways (So et al., 
2011a, So et al., 2011b), which may be areas for further study. 
Another avenue of research that is yet to be explored is the effect of FIV Env-
induced signalling on the infection of resting T cells and the implications for 
viral latency.  HIV-1 establishes latent reservoirs within the host which persist 
for many years (Siliciano et al., 2003).  The latently infected cells seed new 
infections when they periodically reactivate, preventing the full eradication of 
the virus despite intensive anti-retroviral treatment (Richman et al., 2009).  This 
is an important problem by itself and will be explored in the next chapter.   
It has been demonstrated that most of the latently infected cells in HIV-1 
infection are memory T cells that have been infected when they were in an 
activated state (Chun et al., 1997, Pierson et al., 2000, Brenchley et al., 2004a, 
Chomont et al., 2009).  In contrast, the direct infection of resting T cells (naïve 
T cells or quiescent memory T cells) is not thought to be important in the 
establishment of latent reservoirs because infection of resting T cells is very 
inefficient (Stevenson et al., 1990, Pierson et al., 2000, Vatakis et al., 2010).  
However, it has been shown recently that HIV DNA isolated from the memory T 
cells of patients receiving antiretroviral treatment decreases over time while 
HIV DNA from naïve T cells remained stable (Wightman et al., 2010).  This 
suggested that as infected memory T cells were lost from the reservoir due to 
reactivation, the proportion of naïve T cells in the reservoir increased slowly due 
to direct infection. 
One of the obstacles to the direct infection of naïve resting T cells is the static 
nature of their cytoskeleton.  Recently, a mechanism has been put forward to 
explain how HIV-1 overcomes this.  The binding of HIV-1 Env to CXCR4 triggers G-
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protein dependent signalling which ultimately activates the cellular actin-
depolymerizing molecule cofilin and facilitates the transport of the viral pre-
integration complex towards the nucleus (Yoder et al., 2008).  FIV can establish 
a latent infection in feline T cells (Joshi et al., 2004) and uses CXCR4 as its co-
receptor (Willett et al., 1997).  Does FIV Env trigger signalling downstream of 
CXCR4 in the same way as HIV-1?  In one experiment the addition of FIV GL8 SU 
Fc proteins to feline MYA-1 CD4+ T cells appeared to affect cellular proliferation 
as demonstrated using the CFSE assay.  Further experiments should be 
performed to confirm these results and to deduce the signalling pathways that 
are involved.  If it is proven that the binding of FIV to resting feline T cells can 
stimulate significant cell signalling, then will this signalling be required in the 
successful establishment of post-integration latency?  If so, will this lead to a 
higher proportion of naïve T cells within the latent reservoirs of cats compared 
with humans and will this result in differential responses to latency reversing 
therapies between the two species?  These are questions worthy of further 
research. 
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4 Dual action of phorbol esters on FIV production 
illustrates shared principles in the replication of 
both HIV-1 and FIV 
 
4.1 Part 1 – establishment of FIV latency in MYA-1 CD4+ T 
cells 
In addition to being an interesting scientific question, the molecular mechanisms 
behind HIV-1 latency have huge public health implications worldwide (Richman 
et al., 2009).  The estimated number of latently infected memory T cells within 
an individual is small, around 106 cells (Chun et al., 1997).  However, this pool of 
latently infected cells serves as a major reservoir of virus in the host and a 
source of new virus following reactivation.  With an extremely slow decay rate, 
even under intensive HAART (Finzi et al., 1999, Siliciano et al., 2003, Pace et 
al., 2011), this small population of latently infected cells ensures lifelong 
infection of the host and is a stumbling block for complete virus eradication. 
The most practical strategy to attempt to eliminate the latent reservoir is to use 
drugs to reactivate virus production under intensive HAART without causing 
global activation of uninfected T cells or other undesirable side-effects (Marsden 
and Zack, 2009, Richman et al., 2009).  However, as viral replication is 
intricately tied to cellular activation (Stevenson et al., 1990), reactivating the 
latent viruses while at the same time avoiding T cell activation has been 
challenging (Prins et al., 1999).  In order to successfully deduce a precise 
method to reverse HIV-1 latency, its molecular mechanism has been studied at 
both the cellular and whole animal level.  Yet difficulties such as a limited 
supply of suitable cells and the use of heavily modified virus in an unnatural host 
like the SCID mice remain.  This part of chapter 4 presents the development of 
an in vitro model of lentiviral latency using FIV and the feline CD4+ T cell line 
MYA-1. 
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4.2 Results 
4.2.1 Attempts to establish latent infection in MYA-1 CD4+ T cells 
It has been demonstrated that factors such as low cellular activation level, the 
lack of cellular transcription factors and a restrictive chromatin environment 
contribute to the maintenance of lentiviral latency (reviewed in (Han et al., 
2007, Coiras et al., 2009, Colin and Van Lint, 2009)).  However, it is the level of 
cellular activation, more specifically the host cell NFκB activation status during 
infection that determines whether a productive or latent infection will result 
(Stevenson et al., 1990, Duverger et al., 2009).  Based on this understanding it 
may be possible to latently infect feline MYA-1 CD4+ T cells with FIV by blocking 
NFκB activation of the cells using NFκB inhibitors before or during viral entry.  
To find a working concentration for each NFκB inhibitor that would cause 
minimum toxicity, the MYA-1 CD4+ T cells were incubated for 10 days with the 
NFκB inhibitors CAPE, BOT64, SC514 and BAY 11-7082 at a range of 
concentrations starting from their respective half maximal inhibitory 
concentrations (IC50) (Table 4-1).  Results showed that BOT64 and SC514 were 
relatively non-toxic, with viabilities comparable with the DMSO control even at 
IC50 concentrations (Fig. 4-1B and C).  Based on these data working 
concentrations of 10 μM and 3 μM for SC514 and BOT64 respectively were 
chosen.  CAPE at a concentration of 88 μM (which is the IC50) showed 
considerable toxicity, reducing the viability of the cells to less than 50% by day 
6(Fig. 4-1A).  Thus a lower concentration of 44 μM was chosen as the working 
concentration for CAPE.  BAY 11-7082 was found to be the most toxic NFκB 
inhibitor out of the group; when used at its IC50 of 15 μM, it caused a drop of 80-
90% in cell viability from the start of the assay (Fig. 4-1D) and thus it was not 
used for further experiments. 
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Inhibitor      
CAPE 88 μM* 44 μM 22 μM 
BOT64 3 μM* 1.5 μM 0.75 μM 
SC514 10 µM* 5 μM  
BAY 11-7082 15 μM* 7.5 μM 3.75 μM 
 
Table 4-1 - The IC50 (*) and other concentrations of the NFκB inhibitors tested 
in the viability assay of feline MYA-1 CD4+ T cells. IC50 based on the 
manufacturer’s protocols. 
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Figure 4-1 – Effect of different NFκB inhibitors on the viability of MYA-1 CD4+ 
T cells.  Feline MYA-1 CD4+ T cells supplemented with IL-2 (100U/ml) were 
incubated with different concentrations of (A) CAPE, (B) BOT64, (C) SC514 and 
(D) BAY 11-7082 for 10 days.  Viability was measured by trypan blue exclusion 
assay at day 0, 1, 2, 4, 6 and 10.  
Next, the NFκB inhibitors CAPE (44 µM), BOT64 (3 µM) and SC514 (10 µM) were 
added to cells 24 hours before infection with FIV strains GL8 or PPR at an MOI of 
0.001 to see if productive infection could be stopped.  Supernatant samples 
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were collected at days 0, 1, 3, 5, 7 and 10 post infection and FIV production 
measured by an ELISA that detects the FIV p24 (Gag) protein.   Productive FIV 
infection was almost completely abrogated in cells incubated with CAPE during 
the 10-day period (Fig. 4-2).  The presence of BOT64 and SC514 appeared to 
have more than doubled the production of FIV strain GL8 by day 10 post 
infection (Fig. 4-2A), while the replication of FIV PPR was not affected by BOT64 
and was slightly reduced by SC514 (Fig. 4-2B).   
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Figure 4-2 – Productive FIV infection of MYA-1 CD4+ T cells is blocked by 
CAPE.  IL-2-supplemented (100 U/ml) MYA-1 CD4+ T cells were pre-incubated 
with NFκB inhibitors CAPE (44 µM), BOT64 (3 µM), SC514 (10 µM) and mock 
treated (DMSO) for 1 hour before infection with FIV (A) GL8 or (B) PPR (MOI 
0.001) and virus production was monitored in the culture supernatants by FIV p24 
ELISA.   
To check if the FIV infection would remain latent after the withdrawal of CAPE, 
IL-2-supplemented infected cells treated with CAPE were washed at day 3 or day 
7 post infection and resuspended in fresh, IL-2-supplemented medium without 
CAPE.  After an extended study period of 20 days, virus production was detected 
in the supernatant of CAPE-treated FIV PPR-infected cells but not FIV GL8 
infected cells (Fig. 4-3A) The removal of CAPE at day 3 or day 7 post infection 
resulted in the return of productive infection afterward (Fig. 4-3C and D), 
suggesting that CAPE had to be present constantly to ensure a non-productive 
infection.  Under all the different conditions, FIV PPR was less sensitive to the 
effects of the NFκB inhibitors than FIV GL8 and the titre of FIV PPR always 
A B 
 Chi Ngai Chan, 2012                                                                   Chapter 4,   100 
reached a plateau before FIV GL8, illustrating the differences in viral replication 
dynamics between strains (See Chapter 5). 
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Figure 4-3 – The continuous presence of CAPE is necessary to maintain 
non-productive infection.  Parallel experiments were performed in which IL-2 
supplemented (100 U/ml) MYA-1 CD4+ T cells were pre-incubated with NFκB 
inhibitor CAPE (44 μM) 1 hour before and during infection with FIV GL8 or PPR 
(MOI 0.001), after which the cells were (A) continuously maintained in medium 
containing CAPE, (B) kept in medium without CAPE, (C) maintained in CAPE-
containing medium for 3 days or (D) 7 days.  Supernatant samples were collected 
at intervals for up to 20 days post infection and virus production measured by FIV 
p24 ELISA.  Each bar represents the mean +/- standard error (n=3).  
It has been shown previously that PKC activating phorbol esters are potent 
reactivating agents of latent HIV-1 infection (Marquez et al., 2008) and among 
them Prostratin, with its non-tumour-promoting property, could be developed 
into a viable therapy to purge the reservoir of latently infected cells (Kulkosky 
et al., 2001, Rullas et al., 2004).  To test whether the non-productive infection 
A B 
C D 
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maintained by CAPE was comparable to latent infection of MYA-1 T cells by HIV-
1, Prostratin and PMA, a powerful, tumour promoting phorbol ester, were added 
to infected cells incubated with CAPE at day 2 post-infection.  The phorbol 
esters did not rescue virus production in CAPE incubated cells during the 10 day 
experiment (Fig. 4-4A) and furthermore lowered the virus titre in the 
productively infected control cells, especially Prostratin, which reduced virus 
titre in both strains by more than 50%.  PMA reduced the viability of the cells 
incubated with/without CAPE by 20% and 15% respectively (Fig. 4-4B), while 
Prostratin did not markedly reduce cell viability.  This demonstrated that the 
reduction in virus titre was not due to the toxicity of the compounds added to 
the medium.  It has been shown previously that Prostratin has the dual effect of 
inhibiting productive HIV-1 infection as well as reactivating latently infected 
viruses (Kulkosky et al., 2001, Biancotto et al., 2004, Rullas et al., 2004).  The 
failure by Prostratin to rescue virus production from cells incubated with CAPE 
suggested the CAPE induced non-productive infection was not a true latent 
infection.  
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Figure 4-4 – The phorbol esters PMA and Prostratin do not rescue virus 
replication from FIV infected MYA-1 CD4+ T cells incubated with CAPE.  IL-2 -
supplemented MYA-1 CD4+ T cells were pre-incubated with the NFκB inhibitor 
CAPE (44 μM) or DMSO (no CAPE) for 1 hour before and during infection with FIV 
GL8 or PPR (MOI 0.001), after which the cells were resuspended either in 
complete medium + IL-2 with CAPE or without CAPE (no CAPE).    PMA (0.08 
µM) and Prostratin (Pro) at 0.5 µM were added to the cells 2 days post infection.  
A B 
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(A) Virus production was measured by FIV p24 ELISA at day 10 post-infection.  
(B) Cell viability in the treated cells in the presence of FIV infection was measured 
10 days post-infection. Each bar represents the mean +/- standard error (n=3) 
In the previous experiments the MYA-1 CD4+ T cells were supplemented with 
exogenous IL-2 because it is an IL-2-dependent cell line.  IL-2 is a major 
promoter of T cell expansion, survival and differentiation (Gaffen and Liu, 2004, 
Malek, 2008).  IL-2 is also a known activator of latent HIV-1 and FIV infections 
(Prins et al., 1999, Joshi et al., 2005a).  Could depleting the cells of IL-2 lead to 
a latent FIV infection?  First, the growth characteristics of the cells in the 
presence or absence of IL-2 were examined.  In the absence of exogenous IL-2 
cell growth ceased and viability fell to approximately 20-30% within 6 days (Fig 
4-5A and B).  In contrast, the addition of exogenous IL-2 maintained both cell 
viability and cell growth, with an exponential expansion phase that lasted for 
approximately 6 days, after which the culture reached confluence and further 
expansion required sub-culture.   
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Figure 4-5 – Effect of exogenous IL-2 on the growth and viability of MYA-1 
CD4+ T cells.  Total cell number (A) and cell viability (B) of MYA-1 CD4+ T cells 
grown in the presence or absence of exogenous IL-2 (100 U/ml).  Each point 
represents the mean +/- standard error (n=3). 
Next the susceptibility of cells grown in the presence and absence of IL-2 to 
infection with FIV is compared.  Since IL-2 depletion would reduce cell growth 
and viability, which in turn would decrease the virus production, a higher dose 
of FIV (M.O.I = 0.1) was used.  When IL-2 was depleted 2 days post infection, 
productive infection of FIV PPR was detected from day 2 and FIV GL8 at day 4 in 
A B 
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both treatment and IL-2 positive control cells, indicating that the attempt to 
establish a latent infection was unsuccessful (Fig. 4-6B).   
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Figure 4-6 – Removing IL-2 post infection does not establish latent infection.  
(A) Experimental protocol: MYA-1 CD4+ T cells were infected with FIV (M.O.I = 
0.1) and IL-2 was removed 2 days post infection. (B) FIV p24 ELISA showing 
supernatant FIV levels over a period of 10 days.  
When exogenous IL-2 was removed from actively growing MYA-1 cells 24 hours 
prior to infection, no virus production could be detected using FIV p24 ELISA 
(Fig. 4-7A).  It has been shown that for HIV-1 infection, the majority of the 
latently infected CD4+ T cells are memory T cells (Chomont et al., 2009) and it 
is likely that most of these cells were infected when they were in an activated 
state and subsequently return to quiescence when they become memory cells 
(Siliciano and Greene, 2011).  The depletion of IL-2 from activated CD4+ T cells 
causes the cells to enter a resting state analogous to the transition of effector 
cells to memory cells (McKinstry et al., 2007).  Does the lack of virus production, 
as determined by ELISA, mean that I have re-created the transition from 
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infected effector to latently infected memory T cell? To characterise the viral 
replication dynamics within these IL-2-depleted T cells, intracellular DNA and 
RNA were extracted over 10 days and the amount of intracellular FIV DNA and 
unspliced FIV RNA (Tomonaga et al., 1995) quantified using quantitative PCR 
(qPCR), amplifying a 78bp region at the 5’ end of the FIV gag gene.  Data was 
analysed using the ΔΔCt method with a primer set that amplifies the 18S rRNA 
sequence as the internal control.  The qPCR detected less intracellular viral DNA 
within the IL-2-depleted resting MYA-1 T cells compared with IL-2 supplemented 
cells 2 hours post infection (Fig. 4-7B).  Subsequently there was an increase in 
intracellular FIV DNA among IL-2-depleted cells, which reached a plateau four 
days post infection.  However, this increase was noticeably smaller than the 
increase in intracellular FIV DNA detected from cells grown in the presence of IL-
2 (Fig. 4-7B).  These data indicated a defect in reverse transcription and viral 
spread among the infected resting MYA-1 T cells.  This is consistent with 
previous studies that showed HIV-1 entry and reverse transcription is less 
efficient in resting T cells compared with stimulated T cells (Pierson et al., 
2002b, Vatakis et al., 2007).  The qPCR also detected the production of 
unspliced intracellular FIV RNA in the resting MYA-1 T cells that reached a 
plateau after 4 days post infection (Fig. 4-7C).   The quantity of intracellular 
viral RNA produced within the resting cells was markedly lower compared with 
the quantity within the IL-2 supplemented cells.  The presence of a small 
amount of unspliced intracellular lentiviral RNA does not demonstrate full 
productive infection, since a low-level of unspliced RNA can be found within HIV-
1 and FIV infected resting T cells  (Tomonaga et al., 1995, Lassen et al., 2004). 
To assess the contribution of de novo infection to viral nucleic acid production 
and the virus titre in the culture supernatant, a parallel experiment was 
performed using IL-2 supplemented, FIV infected MYA-1 T cells in the presence 
of the retroviral integrase inhibitor Raltegravir (RGV) and the reverse 
transcriptase inhibitor Zidovudine (AZT) at concentrations previously shown to 
be effective against FIV (Savarino et al., 2007, Bisset et al., 2002).  The 
antiretroviral drugs were added 24 hours post infection, which would allow virus 
production from cells infected during the initial inoculation but would block any 
subsequent reverse transcription and integration.  Results showed that similar to 
the IL-2- depleted cells, the levels of viral p24 in the supernatant, as well as the 
production of intracellular FIV DNA and RNA were noticeably reduced in 
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antiretroviral treated cells compared with untreated IL-2 supplemented cells 
(Fig. 4-7A-C).  Intracellular FIV DNA and RNA levels of the RGV+AZT treated cells 
reached a plateau by day 4 post infection (Fig. 4-7B and C).  However, the 
relative quantity of intracellular FIV DNA and RNA was higher in the 
antiretroviral treated cells compared to the IL-2-depleted cells, which is a 
further indication of a latent infection within the IL-2- depleted cells. 
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Figure 4-7 – A low level of persistent FIV replication can be detected in IL-2- 
depleted resting MYA-1 T cells.  (A) Virus production was not detected from IL-
2- depleted cells infected with FIV GL8 (M.O.I. = 0.01) or from infected, IL-2 
supplemented cells treated with RGV (1 μM) and AZT (5 μM) at 24 hours post 
infection during the entire 10 day study period using the FIV p24 ELISA.  The 
relative quantities of intracellular FIV DNA (B) and intracellular unspliced RNA (C) 
from approximately 1x106 cells were quantified by qPCR.  Samples for day 0 were 
taken at 2 hours post infection.   Data was analysed using the ΔΔ Ct method, 
normalised to the amount of cellular 18S rRNA detected and relative to the 
average ΔCt values of the IL-2-depleted cells (-IL-2) at Day 0 post infection.  (D) 
A B 
C D 
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The quantities of FIV unspliced RNA in the culture supernatant over 10 days were 
measured by qPCR.  Each point represents mean +/- standard deviation (n=3) of 
the calculated relative quantities/copy number for the qPCR data and mean +/- 
standard error (n=3) for the p24 ELISA data.  Results are representative of two 
independent experiments. 
As shown previously, using the FIV p24 ELISA no virus production was detected 
from the infected IL-2-depleted MYA-1 T cells.  However, the ELISA was not 
sensitive enough to detect the low level ongoing viral replication from the 
infected IL-2 supplemented cells that were treated with antiretrovirals (Fig. 4-
7A).  Thus the more sensitive qPCR was used to check whether ongoing 
productive infection was occurring among the IL-2-depleted cells.  A background 
of fewer than 2000 copies of FIV RNA per ml was detected at the start of the 
experiment, which represented the virions from the initial inoculation that had 
remained behind after washing (Fig. 4-7D).  The quantity of FIV RNA in the 
culture supernatant of the IL-2-supplemented infected cells rose dramatically 
during the experiment, reaching almost 1x109 copies/ml by day 10 post infection 
(Fig. 4-7D), which is consistent with the results from FIV p24 ELISA.  In contrast, 
a low level of virus production was occurring in the IL-2-depleted cells, peaking 
at approximately 30,000 copies/ml of culture supernatant by day 7 post-
infection (Fig. 4-7D).  During the same period the rate of virus production from 
IL-2-supplemented infected cells treated with RGV and AZT was also much lower 
compared with IL-2-supplemented cells not treated with antiretrovirals, 
reaching a maximum of approximately 55,000 copies/ml of culture supernatant 7 
days post infection. However, this level of virus production was initially higher 
than the rate of virus production from IL-2-depleted cells.  Virus production from 
the antiretroviral-treated cells began to decline 7 days post infection.  Since de 
novo FIV infection was blocked by antiretrovirals, this could be an indication of 
the cytopathic effects of productive infection.  The above data indicate that 
rather than establishing a latent infection whereby the infected MYA-1 T cells 
entered a quiescent state that led to the complete shutdown of viral production, 
low-level productive infection was still occurring while new infection of resting 
MYA-1 T cells was blocked completely. 
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4.2.2 Effect of phorbol esters on resting MYA-1 T cells infected 
with FIV 
Stimulation of the FIV-infected, IL-2-depleted cells with either PMA or Prostratin 
post infection induced virus production from day 6 post infection onward, 
reaching a peak similar to the level reached by cells in the presence of IL-2 (Fig. 
4-8A).  Due to the loss of cell viability, the IL-2-depleted MYA-1 T cells were left 
unstimulated for no more than 10 days post infection during our assays.  To 
examine the ability of Prostratin to stimulate productive infection from the 
resting MYA-1 T cells during this 10 day period, parallel cultures of FIV-infected, 
IL-2-depleted cells were stimulated with Prostratin at 2, 4, 6, 8 or 10 days post 
infection and cultured for an additional 8 days post-stimulation.  Virus 
production could be induced at all time points post infection and up to 10 days 
post infection (Fig. 4-8C and D).  Standard PCR was used to confirm the presence 
of FIV DNA within the total extracted cellular DNA of unstimulated, resting MYA-
1 T cells, although it should be noted that this PCR did not confirm the 
integration of the provirus (Fig. 4-8B). 
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Figure 4-8 – The phorbol esters PMA and Prostratin can stimulate productive 
infection from resting MYA-1 T cells.   (A) MYA-1 CD4+ T cells were seeded in 
the presence or absence of IL-2 and 24 hours post-seeding the cells were infected 
with FIV GL8 (M.O.I. = 0.01) and virus production was monitored by p24 ELISA.  
Four days post infection, the IL-2-depleted cells were stimulated with either PMA 
(0.08 μM), Prostratin (Pro - 1 μM) or mock stimulated with solvent (DMSO).  (B) 
Detection of FIV DNA in latently infected cells.  DNA was extracted from FIV 
infected cells and screened by PCR for either a 466 bp FIV LTR-gag product or a 
GAPDH control.  Lanes: (1) -FIV, +IL2; (2) +FIV,+IL-2; (3) +FIV, -IL-2, +DMSO; (4) 
+FIV, -IL-2, +PMA; (5) +FIV -IL-2, +Prostratin, (6) FIV plasmid positive control, (7) 
dH20 negative control. (C) MYA-1 CD4
+ T cells depleted of IL-2 supplement for 24 
hour were infected with FIV GL8 (M.O.I. = 0.01) and maintained in the absence of 
IL-2 for 2, 4, 6, 8 or 10 days post-infection before stimulation with Prostratin. Cells 
were incubated for a further 8 days before culture supernatant samples were 
harvested and stored at -80oC.  Virus production was quantified by a non-isotopic 
reverse transcriptase (RT) assay (D).  Each point represents the mean +/- 
standard error (n=3) and all results are representative of three independent 
experiments. 
 
Next, the contribution of de novo infection to virus production following PMA 
and Prostratin treatment was assessed by stimulating the cells with the phorbol 
esters in the presence of RGV.  Virus production was detected using a reverse 
transcriptase activity assay, which showed a dramatic reduction in virus 
production among RGV treated, PMA and Prostratin stimulated cells compared 
with cells not treated with RGV (Fig. 4-9A and B).  The low level of FIV 
production in the presence of RGV was consistent with a similar experiment with 
HIV-1(Yang et al., 2009) and indicated that both phorbol esters stimulate FIV 
production from integrated provirus but that following stimulation, the majority 
of virus production then results from the de novo infection of adjacent cells.        
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Figure 4-9 – Reactivation of integrated provirus by phorbol esters. (A) IL2-
depleted MYA-1 CD4+ T cells were infected with FIV GL8 (M.O.I. = 0.06). Two 
days post infection cells were treated with PMA (0.08 μM), Prostratin (Pro – 1 μM) 
or mock-treated (DMSO). Supernatant was collected at day 10 post infection and 
virus production was quantified by a non-isotopic reverse transcriptase (RT) 
assay. (B) Parallel experiment to (A) in which Raltegravir (RGV – 1 μM) was 
added to the FIV-infected cells 24 hours post-infection (24 hours prior to treatment 
with PMA or Pro).  (C) Control experiment demonstrating the potency of RGV at 
blocking productive infection with FIV. RGV (1 μM) added to IL-2-supplemented 
cells in the presence 24 hours prior to infection with FIV and was maintained post-
infection. Each bar represents the mean +/- standard error (n=3) and 
representative of three independent experiments.  
 
PCR amplifying the LTR to gag region of FIV cannot distinguish between 
integrated or unintegrated viral DNA.  Alu-PCR, which involves the use of a pair 
of primers that bind to the highly repetitive chromosomal Alu elements and 
within HIV-1 sequence, is a popular method to detect integrated HIV-1 
sequences (Yamamoto et al., 2006, Han et al., 2007).  Unfortunately, no suitable 
repeat element had been discovered in the cat genome at the time of writing to 
develop a similar assay. 
Unintegrated viral DNA, by its nature, is low in molecular weight compared with 
genomic DNA and should remain as physically separate entities.  An attempt was 
made to demonstrate the presence of integrated provirus by separating out the 
high molecular weight (HMW) genomic DNA from the low molecular weight 
(LMW) DNA containing unintegrated viral DNA. The Hirt Protocol (Hirt, 1967), 
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which was originally conceived to isolate Polyoma viral DNA from infected cells 
without contamination by genomic DNA, was modified for this purpose.  5x106 
MYA-1 CD4+ T cells were infected with FIV GL8 (MOI 0.01) with/without pre-
incubation by the integrase inhibitor RGV.  The cells were then grown for five 
days and washed with PBS.  The cell pellet was resuspended in 1 ml of Hirt Lysis 
buffer (0.6% sodium dodecyl sulphate - SDS, 10 mM EDTA pH 7.5) and 250 μl of 
5M NaCl was then added.  The mixture was kept at 4°C overnight and 
centrifuged at 13,000 rpm for 45 minutes at 4°C.  The supernatant, which 
contained the LMW unintegrated viral DNA, was removed and kept as a control.  
The HMW DNA pellet was precipitated by SDS and was washed once by PBS 
before being dissolved in 500 μl of 10mM EDTA.  DNA from both the LMW and 
HMW portions were extracted using the phenol-chloroform method.  PCRs that 
amplify a region between the FIV 5’LTR and gag (which detects both integrated 
and unintegrated viral DNA) and 1 or 2-LTR circles (which detects unintegrated 
viral DNA only) were performed to confirm the presence of FIV DNA and to check 
for contamination of the HMW DNA by unintegrated LTR-circular DNA.   A sample 
of HMW DNA containing integrated FIV provirus should be positive for FIV LTR-
gag but not for FIV circles.  Cells pre-incubated with RGV should be positive for 
FIV LTR-gag only in the LMW samples, because RGV should not block reverse 
transcription and would still produce unintegrated FIV DNA species.   
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Figure 4-10 – Unintegrated FIV DNA contaminates genomic High molecular 
weight DNA.  (A) FIV LTR-gag, (B) FIV LTR-circles and (C) GAPDH control PCR 
of DNA samples extracted from infected MYA-1 CD4+ T cells using the modified 
Hirt method.  L = LMW DNA.  H = HMW DNA.  (+) = Positive control is total DNA 
of productively infected MYA-1 CD4+ T cells.  (-) = dH2O control. RGV = 
Raltegravir (1 μM). 
Results showed that all the samples, including the RGV HMW, were positive for 
FIV LTR-gag (Fig. 4-10A).  The presence of the FIV LTR-gag sequence from the 
HMW DNA of cells treated with RGV could be explained by the presence of 
contaminating unintegrated LTR-circles (which can be amplified by the FIV LTR-
gag primer set), rather than the failure of the antiretroviral drug (Fig. 4-10B).  
Further improvements of the method were made.  The HMW DNA pellet was 
washed 2 more times with PBS before being dissolved by EDTA.  The phenol- 
chloroform extraction step was replaced by the use of Qiagen DNA extraction 
columns to simplify the protocol. To extract LMW DNA from the Hirt 
supernatant, 3 volumes of the Qiagen QG buffer was added to correct the pH 
and salt concentration for DNA extraction using the Qiagen Gel Extraction 
columns.  To extract the HMW DNA dissolved in EDTA, the lysis buffer from the 
Qiagen DNA Mini kit was added to correct the pH and salt concentration and the 
samples were processed using the DNA Mini columns according to the 
manufacturer’s protocol.  The quality of the DNA extracted by the columns was 
good (determined using the Nanodrop spectrophotometer – data not shown).  
However, the contamination of the HMW DNA by FIV circles persisted (Fig 4-
RGV + RGV - 
 L  L  H H +  - 
B 
A 
C 
  300 
  400 
 400 
 500 
 1500 
 1000 
 (Bp) 
FIV 
LTR- 
gag 
FIV LTR-
circles 
GAPDH 
 Chi Ngai Chan, 2012                                                                   Chapter 4,   113 
11B), albeit at a lower level than recorded before, as shown by the weaker FIV 
gag product for the RGV+ HMW sample.  Due to time constraints I was unable to 
optimise this method of isolating HMW DNA further.    
 
Figure 4-11 – Improvement in DNA purification reduces contamination of 
HMW DNA by unintegrated FIV DNA.  FIV LTR-gag (A) and FIV circles (B) PCR 
of DNA samples extracted from cells using the modified Hirt method.  L = LMW 
DNA.  H = HMW DNA.   No IL-2 = latently infected cells.  (-) = Negative control 
(total DNA from uninfected MYA-1 CD4+ T cells).  RGV = Raltegravir (1 μM). 
4.2.3 Effect of phorbol ester on cell growth and viability 
PMA is a recognised tumour-promoting agent (Hecker et al., 1964) and thus 
would not be suitable for in vivo use. However, previous studies have indicated 
that Prostratin lacks the tumour-promoting activity associated with PMA (Szallasi 
and Blumberg, 1991), indicating a potential for clinical use in the reactivation of 
latent lentiviral reservoirs.  Given that both PMA and Prostratin reactivated 
latent infection of MYA-1 CD4+ T cells with FIV, the effects of both agents on cell 
growth and viability were examined.  The addition of either PMA or Prostratin 
maintained cell viability in IL-2-depleted cells (Fig. 4-12A), viability remaining 
stable approximately 80% in treated cultures compared with untreated cultures 
where viability dropped sharply to 40% over the 8 day study period.  Over this 
period, both PMA and Prostratin triggered a modest expansion of the cells, 
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reflected in an increase in cell number, most notably with PMA where cell 
number expanded from 8x105/ml to 1x106/ml.  The addition of exogenous IL-2 
resulted in a doubling of cell number over an eight-day period to 1.6x106/ml 
(Fig. 4-12B).  The addition of either PMA or Prostratin in the presence of IL-2 had 
little effect on cell viability although a modest reduction in viability was noted 
with PMA (Fig. 4-12C). In the presence of IL-2, both PMA and Prostratin reduced 
cell growth, the effect with Prostratin being more evident and the treated 
cultures achieving a final density of 1.1x106/ml compared with 1.6x106/ml in the 
untreated cultures (Fig. 4-12D).  When IL-2-depleted cells were loaded with 
CFSE as a mean of tracking cell division, the proliferation enhancing and 
cytoprotective properties of PMA and Prostratin was confirmed (Fig. 4-12E,F), a 
dramatic shift in fluorescence evident in the PMA and Prostratin treated cultures 
and mirroring the effect of adding exogenous IL-2.  These data support previous 
observations describing the cytoprotective properties of Prostratin (Gustafson et 
al., 1992, Korin et al., 2002).  Curiously, stimulation of the feline MYA-1 CD4+ T 
cells with PMA or Prostratin resulted in the acidification of the medium in the 
presence or absence of exogenous IL-2 (Fig. 4-12G, H).  Acidification is usually 
associated with cell growth and metabolism, as cells without IL-2 supplement do 
not cause acidification (Fig. 4-12H).  This result may indicate that PMA and 
Prostratin can stimulate cellular metabolism without causing cell growth.  The 
addition of the phorbol esters to the culture medium in the absence of cells did 
not cause a change in pH over the same experimental period (Fig. 4-12I). 
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Figure 4-12 – Effect of phorbol esters on cell growth and viability. The effect 
of PMA and Prostratin on the growth and viability of MYA-1 CD4+ T cells was 
examined in the presence or absence of IL-2. (A) Cell viability and (B) total cell 
count of IL-2-depleted cells stimulated with PMA (0.08 μM), Prostratin (Pro – 1 
μM) or mock stimulated with solvent (DMSO) compared with IL-2-supplemented 
(100 U/ml) cells treated with DMSO. (C) Cell viability and (D) total cell count of IL-
2-supplemented cells stimulated with PMA or Prostratin (Pro) or mock stimulated 
with solvent (DMSO) compared with IL-2-depleted cells treated with DMSO.  Each 
point represents the mean +/- standard error (n=3) and representative of three 
independent experiments. (E) CFSE assay comparing proliferation of IL-2-
depleted cells treated with PMA, Prostratin, DMSO, or control cells treated with IL-
2.  Percentage of proliferating cells was estimated as the percentage of cells with 
fluorescence values lower in the gated region designated in (F), arbitrarily set at a 
value of 10%.  Results are representative of three independent experiments.  The 
effect of stimulation by phorbol esters on the pH of the culture medium was 
monitored.  RPMI medium contains the pH indicator Phenol red, which would turn 
yellow if the pH of the solution decreases and would turn bright pink if pH 
increases.  Cells were incubated with DMSO, PMA or Prostratin in the presence 
(G) or the absence (H) of IL-2 for 8 days.  (I) The phorbol esters were added to 
culture medium and incubated at the same conditions as the cells during the 
experiment to account for any change in pH due to possible chemical reaction of 
the phorbol esters with the constituents of the medium. 
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4.2.4 Reactivation of productive infection from resting MYA-1 
CD4+ T cells required PKC-mediated signalling 
Phorbol esters such as Prostratin are potent activators of the PKC pathway in 
human cells and their HIV-1 reactivating effects have been shown to depend on 
this pathway (Castagna et al., 1982, Kikkawa et al., 1983, Williams et al., 2004).  
I therefore asked whether the specific inhibitor of PKC “Gö6850”, a compound 
that targets both conventional and novel PKC isoforms, would inhibit the FIV 
stimulating effects of Prostratin in vitro.  The application of Gö6850 (at a 
concentration of 2.5 μM, which should inhibit most novel and conventional 
isoforms of PKC (Martiny-Baron et al., 1993)) completely blocked the stimulation 
of productive FIV infection by Prostratin in IL-2-depleted resting MYA-1 CD4+ T 
cells (Fig. 4-13A).  The ability of exogenous IL-2 added post infection to 
reactivate viral replication from infected resting cells was similarly abrogated by 
Gö6850 (Fig. 4-13A), confirming a common mechanism of action of Prostratin 
and IL-2 in the stimulation of FIV replication and spread.  Treatment with 
Gö6850 also reversed the cytoprotective effect of Prostratin in IL-2-depleted 
cells, suggesting a correlation between the maintenance of cellular viability and 
the induction of viral growth (Fig. 4-13B) and consistent with the vital 
modulatory role of PKC in T cell activation and IL-2-dependent signalling (Isakov 
and Altman, 2002) (Tan and Parker, 2003).  
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Figure 4-13 – Reactivation of productive infection from infected resting MYA-
1 T cells is PKC-dependent. IL-2-depleted MYA-1 cells were infected with FIV 
GL8 (M.O.I. = 0.01) and virus production was monitored by a non-isotopic reverse 
transcriptase (RT) assay (A).  Cells were treated with DMSO, Prostratin (Pro – 1 
μM), Prostratin + the PKC inhibitor Gö6850 (2.5 μM), IL-2 (IL-2 100 U/ml), IL-2 + 
Gö6850 or Gö6850 alone 2 days post-infection with FIV. (B) Cell viability in the 
treated cells in the presence or absence of FIV infection as measured 8 days post-
infection. (p.i.) indicates IL-2 was added post infection.  Each bar represents the 
mean +/- standard error (n=3) and results are representative of three independent 
experiments (One Way ANOVA *p<0.05; **p<0.01) 
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4.2.5  Possible synergistic reactivation of productive FIV infection 
from resting MYA-1 T cells by Prostratin and the HDAC 
inhibitor valproic acid 
As well as the regulation of PKC, the modulation of histones and nucleosomes 
has been shown to be important to HIV-1 latency (Reviewed in (Colin and Van 
Lint, 2009) and (Coiras et al., 2009)).  The use of Histone deacetylase (HDAC) 
inhibitors to reactivate latent virus in vitro and in clinical trials had been 
performed before (Van Lint et al., 1996, Lehrman et al., 2005).  Recently, a 
study has found that reactivation is enhanced by the use of both Prostratin and 
HDAC inhibitors (Reuse et al., 2009).  Thus an experiment was carried out to 
investigate the effects of two HDAC inhibitors, valproic acid and sodium 
butyrate, on the infected resting MYA-1 T cells.  Results showed that the 
application of the two HDAC inhibitors on their own did not have any stimulatory 
effects on virus replication.  However, when valproic acid was administered 
together with Prostratin, an enhancement of Prostratin’s activity was observed 
(Fig. 4-14).  Both valproic acid and sodium butyrate exhibited cytotoxic effects, 
but viability of cells treated with valproic acid was rescued by Prostratin (Fig. 4-
14B).  However, due to time and resource constraints no further repeats were 
performed to confirm these findings. 
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Figure 4-14 – Valproic acid enhances reactivation of productive FIV infection 
from infected resting MYA-1 T cells by Prostratin.  IL-2-depleted MYA-1 CD4+ 
T cells were infected with FIV GL8 and virus production was monitored in the 
culture supernatants by a non-isotopic reverse transcriptase (RT) assay at Day 7 
post infection (A).  Cells were treated with DMSO, valproic acid (VPA – 1.25 mM), 
sodium butyrate (NaB – 1.5 mM), Prostratin (Pro – 1 μM), Prostratin + valproic 
acid or sodium butyrate.  (B) Cell viability measurements were carried out on day 7 
post infection.  Each bar represents the mean +/- range (n=2). 
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4.3 Part 2 – Phorbol esters inhibit productive FIV 
infection 
Both PMA and Prostratin have been shown by multiple studies to have anti- HIV-1 
replication activity (Gustafson et al., 1992, Gulakowski et al., 1997, Kulkosky et 
al., 2001, Biancotto et al., 2004, Rullas et al., 2004, Warrilow et al., 2006).  The 
paradoxical dual effect of activating latent lentiviral infection and inhibiting 
productive lentiviral replication exhibited by the phorbol esters makes them 
potential candidates for therapeutic use in anti-latency treatment.  In this part 
of the thesis I investigate whether phorbol ester Prostratin could also inhibit 
productive FIV infection. 
 
4.4 Results 
4.4.1 Prostratin significantly blocked productive FIV infection and 
this was mediated by PKC 
Actively growing, IL-2 supplemented feline CD4+ MYA-1 T cells were infected 
with FIV and 2 days post infection Prostratin was added to the cultures.  
Supernatant samples were taken at day 8 post infection and virus titre was 
measured by a reverse transcriptase activity assay.  The addition of Prostratin 
significantly reduced FIV production by more than 50% (Fig. 4-15A, C).  
Furthermore, the inhibition of virus production was reversed by the simultaneous 
treatment of the cells with Gö6850, suggesting that the inhibitory effect 
required PKC-dependent signalling.  An assessment of cell viability (Fig. 4-15B) 
indicated that Prostratin did not reduce the number of viable cells and thus the 
inhibitory effect on virus growth was not the result of a non-specific toxic 
effect.  Importantly, the addition of Gö6850 on its own did not increase 
productive infection relative to mock stimulated cells and in two of the four 
independent experiments Gö6850 reduced FIV production as well as the viability 
of infected cells (Fig. 4-15C, D). 
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Figure 4-15 – Inhibition of productive infection with FIV by Prostratin in the 
presence of IL-2 is PKC dependent.  MYA-1 CD4+ T cells were cultured in the 
presence of IL-2 and infected with FIV GL8 (M.O.I. = 0.01). 2 days post-infection, 
Prostratin (Pro – 1 μM)), Prostratin and Gö6850 (2.5 μM), Gö6850, or DMSO were 
added to the cells 2 days post-infection.  At day 8 post-infection, (A) Virus 
production was quantified in the culture supernatant by non-isotopic reverse 
transcriptase assay while (B) the viability of infected and uninfected cells was 
assessed by Trypan Blue exclusion.  Each bar represents the mean +/- standard 
error (n=3) and is representative of 2 independent experiments.  In separate 
experiments, virus production was quantified at day 8 post-infection by FIV p24 
ELISA (C) and the viability of FIV infected cells were assessed by Trypan Blue 
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exclusion (D).  Each bar represents the mean +/- standard error (n=4) and the 
data are the combination of two independent experiments (One Way ANOVA    
*p< 0.05; **p<0.01) 
 
4.4.2 Manipulation of NFκB has no effect on productive infection 
with FIV  
Earlier, in an attempt to establish latent infection various NFκB inhibitors were 
incubated with IL-2 supplemented feline MYA-1 CD4+ T cells and surprisingly the 
inhibitor SC514 enhanced FIV GL8 production (Fig. 4-2A).  If this could be 
replicated it may illustrate new principles governing host-pathogen interactions.  
MYA-1 CD4+ T Cells were infected with FIV GL8 and incubated with different 
concentrations (5 μM – 20 μM) of SC514 and another NFκB inhibitor, JSH23, 
immediately after infection (JSH-23 was chosen because it interferes with a 
different step of the NFκB signalling pathway to SC514, namely the nuclear 
translocation process of NFκB (Shin et al., 2004) while SC514 is a selective IKK-2 
inhibitor (Kishore et al., 2003)).  Virus production during the subsequent 14 days 
was measured by FIV p24 ELISA.  In the initial experiment, the titre of virus in 
the cell culture supernatant was doubled by the addition of 10 μM SC514 (Fig 4-
2A).  This was not replicated in subsequent experiments; rather the addition of 
SC514 did not increase the rate of virus production (Fig. 4-16A).  The addition of 
JSH23 also did not increase the rate of virus production during the course of the 
experiment.  Large errors were observed in the cultures incubated with NFκB 
inhibitors but not in DMSO solvent added culture.  This persisted in every repeat 
experiment and the significance of this observation is unknown.  If the large 
errors were ignored the data shows that the NFκB inhibitors actually reduced the 
rate of virus production during the early phase of the experiment, eventually 
reaching a plateau by day 10 post-infection.  Based on the available data it was 
concluded that the application of the NFκB inhibitors SC514 and JSH23 does not 
have any FIV enhancement effect, contrary to my initial findings. 
 
 Chi Ngai Chan, 2012                                                                   Chapter 4,   124 
Days post-infection
4 6 8 10 12 14
V
ir
u
s
 p
ro
d
u
c
ti
o
n
p
2
4
 E
L
IS
A
 (
A
4
5
0
n
m
)
0
1
2
3
4
5
DMSO
SC514 (5µM)
SC514 (10 µM)
SC514 (15µM)
SC514 (20 µM)
Days post-infection
4 6 8 10 12 14
V
ir
u
s
 p
ro
d
u
c
ti
o
n
p
2
4
 E
L
IS
A
 (
A
4
5
0
n
m
)
0
2
4
6
8 DMSO
JSH23 (5µM)
JSH23 (10 µM)
JSH23 (15 µM)
JSH23 (20 µM)
 
 
Figure 4-16 – NFκB inhibitors do not enhance productive infection contrary 
to initial findings.  IL-2 supplemented feline MYA-1 CD4+ T cells were infected 
with FIV GL8 (MOI = 0.001) for 2 hours, washed and incubated with the NFκB 
inhibitors SC514 (A) and JSH23 (B) at indicated concentrations.  Samples of 
supernatant were taken at day 4, 6, 8, 10, 12 and 14 post-infection.  Supernatant 
virus titre was measured by FIV p24 ELISA.  Each point represents mean +/- 
range (n=2) and is representative of three independent experiments.         
Previous studies have suggested that the inhibition of productive infection with 
HIV-1 by Prostratin is mediated by the down-regulation of viral primary receptor 
CD4 and co-receptor(s) CCR5 and CXCR4 (Kulkosky et al., 2001, Rullas et al., 
2004, Warrilow et al., 2006).  Thus the effect of Prostratin on the expression of 
both CD134 and CXCR4 (the FIV primary receptor and co-receptor respectively) 
on MYA-1 CD4+ T cells in the presence of IL-2 was examined over a 7 day period.  
The expression of CD134 showed a general decline over the experimental period 
from ~70% to ~40% positive (Fig. 4-17A).  The application of Prostratin to the 
cells had variable effects on the expression of CD134 between experiments, 
which was probably a reflection of the nature of the MYA-1 CD4+ T cells as they 
cycle through phases of blasting, rapid expansion and then resting (Fig. 4-17A, 
C).  However, when the cells were treated with Prostratin plus Gö6850 or 
Gö6850 alone the expression of CD134 was dramatically reduced to below the 
detection limit of flow cytometry (Fig. 4-17A, C).  The expression of CXCR4 on 
the MYA-1 CD4+ T cells was relatively low compared with CD134 (Fig. 4-17B, D).  
Again the effect of Prostratin on the expression of CXCR4 was variable between 
experiments, but crucially the expression of CXCR4 was completely down-
regulated when the cells were treated with Gö6850 alone or with Prostratin plus 
A B 
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Gö6850, a treatment which rescued FIV replication from Prostratin-induced 
inhibition (Fig. 4-17B, D).  Thus the ability of Prostratin to inhibit productive 
infection with FIV cannot be explained by the down-regulation of expression of 
either CD134 or CXCR4. 
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Figure 4-17 – Effect of Prostratin and Gö6850 on the expression of CD134 
and CXCR4 on MYA-1 CD4+ T cells.  MYA-1 CD4+ T cells were cultured in IL-2-
supplemented medium in the presence of Prostratin (Pro – 1 μM), Prostratin plus 
Gö6850 (Pro + Gö6850 – 2.5 μM), or solvent (DMSO). Sequential samples were 
collected over a 7 day period and the expression of (A) CD134 and (B) CXCR4 
was quantified by flow cytometry.  Each point represents the mean +/- standard 
error (n=3) and is representative of three independent experiments.  In an 
additional experiment the effect of applying Gö6850 alone on the expression of 
CD134 (C) and CXCR4 (D) was investigated.  Each point represents the mean +/- 
standard error (n=3). 
B A 
C D 
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4.4.3 Pre-incubation with Prostratin did not reduce virus titre 8 
days post infection 
Next the effect of pre-incubation with Prostratin and the PKC inhibitor Gö6850 
on virus production was investigated.  MYA-1 CD4+ T cells were pre-incubated 
with Prostratin, Gö6850 or Prostratin plus Gö6850 overnight before infection 
with FIV.  Cells were then washed and resuspended in fresh medium plus 
exogenous IL-2 and sequential samples were supposed to be taken at day 4, 6 
and 8 post infection.  Due to constraints of resources only the samples from the 
end of the experiment at day 8 post infection were processed by reverse 
transcriptase activity assay.   Results indicated that none of the treatments had 
reduced virus titre compared with solvent control at the end of the experiment 
(Fig. 4-18).  However, since virus replication was not monitored throughout the 
experiment, a small defect in viral entry during the first round of infection might 
be masked by subsequent de novo infection. 
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Figure 4-18 – Pre-incubation of cells with Prostratin before FIV infection 
does not reduce final virus titre.  MYA-1 CD4+ T cells were pre-treated with 
Prostratin (Pro – 1 μM), Prostratin + Gö6850 (2.5 μM), Gö6850 or mock-treated 
(DMSO) overnight before infection with FIV GL8 (MOI = 0.01).  Cells were then 
washed twice and re-suspended in complete RPMI + IL-2 in the absence of 
Prostratin or Gö6850.  Virus titre in the culture supernatant eight days post 
infection was quantified by non-isotopic reverse transcriptase assay.  Each bar 
represents the mean +/- standard error (n=3). 
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4.4.4 Measuring virus entry by luciferase assay 
Infection of cells with a luciferase reporter virus is an established method to 
study viral entry and other aspects of the viral lifecycle (Connor et al., 1995, 
Samman et al., 2009, Gonzalez et al., 2010).  To further investigate the effect 
of Prostratin on viral entry, MYA-1 CD4+ T cells were infected with HIV-
luciferase pseudotypes containing FIV GL8 Env and luciferase activity assays 
were performed.  First, the cells were maintained in the presence or absence of 
exogenous IL-2 supplement for three days to simulate the conditions of the 
aforementioned resting T cell or productive infection assays.  Then the cells 
were pre-incubated with Prostratin for 1 hour before infection.  Luciferase 
activity of each culture was measured after a further incubation of 72 hours in 
the presence of Prostratin.  Results showed that in the presence of IL-2, 
Prostratin did not noticeably alter luciferase activity (by causing less than one 
log difference in cpm) of the cells (Fig 4-19A).  In the IL-2-depleted cells, a 
marked reduction in luciferase activity in the mock-treated cells was observed 
(Fig. 4-19B).  This reduction in luciferase activity was rescued by Prostratin, 
which brought activity back to a level comparable to IL-2-supplemented samples 
(Fig. 4-19B). 
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Figure 4-19 – Prostratin increases luciferase activity in IL-2-depleted MYA-1 
CD4+ T cells but not the luciferase activity of IL-2 supplemented cells.   MYA-
1 CD4+ T cells were kept in the presence (A) or absence (B) of exogenous IL-2 
supplement for three days, followed by a pre-incubation with DMSO or Prostratin 
(Pro – 1 μM) for 1 hour.  Infections with HIV (FIV) pseudotypes were then 
A B 
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performed and the cells were maintained for another 72 hours in the presence of 
Prostratin or DMSO before luciferase activity was measured.  NC = no pseudotype 
control.  Each bar represents the mean +/- standard error (n=3) and is 
representative of two independent experiments. 
The enhancement of luciferase activity in IL-2-depleted cells by Prostratin could 
be due to an increase in viral entry or the stimulation of cellular signalling 
pathways, which increases the subsequent expression of the luciferase gene.  To 
answer this question, cells were infected with the HIV (FIV) pseudotypes and 
then re-suspended in fresh medium supplemented with exogenous IL-2, 
Prostratin or DMSO.  In this arrangement viral entry was assumed to be constant, 
therefore any difference in luciferase activity between phorbol ester treated 
and untreated cells would be due to post-entry effects.  Results indicated that 
the addition of exogenous IL-2 or Prostratin after infection markedly increased 
luciferase activity (Fig. 4-20).  Since Prostratin had an entry-independent 
stimulatory effect on luciferase activity, it was concluded that the luciferase 
assay is an unreliable method to deduce the effect of Prostratin on viral entry. 
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Figure 4-20 – Phorbol esters increase the activity of the luciferase assay 
independent of effects on viral entry.  MYA-1 CD4+ T Cells were pre-incubated 
with exogenous IL-2 supplement (100 U/ml) for three days before infection with 
HIV (FIV) pseudotypes.  Cells were then washed and resuspended in fresh 
medium and were maintained in the presence of IL-2, DMSO or Prostratin (1 μM) 
for a further 72 hours before the luciferase activity assay was performed.  NC = no 
pseudotype control.  Each bar represents the mean +/- standard error (n=3).   
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4.4.5 FIV p24 ELISA to detect intracellular gag 
Another method to quantify viral entry is to directly measure the amount of viral 
Gag protein that has entered the cell just after infection.  MYA-1 CD4+ T cells 
supplemented with exogenous IL-2 were pre-incubated with Prostratin, 
Prostratin plus Gö6850, Gö6850 alone or mocked-treated for 24 hours before 
infection with a high titre (MOI=0.1) of FIV GL8.  Cells were then washed 1 hour 
after infection and trypsin-digested to remove surface-bound viruses.  To 
measure internalized FIV Gag the cells were lysed and the lysates were 
processed by a FIV p24 ELISA.  The high titre was necessary to allow detection of 
the viral Gag in the lysate.  The results showed a small reduction of FIV p24 in 
the lysate of cells pre-incubated with Prostratin compared with control cells 
(DMSO) and cells pre-incubated with Prostratin and Gö6850 (Fig. 4-21).  
However, the difference was not significant (confirmed by One Way ANOVA, p > 
0.05).  Since a very high titre of FIV had to be used in order to provide enough 
FIV Gag to be detected by the FIV p24 ELISA, the result of this experiment may 
not be physiologically relevant. 
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Figure 4-21 – Effect of Prostratin and Gö6850 on the amount of internalized 
FIV p24 post infection.  IL-2 supplemented MYA-1 CD4+ T Cells were pre-
incubated with solvent (DMSO), Prostratin (Pro – 1 μM) or Prostratin plus Gö6850 
(2.5 μM) for 24 hours before infection with FIV GL8 (MOI = 0.1).  One hour post 
infection the cells were then washed, trypsin treated, lysed and the amount of 
intracellular FIV Gag was quantified by ELISA.  Each bar represents the mean +/- 
standard error (n=3).  The differences between the absorbance values of DMSO, 
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Prostratin and Prostratin plus Gö6850 are not statistically significant (One Way 
ANOVA, p > 0.05). 
4.4.6 Quantification of intracellular FIV DNA  
Quantifying the total viral DNA within cells immediately after the completion of 
reverse transcription is another method to measure viral entry, assuming that 
reverse transcription is not affected by the experimental treatment. IL-2-
supplemented MYA-1 CD4+ T cells were pre-incubated with Prostratin, Prostratin 
plus Gö6850, Gö6850 or DMSO for 24 hours before infection with FIV.  Cells were 
harvested 2 hours post infection and total cellular DNA extracted to allow the 
quantification of intracellular FIV DNA by qPCR.  Results from three independent 
experiments found no significant differences (One Way ANOVA, p>0.05) in the 
relative quantities of FIV DNA between cells subjected to the four treatments 
(Fig. 4-22), which further supports the hypothesis that the anti-FIV mechanism 
of Prostratin is post-entry. 
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Figure 4-22 – Pre-treatment of MYA-1 CD4+ T cells with Prostratin or Gö6850 
does not reduce intracellular FIV DNA detected 2 hours post infection.  IL-2 
supplemented CD4+ MYA-1 T cells were pre-incubated with Prostratin (Pro – 1 
μM), Prostratin plus Gö6850 (2.5 μM), Gö6850 alone or mocked treated with 
solvent (DMSO) for 24 hours before infection with FIV GL8 (M.O.I. = 0.01).  2 
hours post infection the cells were washed twice and total cellular DNA extracted.  
qPCR amplifying a region of the FIV gag gene was performed on the DNA 
samples and the results were analysed using the ΔΔCt method relative to the 
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average ΔCt value of the mock treated (DMSO) cells.  Each bar represents the 
mean +/- standard deviation of the calculated relative quantities (n=3) and is 
representative of three independent experiments. 
4.4.7 Phorbol esters and innate restriction factors  
Recently, a number of intrinsic viral restriction factors have been discovered in 
cells; these include TRIM5α (Hatziioannou et al., 2004, Stremlau et al., 2004), 
tetherin (Neil et al., 2008, Van Damme et al., 2008) and APOBEC3G (Sheehy et 
al., 2002).  These factors are expressed endogenously in host cells and are the 
first line of defence against viral pathogens.  They can also mediate species-
specific tropism of closely related viruses like HIV-1, SIV and FIV (Stremlau et 
al., 2005, Dietrich et al., 2011a).  Furthermore, the expression and functions of 
these factors are connected to changes in cell signalling (Rose et al., 2004, 
Pertel et al., 2011).  Thus, I planned to investigate the effect of Prostratin on 
the expression of these restriction factors.   
TRIM5α belongs to the tripartite motif family of proteins and has been 
demonstrated to have an anti-retroviral effect before or during reverse 
transcription (Stremlau et al., 2004).  TRIM5 gene expression is up-regulated by 
type I but not type II interferon signalling, indicating a connection between it 
and innate immune signalling (Carthagena et al., 2009).  Furthermore, a recent 
study suggested that TRIM5α can mediate innate immune signalling by 
stimulating AP-1 and NFκB (Pertel et al., 2011).  However, it is unlikely that 
feline TRIM5α plays an active anti-viral role in feline cells because of a 
truncation in its B30.2 SPRY domain (McEwan et al., 2009), which means that it 
is unable to interact with the viral capsid and thus incapable of restricting virus 
replication (Stremlau et al., 2005, McEwan et al., 2009).   
Next, tetherin is an interferon inducible membrane protein and a restriction 
factor of enveloped viruses (Van Damme et al., 2008, Neil et al., 2008) that has 
been shown to prevent FIV particle release (Dietrich et al., 2011b).  However, 
the expression of tetherin also increases syncytium formation in adherent CRFK 
(ID-10) cells infected with a cell-culture adapted FIV strain (F14), indicating an 
enhancement of cell-to-cell transmission.  To take advantage of this 
phenomenon, ID-10 cells were infected with FIV F14 and stimulated with 
Prostratin 24 hours post infection.  When feline interferon omega (IFN-ω) was 
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added to ID-10 cells, it up-regulated feline tetherin expression and reduced virus 
concentration in the supernatant while at the same time increased syncytium 
formation (Fig. 4-23A, B and (Dietrich et al., 2011b)).  Thus if Prostratin 
stimulated the expression of feline tetherin in ID-10 cells, it would be expected 
that supernatant virus titre would be reduced while more syncytia would be 
observed.  However, results showed that Prostratin did not reduce the release of 
FIV at day 3 post infection (Fig. 4-23A) and did not enhance syncytium formation 
(Fig. 4-23B) in comparison with solvent control cells.  The data indicate that 
Prostratin restricted viral replication by means other than tetherin, although this 
only applied to ID-10 cells, which are not the natural cellular targets of FIV.   
0
0.5
1
1.5
2
2.5
3
D
M
S
O
P
ro
IF
N
 ω
N
o
 F
IV
R
T
 a
c
ti
v
it
y
 (
A
 4
0
5
n
m
)
 
 
Figure 4-23 – Prostratin restricts FIV replication by means other than the up-
regulation of tetherin.  CRFK (ID-10) cells were plated onto six-well plates and 
infected with FIV F14.  24 hours post-infection the cells were stimulated with 
No FIV DMSO 
Pro 
B 
IFN-ω 
A 
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Prostratin (Pro - 1 μM), solvent (DMSO) or feline IFN-ω for a further 48 hours 
before (A) virus titre in the culture supernatant was measured by a non-isotopic 
reverse transcriptase (RT) assay and (B) cell monolayers were stained with 
methylene blue/basic fuchsin to visualise the syncytia.  Each bar represents mean 
+/- range (n=2).  Representative syncytia are indicated by red arrows. 
To investigate further the dynamics of viral replication when infected cells were 
treated with Prostratin, the viral entry experiment in which cells were pre-
incubated with Prostratin before infection was continued for a further 7 days.  
24 hours after infection, RGV and AZT were added to the culture supernatant.  
In the absence of de novo infection, FIV RNA in the supernatant 3 days or 7 days 
after infection was quantified using qPCR.  Surprisingly Prostratin treated cells 
produced more extracellular viral RNA than either DMSO or Prostratin plus 
Gö6850-treated cells at day 3 and day 7 post-infection (Fig. 4-24A, B).  
Supernatant RT activity at day 7 was also measured and higher RT activity was 
detected from the supernatant of Prostratin-treated cells (Fig. 4-24C).  In a 
parallel experiment where antiretroviral drugs were not added, Prostratin 
blocked virus replication but curiously Gö6850 did not rescue productive 
infection (Fig. 4-24D).  This anomaly was attributed to the timing of the 
application of Gö6850 to cells.  It has been demonstrated previously that Gö6850 
could inhibit the effects of IL-2 (Fig. 4-13, 4-15).  The addition of Gö6850 before 
infection may be analogous to removing IL-2 prior to infection, which leads to a 
non-productive infection.  Based on the available results it appears that 
Prostratin blocked productive infection of FIV at a step other than entry or 
egress.     
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Figure 4-24 – Prostratin treatment does not reduce FIV production per 
infected cell.  MYA-1 CD4+ T cells were pre-treated with Prostratin (Pro – 1 μM), 
Prostratin plus Gö6850, Gö6850 alone and mock treated (DMSO) 24 hours before 
infection with FIV GL8 (M.O.I. = 0.01).  Cells were washed and the antiretroviral 
drugs RGV (1 μM) and AZT (5 μM) were added 24 hours post infection.  The 
quantity of FIV RNA in the supernatant at day 3 (A) and day 7 (B) post-infection 
was measured using qPCR.  Each bar represents the mean +/- standard deviation 
(n=3).  (C) Supernatant RT activity at day 7 post infection was also measured.  
Each bar represents the mean +/- standard error (n=3).  (D) A parallel experiment 
without the addition of antiretroviral drugs was also performed.  Virus production 
was measured by FIV p24 ELISA.  Each bar represents the mean +/- standard 
error (n=3).   
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4.5 Discussion 
The ability of HIV-1 to establish a latent reservoir within the host makes the 
virus invulnerable to eradication from the body by current antiretroviral 
treatments.  In the absence of an effective vaccine against the virus, a practical 
method of reactivating latent viruses within the body and thus rendering them 
susceptible to antiretroviral drugs and the immune response may prove to be the 
only way to stem the global HIV-AIDS epidemic.  A suitable small animal model 
of HIV-1 latency and reactivation is vital to the development of such therapeutic 
regimes and the research presented in this chapter has shown that FIV infection 
of the domestic cat may fulfil the necessary criteria.   
Previous studies have shown that the majority of the latently infected CD4+ T 
cells in asymptomatic patients are memory T cells (Pierson et al., 2000, 
Chomont et al., 2009).  However, direct infection of resting T cells replenishes 
the latent reservoir as the infection progresses (Wightman et al., 2010).  It has 
been well established that lentiviruses can infect resting T cells, but viral 
replication and further spread is very inefficient (Joshi et al., 2004, Vatakis et 
al., 2010).  This may be due to defects at various stages of the viral lifecycle, 
including reverse transcription, integration and viral protein expression (Vatakis 
et al., 2007, Vatakis et al., 2009).  This chapter described two strategies that 
were used to attempt to establish FIV latently infected feline CD4+ T cells.  The 
first strategy of using NFκB inhibitors to induce latency was unsuccessful, 
whereas the second strategy of infecting IL-2-depleted MYA-1 CD4+ T cells as 
they slowly became quiescent was more successful.  The depletion of exogenous 
IL-2 from MYA-1 CD4+ T cells in this assay is analogous to the progression of 
activated T cells to quiescence during the formation of memory cells (McKinstry 
et al., 2007) and led to a significant defect in virus replication and spread within 
the cell population.  However, on-going low-level virus replication among the IL-
2-depleted cells was detected, indicating that rather than successfully re-
creating the latently infected memory T cells, this assay may be more similar to 
the direct infection of resting T cells.   
The low level continuous viral replication detected in my in vitro assay may be 
the result of an incomplete but uniform down regulation of viral replication by 
all of the infected cells or a small number of infected cells replicating virus at 
the normal rate as the population enters the quiescent state in a non-uniform 
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fashion.  The assay used was unable to distinguish between these two 
possibilities.  To eliminate this continuous viral gene expression or replication 
completely in an in vitro system of latent infection is difficult, and other models 
have displayed similar “leaks” of low-level virus expression (Bosque and 
Planelles, 2009, Yang et al., 2009, Saleh et al., 2011). The existence of low-level 
virus gene expression or replication may actually reflect the nature of the latent 
reservoir in vivo, as it has been proposed that there is a range of different levels 
of viral activation within the reservoir, analogous to the fact that the resting T 
cell population in the body is not homogenous in terms of cellular activation 
(Pace et al., 2011).  Another limitation of the assay is that the qPCR primers 
used cannot distinguish between integrated or non-integrated viral DNA.  
Integrated HIV-1 provirus can be detected using techniques such as Alu-PCR 
(Sonza et al., 1996).  Unfortunately no equivalent reliable method of confirming 
FIV integration is available at the time of writing.  The attempt to separate 
unintegrated viral DNA from the host genome using the modified Hirt Protocol 
failed due to persistent contamination by the unintegrated viral DNA.  Using the 
integrase inhibitor RGV a small increase in virus production was repeatedly 
demonstrated when IL-2-depleted resting MYA-1 T cells were stimulated with 
PMA or Prostratin compared with mock-stimulated cells.  However, it was not 
certain whether this increase in virus production came from latently infected 
cells or from the cells which were persistently producing virus.  These problems 
are not limited to this assay and represent a degree of uncertainty as to which 
kinds of viral DNA had been identified and where the viraemia came from in 
many of the published HIV-1 latency models (Han et al., 2007). 
Despite these shortcomings with the in vitro assay, the parallels between the 
regulation of FIV and HIV-1 replication and spread are clear.  Replication of both 
viruses is stimulated by IL-2 (Oswald-Richter et al., 2004a); while Prostratin can 
both stimulate HIV-1 and FIV replication in resting T cells and inhibit productive 
infection in activated T cells (Gustafson et al., 1992, Kulkosky et al., 2001, 
Biancotto et al., 2004, Rullas et al., 2004, Warrilow et al., 2006).  This 
illustrates a shared reliance on PKC-dependent signalling by both HIV-1 and FIV.  
Lentivirus production is very dependent on the activation status of the host cell 
(Stevenson et al., 1990, Joshi et al., 2004). The IL-2-dependency of FIV infection 
of MYA-1 CD4+ T cells mirrors the behaviour of CD4+CD25+ T cells isolated from 
feline peripheral blood mononuclear cells, which could be non-productively 
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infected by FIV in the absence of IL-2 (Joshi et al., 2005a).  The similarities 
between the two systems suggest that the MYA-1 CD4+ T cell culture system 
described herein reflects the characteristics of CD4+ T cells ex vivo.   In regard 
to the practicalities of investigating lentiviral latency in a laboratory setting,  
FIV infection of feline CD4+ T cells offers a safe and accessible system in which 
primary, wild-type viruses may be investigated without a requirement for a high 
level of biological containment.  These characteristics are highly desirable in a 
physiologically relevant small animal model of HIV-1 latency.  
Although Prostratin is able to stimulate FIV production from infected resting 
MYA-1 T cells, its ability to block de novo infection could potentially make it 
difficult to detect reactivation.  My results suggested that the ability of 
Prostratin to block FIV production is actually dependent on the background 
activation status of the host cell.  Replication of HIV-1 and FIV in resting T cells 
is very inefficient (Joshi et al., 2004, Vatakis et al., 2010).   Despite on-going 
low level production of virus within the model system, the spread of FIV was 
almost completely blocked by the depletion of IL-2.  By administering the 
antiretroviral drugs RGV and AZT post infection, it was established that most of 
the virus produced in the reactivation assay came from the ability of Prostratin 
or IL-2 to promote de novo infection after an initial burst of virus production.  
Thus in a state of low cellular activation such as after the removal of exogenous 
IL-2, Prostratin becomes a substitute for IL-2 and acts to stimulate, rather than 
block lentiviral replication and spread.  When IL-2 is present, most of the cells 
within the population would be stimulated in a relatively consistent manner, and 
it appears that further stimulation of the cells by Prostratin would have an 
inhibitory effect on virus replication in most of the cells.  It is intriguing that 
phorbol esters have two apparently contradictory effects on lentiviral 
replication. 
The effect of HDAC inhibitors valproic acid and sodium butyrate on the infected 
resting MYA-1 T cells was also investigated.  Although reactivation of productive 
FIV infection was not detected when infected resting MYA-1 T cells were 
stimulated with either compound, valproic acid was able to enhance Prostratin-
mediated reactivation.  This is in agreement with a recent study which reports 
the synergistic activation of HIV-1 when Prostratin and HDAC inhibitors are 
added simultaneously (Reuse et al., 2009).  The lack of reactivation by sodium 
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butyrate was attributed to the high toxicity of the compound.  In contrast, 
valproic acid caused much less cell death but it only had a measurable effect on 
reactivation of productive infection when used in conjunction with Prostratin.  
The fact that stimulation of virus production from infected cells could only be 
reliably detected by FIV p24 ELISA or the RT activity assay after amplification by 
de novo infection may explain why adding valproic acid alone to infected resting 
MYA-1 T cells apparently failed to stimulate virus production.  Valproic acid may 
stimulate viral replication but it may not be able to make the surrounding 
resting T cells permissive to infection in the same way Prostratin could.  A 
previous study has shown that the administration of valproic acid does not cause 
the activation of human CD4+ T cells or make them more conducive to HIV-1 
infection (Ylisastigui et al., 2004).  It is important to note that valproic acid is a 
weak HDAC inhibitor and a weak latency-reversing agent (Colin and Van Lint, 
2009) and other more potent HDAC inhibitors such as suberoylanilide hydroxamic 
acid (SAHA) (Archin et al., 2009, Contreras et al., 2009) may be tested in future 
experiments.  The use of more sensitive techniques such as qPCR should be 
considered when evaluating the effects of compounds which do not enhance de 
novo infection.  Recently, a study has demonstrated that FIV infection in vivo 
leads to the establishment of latently infected CD4+ T cells analogous to the 
latent infections of HIV-1 in humans (Murphy et al., 2012).  Indeed, SAHA is 
shown to reactivate latent viruses ex vivo subsequently (McDonnel et al., 2012), 
which adds support to the idea of using FIV-infected cats as a small animal 
model for HIV-1 latency. 
The inhibition of the dual actions of Prostratin by the PKC inhibitor Gö6850 
suggested a central role for this enzyme family in the replication of FIV.  The 
PKC family of enzymes play an important role in T cell receptor signalling and T 
cell activation (Isakov and Altman, 2002).  Because both HIV-1 and FIV target 
activated CD4+ T-cells, the viruses have acquired the ability to exploit the 
cellular pathway of T cell activation by encoding binding sites for several 
transcription factors of the PKC signalling cascade. For example the HIV-1 LTR 
contains sites for NFAT, NFκB, and AP-1, while the FIV LTR contains sites for AP-
4, AP-1/ATF and possibly NFκB (Tang et al., 1999, Sparger et al., 1992, 
Thompson et al., 1994) (Fig. 4-25A).  Using site-specific mutagenesis of the FIV 
LTR it has been demonstrated that the AP-1 site of the FIV LTR responds to 
stimulation of PKC (Sparger et al., 1992).  While our results demonstrate that IL-
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2 stimulation of  MYA-1 CD4+ T cells is sufficient to promote the replication of 
FIV in agreement with previous studies (Oswald-Richter et al., 2004a, Joshi et 
al., 2005a), it was also observed that the PKC inhibitor Gö6850 abrogated the 
reactivation of FIV and the cyto-protective effect of Prostratin in IL-2-depleted 
cells.  Since Gö6850 had a similar effect on the reactivation of FIV by exogenous 
IL-2, these data suggest that IL-2-mediated signalling through a PKC-dependent 
pathway to modulate viral growth and that Prostratin may share a similar mode 
of action.  However, the PKC signalling pathway only appeared to drive FIV 
replication in IL-2-depleted cells, as Gö6850 could not inhibit productive 
infection reliably, suggesting that in the presence of IL-2, the control of viral 
growth was dependent upon other cellular factors.  Engagement of the IL-2 
receptor by IL-2 is thought to initiate signalling through a number of pathways, 
including the JAK/STAT5, MAPK and PI3K (reviewed in (Cheng et al., 2011)); 
these pathways can also stimulate NFAT, NFκB, AP-1 and ATF, transcription 
factors important to HIV-1 and FIV replication (Fruman, 2004, Treinies et al., 
1999, Funakoshi-Tago et al., 2003, Chang et al., 2003) (Fig. 4-25B).   
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Figure 4-25 – The potential relationship between lentiviral gene expression 
and cellular PKC and IL-2 receptor-mediated signalling.  (A) A diagram 
showing the 5’ Long Terminal Repeats (LTR) region of FIV and HIV-1, highlighting 
the binding sites for transcription factors that interact with both virus and cellular 
PKC and IL-2 receptor-mediated signalling (Tang et al., 1999, Sparger et al., 1992, 
Elder and Phillips, 1995).  A putative NFκB binding site was found in the FIV-
Petaluma strain but it is not thought to be transcriptionally active in other FIV 
strains (Sparger et al., 1992, Thompson et al., 1994, Joshi et al., 2005b). (B) A 
diagram showing the transcription factors important in lentiviral replication 
interacting with PKC and IL-2 receptor (IL-2R) signalling pathways (Cheng et al., 
2011).  Both PKC and IL-2 receptor-mediated pathways have common 
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downstream targets such as NFκB, NFAT and AP-1 (Fruman, 2004, Isakov and 
Altman, 2002, Funakoshi-Tago et al., 2003).  PKC activates AP-1 directly (Isakov 
and Altman, 2002, Altman and Villalba, 2003).  IL-2 receptor signalling can 
activate PKC via the PI-3K/PDK-1 cascade (Le Good et al., 1998, Rudd and 
Schneider, 2003).  The JAK/STAT5 pathway activates AP-4 via the cell 
proliferation factor c-MYC (Lord et al., 2000, Jung and Hermeking, 2009).  Another 
IL-2 receptor-mediated pathway, ras/raf/MAPK stimulates ATF (Chang et al., 
2003).   
Multiple factors contribute to the maintenance of lentiviral latency in cells (Han 
et al., 2007, Coiras et al., 2009) but it has been shown that it is the activation 
state of the cell during infection that determines an outcome of latent or 
productive infection (Stevenson et al., 1990, Duverger et al., 2009).  Based on 
this understanding I attempted initially to establish latent FIV infection in MYA-1 
T cells using NFκB inhibitors to reduce cellular activation.  The inhibitors SC514 
and BOT64 were not successful in blocking FIV replication, whereas CAPE could 
restrict virus production only if it was applied continuously.  With hindsight this 
was unlikely to be successful because of the following: firstly, the presence of 
exogenous IL-2 in the cell culture supernatant during these experiments, which 
would continuously stimulate the cells and would drive productive infection as 
soon as the inhibitor was removed; secondly, NFκB is one of many downstream 
effectors that are triggered by IL-2 receptor signalling or PKC activation (Fig. 4-
25B), thus inhibition of NFκB could be circumvented, as demonstrated by the 
results; lastly, NFκB may not play an important in FIV GL8 replication as it was 
shown not to be transcriptionally active in this strain (Thompson et al., 1994).  
Nevertheless NFκB inhibitors may be useful in reducing or even stopping the 
residual virus replication detected after IL-2 depletion, but due to time and 
resource constraints I was unable to test this hypothesis experimentally.  The 
initial results also suggested that the NFκB inhibitor SC514 increased virus 
production.  However, this trend was not reproducible and it was concluded that 
SC514 does not enhance FIV production.  The enhancement of virus production 
seen in early experiments may be caused by the lack of replicates cultures, 
allowing random variations in cell activation and virus production rate to 
generate false positive data. 
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Although the mechanism underlying the reliance of the MYA-1 T cells on PKC to 
maintain viability and drive FIV replication after IL-2 depletion remains to be 
established experimentally, based on the results presented in this chapter it can 
be envisaged that in vivo FIV initially targets activated CD4+ T cells and 
replicates in dividing cells. However, as IL-2 levels diminish, coinciding with the 
formation of memory T cell populations, the virus will establish a latent 
infection. The virus would then remain latent in the memory T cell population 
until antigenic stimulation and IL-2-dependent expansion reactivated the latent 
infection.   
The ability of Prostratin to inhibit FIV replication in the presence of IL-2 would 
seem paradoxical to its effect on the infected resting MYA-1 T cells. As the 
inhibition of PKC signalling by Gö6850 rescued the restriction of viral replication, 
the inhibitory effect would appear to be dependent upon PKC. What is the 
mechanism behind this PKC mediated viral restriction? Using the trypan blue 
exclusion assay no increase in cell death was detected after cells were treated 
with Prostratin in the presence of IL-2, thus it is unlikely that Prostratin inhibits 
virus replication by a non-specific toxicity effect.  Expression of the FIV 
receptors CD134 and CXCR4 was monitored over seven days and it was concluded 
that modulation of the expression of the FIV receptors CD134 and CXCR4 cannot 
be invoked to explain the inhibition of FIV replication by Prostratin.  This is 
because in the experiments the simultaneous addition of Gö6850 and Prostratin 
to cells led to the rapid down regulation of CD134 and CXCR4, yet the 
application of Gö6850 rescued productive infection from Prostratin treatment.   
Other methods were also used to deduce the effect of Prostratin on viral entry.  
HIV-Luciferase pseudotypes with FIV Env have been previously used to 
investigate questions relating to virus binding and entry (Willett et al., 2006b, 
Willett et al., 2009).  However, the application of Prostratin increased luciferase 
activity independent of viral entry, which compromised the reliability of the 
assay in this instance.  Direct measurements of viral components using ELISA and 
PCR were also problematic.  In order to obtain a positive measurement when 
detecting intracellular viral Gag just after infection, a high dose of virus (MOI = 
0.1) had to be used, which may not be physiological and can potentially 
overwhelm any inhibitory effect.  No significant differences between the 
amounts of intracellular viral DNA from the different treatments were detected 
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by qPCR.  However, the quantities of intracellular viral DNA detected in this 
assay depended upon the efficiency of not only viral entry, but also virus 
uncoating and reverse transcription.  Nevertheless, despite each of the problems 
mentioned, every experiment performed indicated that Prostratin had little 
effect on virus entry.   
The down-regulation of CD4, CCR5 and CXCR4 has been observed consistently 
among Prostratin stimulated human CD4+ T cells (Gulakowski et al., 1997, 
Kulkosky et al., 2001, Biancotto et al., 2004, Rullas et al., 2004).  In one study 
the entry of pseudotypes containing HIV-1 Env was inhibited by Prostratin, but 
not VSV-G containing pseudotypes (Rullas et al., 2004). However, a previous 
study on FIV GL8 demonstrated that blockade of the FIV receptors revealed by a 
pseudotype assay does not translate to inhibition of productive infection (Willett 
et al., 2009).  It is possible that Prostratin induced changes to viral receptor 
expression levels amongst activated MYA-1 CD4+ T cells, but the magnitude of 
change was too small to block virus infection.  Another possibility is that HIV-1 
and FIV have different viral entry characteristics.  In addition, the qPCR data 
showed that two hours after infection, Prostratin-stimulated cells contained 
similar amount of intracellular viral DNA compared with mock-treated cells, 
which suggested that viral entry and reverse transcription were not affected by 
Prostratin.   This is contrary to a study of Prostratin’s effect on HIV-1 infection 
of human CD4+ T cells, which found that reverse transcription was partially 
inhibited (Biancotto et al., 2004).  Furthermore this study found that HIV-1 p24 
uptake was blocked and productive infection did not initiate in resting T cells 
pre-treated with Prostratin.  Differences in the experimental protocol may 
account for these discrepancies (for example, it was unclear whether Prostratin 
was washed off after HIV-1 infection).  Most studies on Prostratin’s effects have 
focused on its ability to stimulate virus production from resting cells already 
infected with HIV-1 and did not address the question of whether Prostratin can 
promote direct infection of HIV-1 into resting T cells (Kulkosky et al., 2001, 
Rullas et al., 2004, Reuse et al., 2009, Yang et al., 2009, Saleh et al., 2011).  
However, it is possible that Prostratin causes distinct effects on human and 
feline cells.  If FIV is to be used as a model for HIV-1 latency and growth, it is 
important to carry out more research to characterise the similarities and 
differences between HIV-1 and FIV. 
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HIV-1 encodes multiple accessory proteins such as Vif, Vpr, Vpu and Nef that are 
often dispensable during in vitro infection but would significantly attenuate the 
virus in vivo if absent (Anderson and Hope, 2004).  This indicated that at least 
one of the functions of these genes is to counteract obstacles within the host 
cells that would block infection.  Indeed the use of mutant viruses with an 
accessory gene knocked-out was key to the discovery of the first host restriction 
factor APOBEC3G (Sheehy et al., 2002).  This spurred on the discovery of other 
restriction factors such as TRIM5α (Stremlau et al., 2004), tetherin (Neil et al., 
2008, Van Damme et al., 2008) and more recently SAMHD1, a dendritic and 
macrophage specific restriction factor (Hrecka et al., 2011, Laguette et al., 
2011).  Could the stimulation of the activity of these restriction factors be the 
mechanism behind Prostratin’s anti-FIV effect?  A previous study of feline TRIM5 
has shown that due to a truncation in its B30.2 SPRY domain, it is unable to bind 
to viral capsid and thus unlikely to play an active anti-viral role in feline cells 
(McEwan et al., 2009, Stremlau et al., 2005).   
The effect of Prostratin on feline tetherin was then tested.  Feline tetherin has 
been shown previously to not only inhibit the release of FIV virions, but also 
promote syncytium formation (Dietrich et al., 2011b), supporting the idea that 
lentiviruses can shift their mode of transmission from cell-free to cell-to-cell in 
order to overcome or exploit tetherin mediated restriction (Dietrich et al., 
2011a).  Using a previously established assay of tetherin activity (Dietrich et al., 
2011b), I showed that Prostratin did not reduce viral release or increase 
syncytium formation, indicating that the phorbol ester has no effect on tetherin 
activity.  However, this assay was performed in CrFK ID-10 cells, which are not 
the natural host cell of FIV.   
Next, I demonstrated that when de novo infection was blocked by antiretroviral 
drugs added post-infection, the rate of virus production in IL-2 supplemented, 
Prostratin-stimulated cells was higher than mock-stimulated cells.  A possible 
future experiment to confirm this result would be to treat cells that are 
productively infected by FIV with Prostratin or Gö6850 under conditions which 
prevent de novo infection (for example, by adding antiretroviral drugs post 
infection) and to detect any subtle changes in the initial wave of virus 
production in the cell supernatant using the sensitive qPCR technique outlined in 
this chapter.  If these preliminary findings are confirmed, it means that rather 
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than blocking virus replication at the entry, production or exit step, Prostratin 
somehow affected the ability of the released virions to infect other cells.  One 
family of restriction factors that inhibits viral replication by reducing the 
infectivity of nascent virions is the APOBEC proteins.  In humans APOBEC3G 
restricts lentivirus infection by being incorporated into nascent virions and 
hyper-mutating the retroviral genome once the virus infects another cell (Zhang 
et al., 2003, Mangeat et al., 2003).  The feline homologues of APOBEC3G are the 
APOBECs 3C, 3H and 3CH (Munk et al., 2008) and the FIV Vif protein counteracts 
the anti-lentiviral activities of feline APOBEC proteins by mediating their 
degradation (Munk et al., 2008).  Activation of PKC by phorbol esters has been 
shown to up-regulate the expression of APOBEC3G (Rose et al., 2004, Rose et 
al., 2005), could it be that the combined stimulation of IL-2 and Prostratin may 
induce sufficient expression of APOBEC proteins to overcome Vif-dependent 
antagonism?  Whether high levels of APOBEC expression can overcome Vif 
remains to be proven (Vetter et al., 2009, Mussil et al., 2011, Zielonka et al., 
2010) and more research is urgently needed to address this and to replicate the 
effects of Prostratin on primary CD4+ T cells.  If this theory is proven in cat cells 
does it also apply to human CD4+ T cells?  
To my knowledge, this study is the first demonstration of the anti-viral effect of 
Prostratin against a non-primate lentivirus, indicating that the phenomenon of 
PKC-mediated viral restriction is conserved across mammalian species.  Further 
research into this PKC-mediated retroviral restriction effect would not only 
enhance our understanding of the complications and subtlety of cell signalling, it 
may lead to advancements in the treatment of lentiviral infections if the 
antiviral mechanism proved to be amenable to therapeutic intervention. 
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5 Investigation of viral growth differences 
between strains of FIV 
5.1 Summary 
FIV strains that have been isolated at different stages of disease exhibit 
different biological characteristics, such as an expansion in tropism and 
increased pathogenicity after chronic infection in vivo (Hosie et al., 2002, 
Willett and Hosie, 2010).  The variations between strains isolated in ‘early’ stage 
(or acute phase) and ‘late’ stage (chronic phase) infection may reflect disease 
progression and viral evolution under the selective pressures of the host immune 
system (Willett and Hosie, 2008).  This chapter reports the differences in viral 
replication in MYA-1 CD4+ T cells between the ‘early’ FIV strain GL8 (Hosie and 
Jarrett, 1990) and the ‘late’ FIV strain PPR (Phillips et al., 1990) (both subtype A 
viruses) as well as an attempt to map the viral genomic region associated with 
these differences. 
5.2 Results 
5.2.1 Experimental conditions differentially affect the replication 
kinetics of FIV GL8 and PPR  
First the dynamics of virus replication of the early and late strains of FIV (GL8 
and PPR respectively) was monitored over a 10-day period.  MYA-1 feline CD4+ T 
cells supplemented with exogenous IL-2 were infected with matched doses of FIV 
GL8 or PPR.  Samples of cell culture supernatant were taken at day 0, 3, 7, and 
10 post infection and virus titres of the supernatant were measured by an ELISA 
that detects the FIV p24 (Gag) protein.  Results from three independent 
experiments showed that the rate of FIV PPR replication was higher than FIV GL8 
(Fig. 5-1).   
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Figure 5-1 – FIV PPR replicates at a higher rate than GL8 in MYA-1 CD4+ T 
cells.  In the presence of exogenous IL-2, MYA-1 CD4+ T cells were infected with 
FIV PPR or GL8 (M.O.I. = 0.001) and virus replication was monitored over 10 days 
post-infection by FIV p24 ELISA.  Each point represents the mean +/- standard 
error (n=3) and was representative of three independent experiments. 
Next, MYA-1 CD4+ T cells were seeded in the absence of IL-2 and 24 hours post-
seeding they were infected with the two strains of FIV.  48 hours post infection 
the infected resting MYA-1 T cells were stimulated by the phorbol esters PMA 
and Prostratin, which resulted in productive infection (Fig. 5-2).  Virus 
production from GL8-infected cells stimulated by PMA or Prostratin proceeded at 
a similar rate, whereas virus production from PPR-infected cells stimulated by 
PMA occurred at a higher rate than virus production from PPR-infected cells 
stimulated by Prostratin.  Virus production from PMA-stimulated, PPR-infected 
cells reached a peak by day 8 post infection, but by day 10 virus titres from GL8-
infected cells also reached a similar level with the PMA stimulated, PPR infected 
cells.  Without stimulation the background p24 signal from PPR-infected cells 
was higher than GL8-infected cells. 
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Figure 5-2 – Reactivation of productive infection by phorbol esters is more 
pronounced among FIV PPR-infected cells.  IL-2-depleted cells were infected 
with FIV GL8 or PPR (M.O.I. = 0.01) and virus production was monitored by p24 
ELISA.  2 days post-infection, the cells were stimulated with either PMA (0.08 µM) 
or Prostratin (Pro – 1 µM).  Each point represents the mean +/- range (n=2) and is 
representative of three independent experiments. 
To determine the contribution of viral spread to the variation in virus replication 
between the two strains, IL-2-depleted MYA-1 T cells infected with FIV GL8 or 
PPR were stimulated by phorbol esters in the presence of the integrase inhibitor 
Raltegravir (RGV).  RGV blocks de novo infection, which allows the measurement 
of the rate of virus production from the initial inoculum only.  The mock-
stimulated infected resting MYA-1 T cells retained a very low level of basal FIV 
replication activity (Fig. 5-3), as demonstrated previously (Fig. 5-2 and previous 
chapter); this was more pronounced in PPR-infected cells compared with GL8-
infected cells.  PMA and Prostratin stimulated productive infection from the 
infected resting MYA-1 T cells, as demonstrated by the higher RT activity in the 
supernatant, with higher RT activities detected from the supernatant of PPR-
infected cells compared to the supernatant of GL8-infected cells (Fig. 5-3).  
When de novo infection was blocked by the presence of RGV, higher virus titres 
were observed from the supernatant of reactivated PPR-infected cells compared 
with GL8-infected cells.  These results suggested that FIV PPR has a higher rate 
of virus production per infected cell compared to FIV GL8.  
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Figure 5-3 – FIV PPR demonstrates higher rates of basal replication and 
reactivation than FIV GL8.  IL-2-depleted resting MYA-1 T cells were infected 
with FIV GL8 or PPR (MOI = 0.06).  24 hours post infection the integrase inhibitor 
RGV was added to the appropriate cells and at day 2 post infection cells were 
stimulated with PMA (0.08 μM), Prostratin (Pro – 1 μM) or mock-stimulated with 
solvent (DMSO).  At day 5 post infection supernatant samples were taken to 
quantify virus replication using a non-isotopic reverse transcriptase (RT) assay.  
Each bar represents the mean +/- range (n=2).  Trends are representative of 2 
similar independent experiments using RGV but with different M.O.I. and end 
points. 
PKC has been shown to play a crucial role in FIV replication (See previous 
chapter).  To investigate if the two strains of FIV responded differently to 
inhibition of PKC, the PKC inhibitors Gö6976 or Gö6850 and phorbol esters were 
simultaneously added to IL-2-depleted MYA-1 T cells infected with FIV GL8 or 
PPR.  Gö6850 has been shown to inhibit both conventional and novel isoforms of 
PKC, with IC50 values of 8.4, 18, 210, 132 and 5800 nM against PKC isoforms α, 
β1, δ, ε and ζ respectively (Martiny-Baron et al., 1993).  In contrast Gö6976 is a 
more potent and specific inhibitor of conventional PKC isoforms, with IC50 values 
of 2.3 and 6.2 nM against PKC α and β1 respectively and no inhibitory activity 
against PKC δ, ε and ζ isoforms (Martiny-Baron et al., 1993).  Gö6850 abrogated 
phorbol ester-stimulated production of FIV GL8 and PPR (Fig. 5-4).  In contrast, 
Gö6976 caused complete restriction of FIV GL8 replication but only a partial 
restriction to the production of FIV PPR (Fig. 5-4).  Since both Gö6850 and 
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Gö6976 were used at 2.5 μM, a concentration much higher than the reported IC50 
for most of the PKC isoforms, complete, or near complete down-regulation of 
conventional or novel and conventional PKC isoforms was assumed.  These 
results indicated that virus production from cells infected with FIV GL8 was 
dependent on both novel and conventional PKC isoforms, whereas virus 
production from FIV PPR-infected cells only had a requirement for novel isoforms 
of PKC. 
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Figure 5-4 – Replication of FIV PPR from infected resting MYA-1 T cells 
stimulated with phorbol esters is less sensitive to the inhibitory effect of 
PKC inhibitor Gö6976 than FIV GL8.  IL-2-depleted cells were infected with FIV 
GL8 or PPR (M.O.I. = 0.01).  2 days post infection, the cells were stimulated with 
either PMA (0.08 μM) or Prostratin (Pro - 1 μM) in combination with PKC inhibitors 
Gö6976 (2.5 µM) or Gö6850 (2.5 µM).  Two independent experiments were 
performed and virus production was measured at day 8 post infection by (A) FIV 
p24 ELISA and (B) a non-isotopic reverse transcriptase (RT) assay.  Each bar 
represents the mean +/- range (n=2).  
As shown in the previous chapter, IL-2-dependent productive infection of feline 
CD4+ MYA-1 T cells by FIV GL8 was inhibited by Prostratin and this viral 
restriction effect could be reversed by the addition of the PKC inhibitor Gö6850.  
A parallel experiment with FIV PPR showed that PMA and Prostratin inhibited 
replication of both FIV GL8 and PPR, although the restriction of PPR was not as 
complete as the restriction of GL8 (Fig. 5-5).  Whereas Gö6850 completely 
reversed the inhibitory effect of PMA and Prostratin, Gö6976 could not rescue 
A B 
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virus replication entirely (Fig. 5-5) suggesting that PKC α and β1 played only a 
minor role in mediating the restriction of FIV.  A further level of complexity was 
revealed when the PKC inhibitor Gö6976 failed to reverse PMA-induced inhibition 
of FIV GL8 replication completely, while the replication level of FIV PPR was 
fully restored by Gö6976 (Fig. 5-5).  In summary, these data showed that the 
conventional PKC isoforms are less important in mediating phorbol ester-induced 
inhibition of FIV production and that replication of FIV PPR was less sensitive to 
manipulation of the host PKC activation level than FIV GL8.   
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Figure 5-5 – FIV PPR is less sensitive to phorbol ester-mediated inhibition of 
productive infection than GL8 in MYA-1 CD4+ T cells.  IL-2 supplemented 
MYA-1 CD4+ T cells were infected with FIV PPR or GL8 (M.O.I. = 0.01).  2 days 
post infection, the cells were stimulated with solvent (DMSO), PMA (0.08 μM), 
Prostratin (Pro – 1 μM), PMA or Prostratin and Gö6976 (2.5 µM), PMA or 
Prostratin and Gö6850 (2.5 µM). Virus production at day 8 post infection was 
measured in the supernatant by FIV p24 ELISA.  Each bar represents the mean 
+/- range (n=2).  
Next, attempts were made to map the region(s) of the viral genome that 
mediate the differences in virus replication characteristics between the two 
strains of FIV, based on the approaches by de Rozieres et al in their study of FIV 
inter-clade variations (de Rozieres et al., 2008).  The nucleotide sequence of FIV 
GL8 was 92% identical to FIV PPR (Table 5-1); however, the 8% difference was 
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enough to cause the aforementioned measurable differences in viral replication 
between the two strains.  FIV PPR had a higher basal replication rate than FIV 
GL8.  This could be due to higher viral gene expression mediated by the FIV 5’ 
LTR, which contains the binding sites for cellular transcription factors such as 
AP-1, AP-4 and ATF (Sparger et al., 1992, Thompson et al., 1994) (and Fig. 5-6).  
There are 13 single nucleotide variations between the U3 regions of FIV GL8 and 
PPR, only one of these is within a known transcription factor binding site (ATF - 
Fig. 5-6).  Two single nucleotide variations were detected in a putative NFκB 
site, but previous binding and mutation studies have shown that this is unlikely 
to play an active role in FIV transcription (Sparger et al., 1992, Thompson et al., 
1994, Joshi et al., 2005b).  
The two strains of viruses also differ in receptor usage, mediated by sequence 
variations in the env gene. “Early” strains have stricter requirements for CD134 
(Willett et al., 2006b), while “late” strains are less dependent on CD134 and are 
able to infect previously non-permissive cells when they over-express CXCR4 (de 
Parseval et al., 2004b).  Alternatively, variations at other regions of the viral 
genome could be responsible for the differences in virus replication between the 
strains.  To investigate whether the differences of growth characteristics 
between FIV GL8 and PPR were due to different viral gene expression levels or 
entry requirements, the GL8 5’ LTR or env in the GL8 molecular clone was 
substituted with PPR 5’ LTR or env to assess whether the substitutions would 
modify the GL8 growth profile to resemble that of PPR (Fig. 5-7C, D)  
 
 
 
 
Table 5-1 – Sequence homology of different regions of the viral genome 
between FIV GL8 and PPR.  Percentage homology calculated using 
CLUSTALW2 alignment program.  Numbers in bracket represents nucleotide 
positions in FIV GL8 genome.   
 
Whole genome (9469 bp) 92.00% 
5'LTR → gag ATG (0 – 626) 95.00% 
gag (626 – 1978) 96.00% 
pol (2146 – 5241) 92.00% 
Between pol → env (5241 – 6263) 88.00% 
env (6263 – 8831) 89.00% 
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                                                “NFκB?” 
FIV-GL8   TGGGATGAGTATTGGGACCCTGAAGAAATAGAAAGAATGCTTATGGACTAAAGGACTGTC 60 
FIV-PPR   TGGGATGAGTATTGGGACCCTGAAGAAATAGAAAGAATGCTTATGGACTAA-GAACTGTC 59 
          *************************************************** * ****** 
 
                                                    AP-4            AP-1                               AP-4 
FIV-GL8   ACAAACAAATGATAAATGGAAACAGCTGAGCTTGACTCATAGTTAAAACGTTAGCAGCTG 120 
FIV-PPR   ACAAACAAATGATAAATGGAAACAGCTGAACATGACTCATAGTTAAAGCGCTAGCAGCTG 119 
          ***************************** * *************** ** ********* 
 
                          C/EBP    C/EBP          NF-1                      ATF 
FIV-GL8   CTTAACCGCAAAACCACATCCTATGTAAAGTTTGCCAATGACGCATGTTTTGTTCCACTG 180 
FIV-PPR   CTTAACCGCAAAACCACATCCTATGTAAAGCTTGCCAATGACGTATAATTTGCTCCACTG 179 
          ****************************** ************ **  **** ******* 
 
                            TATA                                      U3 ←                 R                   → U5 
FIV-GL8   TAATAGTATATAATCAGTGCTTTGGGAAGCTTCGAAGAGTCTCTCTGCTGAGGACTTTCG 240 
FIV-PPR   TAAGAGTATATAATCAGTGCTTTGTGAAGCTTCGAAGAGTCTCTCTGCTGAGGACTTTCG 239 
          *** ******************** *********************************** 
Figure 5-6 – Sequence variations between FIV GL8 and PPR in the U3 region 
of the 5’LTR affect only one of the known transcription factor binding sites 
of the FIV LTR.  CLUSTALW sequence alignment of the U3 region, based on the 
sequence of the GL8 molecular clone and the published genome of PPR (Phillips 
et al., 1990).  13 nucleotide variations were found and those which fall within 
known binding sites of transcription factors (Sparger et al., 1992, Thompson et al., 
1994) were highlighted in blue.  The NFκB site is found in FIV-Petaluma but is not 
thought to be transcriptionally active in FIV GL8 and PPR (Sparger et al., 1992, 
Thompson et al., 1994). 
The chimeric viruses were transduced into MYA-1 CD4+ T cells and expanded in 
culture.  The chimeric viruses produced by MYA-1 CD4+ T cells were resequenced 
and it was found that only the R-U5 section of the 5’ PPR-LTR was exchanged, 
despite a full LTR swap in the molecular clone (Fig.5-8).  This was caused by the 
mechanism of reverse transcription: the reverse transcriptase binds to the  5’ 
primer binding site of the viral RNA and reverse transcribed up to the R region, 
before transferring to the 3’ R and continuing the reverse transcription of U3 at 
the 3’ end (See section 1.2.2).  Since the 3’LTR was not altered in the molecular 
clone of the chimeric viruses, the 5’ LTR U3 region was unchanged in the virus 
produced (Fig. 5-8) 
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Figure 5-7 – Schematics of all the chimeric FIV described in this chapter.  
Diagrams (A) and (B) represent the ‘wild-type’ FIV strains.  RRE is Rev-response 
element.  GL8 sequences are in blue.  PPR sequences are in yellow.  The 
arrangements of the actual viruses rather than the molecular constructs are 
shown.  LTR substitutions were performed by cutting at the EcoRI site just before 
U3 within the molecular clone and at the SacI site between U5 and gag. Env 
substitutions were performed by cutting at the MluI site within the env gene and at 
the NdeI site within the Rev response element (RRE).  Wild-type PPR does not 
contain a MluI site and mutagenesis has to be performed to generate PPR-M.  
Since only the 5’LTR was substituted in the molecular clone, after reverse 
transcription the U3 region of the 5’LTR was not substituted. 
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Curiously, when this initial batch of chimeric viruses was used in infections of 
MYA-1 CD4+ T cells under experimental conditions that had previously produced 
a clear distinction in virus replication rate between strains (i.e. productive 
infection driven by IL-2 as well as stimulation of infected resting cells with PMA 
and Gö6976), both of the chimeric viruses with a GL8 backbone showed higher 
virus titres at the end of the assay that were comparable with the titres of PPR 
(Fig. 5-9).  In particular when the infected cells were stimulated with PMA in the 
absence of IL-2, substitution of GL8 LTR or env with their PPR counterparts 
reversed the sensitivity of GL8 to Gö6976 (Fig. 5-9B).   
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Figure 5-9 – Substitution of GL8 5’LTR or env with their PPR counterparts 
increases the replication rate of the chimeric virus.  MYA-1 CD4+ T cells were 
seeded in the presence (A) or absence (B) of IL-2.  24 hours post seeding, cells 
were infected with wild-type GL8, wild-type PPR, GL8 (PPR-LTR) or GL8 (PPR-
env) at the same M.O.I (0.01).  (A) Productively infected cells were maintained in 
the presence of exogenous IL-2 throughout the experiment while (B) infected 
resting MYA-1 T cells were stimulated with simultaneous treatment of PMA (0.08 
μM) and Gö6976 (2.5 μM) 48 hours post infection.  Virus titre in the supernatant at 
day 8 post-infection was measured by a non-isotopic reverse transcriptase (RT) 
activity assay.  Each bar represents the mean +/- standard error (n=3).  
Next, more chimeric viruses were constructed, this time substituting PPR LTR 
and env sequence with their equivalents from GL8 in order to further deduce the 
role of these regions in the dynamics of virus replication (Figure 5-7E to H).  
Because the substitution of either LTR or env appeared to be sufficient to alter 
A B 
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the growth dynamics of FIV GL8 to resemble those of FIV PPR, it is possible that 
in order to make PPR growth resemble that of GL8, both the LTR and env of GL8 
would have to be substituted with those of the PPR molecular clone.  To achieve 
the replacement of PPR env with the GL8 equivalent, the PPR env gene was 
mutated to generate a novel MluI restriction site at the start of the gene.  PPR 
molecular constructs which had undergone this change were named “PPR-M” 
(Fig. 5-7E).  These new viruses were transduced into MYA-1 CD4+ T cells and 
expanded in culture. A new batch of MYA-1 CD4+ T cells were then infected with 
all the chimeric viruses under the same conditions as described previously.  
Unexpectedly, results from this repeat were the opposite of the previous 
findings (Fig. 5-10); GL8 appeared to replicate at a higher rate when compared 
with PPR. The expression levels of the viral receptors CD134 and CXCR4 on this 
batch of CD4+ T cells were assessed by flow cytometry and it was found that 
while the level of CD134 expression was within the expected range (59.2% 
positive), the level of CXCR4 expression had dropped below detection threshold 
compared with the normal CXCR4 expression level of between 1 and 10%.  
However, the CD134 and CXCR4 expression levels of the cells were not measured 
for the cells used in the first chimeric virus infection assay, thus it was not 
certain that CXCR4 expression was higher during the initial experiment.  
Although the results from these two preliminary experiments were not directly 
comparable, comparisons within the dataset of the second chimeric virus 
experiment could still be made: in the presence of IL-2, PPR-M infected cells 
produced a lower viral titre than cells infected with the PPR wild-type virus (Fig. 
5-10A).  When IL-2-depleted cells were treated with PMA and Gö6976, there was 
no difference between the virus titres of the supernatant from PPR wild-type 
and PPR-M-infected cells.  In the presence or absence of exogenous IL-2, 
substitutions of both the env and the LTR regions from PPR-M with GL8 
sequences resulted in an increase in virus replication, but this was not as 
pronounced as when only the GL8 env sequence was introduced into PPR-M (Fig. 
5-10).  Furthermore the introduction of the PPR 5’ LTR into GL8 dramatically 
reduced virus production as detected in the supernatant (Fig. 5-10), even though 
the chimeric virus contained GL8 env.   
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Figure 5-10 – Both the LTR and env influence viral replication efficiency in 
MYA-1 T cells.  MYA-1 CD4+ T cells were seeded in the presence (A) or absence 
(B) of exogenous IL-2 (100 U/ml).  24 hours post seeding cells were infected with 
wild-type GL8, wild-type PPR, PPR-LTR-GL8, PPR-env-GL8, PPR-M, GL8-LTR-
(PPR-M), GL8-env-(PPR-M) or GL8-LTR-env-(PPR-M) at the same M.O.I (0.01).  
Cells were either supplemented with exogenous IL-2 (A) or treated with PMA (0.08 
μM) plus Gö6976 (2.5 μM) 48 hours post infection (B).  Virus titre in the 
supernatant at day 8 post-infection was measured by a non-isotopic reverse 
transcriptase (RT) activity assay.  Each bar represents the mean +/- standard error 
(n=3).  
A 
B 
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5.3 Discussion 
This chapter describes the different growth characteristics of the ‘early’ GL8 
and ‘late’ PPR strains of FIV.  Under different experimental conditions in vitro 
PPR consistently reaches peak virus titre sooner than GL8.  When de novo 
infection was blocked by integrase inhibitor, reactivation of latent PPR produced 
more virus in the culture supernatant than GL8, indicating that the rate of virus 
replication per infected cell for PPR is higher than GL8.   
The progression to AIDS in HIV-1 infected individuals has been associated with a 
shift in co-receptor usage of the virus from CCR5 to CXCR4 (Connor et al., 1997), 
which is largely determined by the sequence of the env gene (Cheng-Mayer et 
al., 1990).  During FIV infection there is an analogous change in receptor 
preferences of different viruses strains which is mediated by the interaction 
between Env and CD134 (Willett and Hosie, 2008); entry of an ‘early’ FIV strain 
into host cells require CD134 and CXCR4, whereas ‘late’ strain viruses exhibits 
less requirement for CD134 (de Parseval et al., 2005, Willett et al., 2006b).  
Attempts were made to map the regions within the FIV genome that are 
responsible for the inter-strain differences by creating chimeric viruses which 
contained the LTR and/or env sequences from a different strain of FIV.  Two 
preliminary experiments were performed; in the first experiment the PPR wild-
type, as well as the GL8 chimeric viruses containing PPR-LTR or PPR env 
replicated at a higher rate than the GL8 wild-type virus, which was in 
concordance with established trends; in the second experiment GL8 wild-type 
virus replicated at a higher rate than PPR.  This was contrary to previous results 
and corresponded with a drop in CXCR4 expression level of the cells below the 
detection limit of flow cytometry.  
The first question that needs to be addressed is the cause of the sudden change 
in viral replication dynamics in the in vitro system using the MYA-1 CD4+ T cells.  
In most of the experiments FIV PPR consistently replicated at a higher rate than 
FIV GL8.  The reversal of the viral replication characteristics can be attributed 
to changes to the efficiency of viral entry because of the following two 
observations: firstly, the expression of CXCR4 on MYA-1 CD4+ T cells during the 
second chimeric virus infection fell below the normal range of expression, 
although expression of the viral receptors was not checked before the first 
chimeric virus infection, so no direct comparison between the two experiments 
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was possible.  Secondly, the substitution of PPR env with the GL8 env led to a 
large increase in virus replication.  Thus it can be hypothesized that the 
dynamics of virus replication are influenced by the expression level of the viral 
receptors only when CXCR4 expression is very low.  In the previous chapter it 
was demonstrated that FIV GL8 does not require a high level of receptor 
expression in order for efficient productive infection to take place.  The data 
from the second chimeric virus experiment also agreed with the above 
conclusion.  Furthermore, the results indicated that PPR replication was more 
sensitive to the lack of CXCR4 than GL8, which is contrary to a previous report of 
PPR infection being less sensitive to blockage of CXCR4 than GL8 (Willett et al., 
2009).  However, more experiments with the chimeric viruses should be carried 
out before a final conclusion is drawn.   
The experiments involving the chimeric viruses were terminated at the 
preliminary stage of development.  However, these early experiments have 
provided valuable insights into the nature of the in vitro system that was used.  
It has been shown that the expression of CD134 and CXCR4 on MYA-1 cells 
fluctuates over time (Fig. 4-17).  As mentioned previously this may be a 
reflection of the change in the physiology of the MYA-1 cells as they undergo 
phases of blasting, rapid expansion and rest.  Thus it would be important to 
monitor the expression levels of the viral receptors closely in future experiments 
with MYA-1.  Alternatively viral binding to the receptors may be manipulated to 
deduce its contribution to the subsequent productive infection by different 
viruses. 
These preliminary results also illustrated the possibility that factors other than 
viral entry influence viral replication dynamics: firstly, both the substitution of 
GL8 env or LTR regions with the PPR counterparts led to an increase in virus 
replication in the first chimeric virus experiment.  Secondly, the substitution of 
both the env and the LTR regions of PPR with their GL8 counterparts resulted in 
an increase in virus replication in the second chimeric virus experiment, but this 
increase was not as high as the increase caused by a substitution of the env 
alone; thirdly, in the presence of IL-2, the introduction of the PPR LTR into the 
GL8 genome markedly inhibited its replication despite the fact that the GL8 env 
was retained by that particular chimera.  These observations indicated that the 
introduction of a LTR from a foreign strain can affect virus replication rate.  
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Sequencing of the chimeric viruses showed that replacing the entire 5’LTR in the 
molecular clone leads to the partial replacement of the 5’ LTR in the viral 
genomes produced.  This is due to the mechanism of reverse transcription as 
explained in the introduction (Section 1.2.2).  In FIV the binding sites for cellular 
transcription factors such as AP-1 and ATF are located in the U3 region and were 
not substituted in the chimeric viruses.  These sites are vital to the 
transcriptional activities of the FIV 5’ LTR (Ikeda et al., 1998).  However, as the 
U3-unchanged, R-U5 substituted viruses exhibited altered replication kinetics, it 
suggests that LTR transcription efficiency does not contribute to the variation in 
viral replication between strains.  Although the aforementioned data were 
preliminary, the suggestion that the efficiency of viral transcription does not 
mediate variation between strains concurs with the conclusion of a similar study 
on FIV (de Rozieres et al., 2008).  In this study of variations between a clade A 
(PPR) strain and a more pathogenic, clade C (C36) strain of FIV, it was found 
that the transcription of chloramphenicol acetyl-transferase driven by the LTR of 
the two strains are the same.  Furthermore, all the chimeric viruses are less 
virulent than the wild-type C36 strain, while FIV PPR chimeras containing C36 
elements did not enhance viral replication compared with wild-type PPR in ex 
vivo experiments.  This led to the conclusion that variations at multiple regions 
of the viral genome, rather than variations at a single site contribute to the 
inter-strain differences in viral growth.  Our limited data also supports such a 
conclusion.      
A possible explanation that may account for these observations is that the 
sequence variations between strains have led to difference in the viral RNA 
secondary structures.  R-U5 falls within the 5’ untranslated leader region (UTR) 
of the viral RNA genome, which forms secondary structures such as stem loops 
and contains sites that are vital to virus replication such as the primer binding 
site (PBS), the polyadenylation (poly A) site, the major slice donor site (mSD) 
and the dimerization initiation site (DIS) (Fig. 5-11A). It has been well-
established that the secondary structures at the 5’ UTR of the retroviral RNA 
genome mediate dimerization and packaging of the viral RNA, processes that 
directly affect the efficiency of viral replication and infectivity (Das et al., 1997, 
Greatorex, 2004, L'Hernault et al., 2007).  In FIV the initial 511 nucleotides of 
the viral RNA are essential for packaging, but there is also a bi-partite packaging 
signal which consists of the first 150 nucleotides of the 5’ UTR and the first 100 
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nucleotides of the gag gene (Kemler et al., 2002, Browning et al., 2003, Kemler 
et al., 2004, Mustafa et al., 2005).  Within the packaging signal several 
conserved RNA stem loops (SLs) and other secondary structures have been 
identified (Kenyon et al., 2008, Kenyon et al., 2011).   These structures have 
been shown to form a long-range interaction (LRI) conformation that facilitate 
dimerization and packaging or the viral genome, or an alternative multiple stem 
loop (MSL) conformation that favours translation of the viral genes (Rizvi et al., 
2010, Kenyon et al., 2011) (Fig. 5-11A).   
The 5’ UTRs of GL8 and PPR contain a number of nucleotide variations, which 
are located in the PBS, SL1, poly-A and SL2 (Fig. 5-12).  Mutating the nucleotide 
sequence of the 5’ UTR has been demonstrated to disrupt RNA secondary 
structure and its associated functions (Rizvi et al., 2010, Kenyon et al., 2011).  
Thus it can be speculated that the sequence variations between the strains led 
to differences in the nature and stability of the viral RNA secondary structures, 
and that substitution of the R-U5 region between different strains may cause 
instability of the RNA secondary structure as the incoming sequence may form a 
structure not evolved to co-ordinate with the rest of the viral packaging signal.    
Such an explanation has been invoked previously to explain similar results from a 
similar experiment (de Rozieres et al., 2008).  In contrast during the first 
experiment, the replacement of GL8 LTR by the PPR LTR increased virus titre at 
day 8 post-infection.  This does not fit with the aforementioned hypothesis on 
RNA secondary structure.  However, samples of the supernatant were taken only 
at the end of the experiment, thus it is possible that LTR-substituted chimeric 
viruses did exhibit growth defects, but by day 8 post infection all the virus titres 
have reached plateau and the defects were hidden.  This emphasises the need 
for more repeats and more frequent sampling of virus titre during experiments. 
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                                                                                 U3   ←      R    →  
FIV-GL8    TAATAGTATATAATCAGTGCTTTGGGAAGCTTCGAAGAGTCTCTCTGCTGAGGACTTTCG 240 
FIV-PPR    TAAGAGTATATAATCAGTGCTTTGTGAAGCTTCGAAGAGTCTCTCTGCTGAGGACTTTCG 239 
           *** ******************** *********************************** 
 
                      ←      R    →       Poly-A                          (U5) → 
FIV-GL8    AGTTCTCCCTTGAGGCTCCCACAGATACAATAAAT-TCTGAGATTGAACCCTGTCAAGTA 299 
FIV-PPR    AGTTCTCCCTTGAGGCTCCCACAGATACAATAAATATTTGAGATTGAACCCTGTCAAGTA 299 
           *********************************** * ********************** 
 
                                                                                           SL1                             _PBS 
FIV-GL8    TCTGTGTAGTCTTTTCTACCTGCGAGGTCTCGGAATCCGGGCCGGGAACTTCGCAGTTGG 359 
FIV-PPR    TCTGTGTAGTCTTTTCTACCTGTGAGGTCTCGGAATCCGGGCCGAGAACTTCGCAGTTGG 359 
           ********************** ********************* *************** 
 
 
                         PBS                                                         SL2                                       . 
FIV-GL8    CGCCCGAACAGGGACTTGAGGAAGAGTGATTGAGGAAGTGAAGCTAGAGCAATAGAAAGC 419 
FIV-PPR    CGCCCGAACAGGGACTTGAGAAAGAGTGATTGAGGAAGTGAAGCTAGAGCAGTAGAAAGC 419 
           ******************** ****************************** ******** 
 
                                                                      SL2                                                          . 
FIV-GL8    TGTTAAGCAGAACTCCTGCTGACCTAAATAGGGAAGCAGTAGCAGACGCTGCTAA-CAGT 478 
FIV-PPR    TGTTAAGCAGAACTCCTGTTGACCTAAATAGGGAAGCAGTAGCAGACGCTGCTAAACAGT 479 
           ****************** ************************************ **** 
 
                                           SL2       SacI site            . 
FIV-GL8    GAGTATCTCTAGTGAAGCAGACTCGAGCTCATAATCAAGTCACTGTTTAAAGGCCCAGAT 538 
FIV-PPR    GAGTATCTCTAGTGAAGCAGACTCGAGCTCATAATCAAGTCACTGTTTAAAGGCCCAGAT 539 
           ************************************************************ 
 
 
A 
B 
SL1 
SL2 
LRI MSL 
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Figure 5-11 – Multiple sequence polymorphisms between FIV GL8 and PPR 
are found within or near RNA secondary structures in the 5’ UTR.  (A) A 
diagram from (Kenyon et al., 2011) showing the LRI and MSL conformation of the 
RNA secondary structures.  SL = stem loops.  PBS = Primer binding site.  mSD = 
major splice donor.  Poly (A) = polyadenylation site.  gag AUG = start codon of the 
gag gene.  DIS = Dimerization initiation site.  Permission obtained from Oxford 
University Press.  (B) CLUSTALW sequence alignment of the UTR from R to the 
Sac-I restriction site, based on known sequence of the GL8 molecular clone and 
the published sequence of PPR, as well as viral DNA amplified from infected cells 
using PCR.  Nucleotide variations are highlighted in green.  The labelled and 
underlined sequences represent the locations of RNA secondary structures 
(Kenyon et al., 2008, Kenyon et al., 2011).  Viral RNA species do not contain U3 
and would begin at the start of the R region.  FIV LTRs in the molecular clones 
were substituted by restriction digest with EcoRI at the 5’ end (which cuts at the 
start of the proviral sequence) and with SacI at the 3’ end (which cuts at nucleotide 
491 of the FIV proviral genome). 
 
Variations in viral entry efficiency and RNA secondary structures are not the only 
possible mediators of inter-strain differences in viral replication.  Mutations or 
polymorphisms at accessory genes can produce dramatic alterations in viral 
growth and pathogenesis, as illustrated by the nef-defective HIV-1 strain 
responsible for the Sydney Blood Bank Cohort (Dyer et al., 1997).  By monitoring 
the sequence of a chimeric FIV-PPR/C36 virus as it was passaged in vivo, residue 
813 of the FIV integrase was identified as vital to in vivo viral growth (Thompson 
et al., 2011).  This residue was subjected to sequential mutations that altered 
the characteristics of the virus, as it was passaged first in vitro, then in vivo.  
This observation illustrated the effect of passaging on the viral sequence, an 
aspect of strain difference that has not been addressed in this thesis.  It is 
known that lab-adapted strains of HIV-1 exhibit different viral entry 
requirements compared with primary strains (Kabat et al., 1994).  Also it has 
been shown that long term infection of cats with a low virulence strain (FIV-Pet 
F14) leads to the emergence of more pathogenic variants of the parental strain 
(Hosie et al., 2002).  These are all potential areas of future research.  
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Another observation from the chimeric virus experiment illustrated a recurring 
principle throughout this and the previous chapter – there is an entry-
independent, PKC-mediated virus restriction mechanism within the CD4+ T cells 
of cats.  The potential identity of this mechanism has been discussed already.  In 
this chapter it has been demonstrated that the two different strains of FIV react 
very differently to this PKC-driven restriction.   
Using the PKC inhibitors Gö6976 and Gö6850 my experiments had demonstrated 
the involvement of PKC in the dual action of the phorbol esters on FIV 
replication.  In all of the experiments, FIV PPR was less sensitive to the effects 
of Gö6976 than FIV GL8 while both strains were sensitive to the effects of 
Gö6850.  Since Gö6976 is a specific inhibitor of conventional PKC isoforms such 
as PKC α and β1 while Gö6850 inhibits both the conventional and novel PKC 
isoforms (such as PKC δ, ε and ζ), it can be speculated that the replication of 
the two FIV strains is controlled by different PKC isoforms.  FIV PPR was also less 
sensitive to the inhibitory effects of PMA or Prostratin when grown in the 
presence of IL-2, although in the absence of IL-2, either phorbol esters could 
stimulate the replication of FIV PPR more robustly than they could stimulate FIV 
GL8.  This could be the result of the higher basal replication rate of PPR, which 
allows it to outgrow GL8 when the situation allows.  Previous studies have shown 
that the AP1/AP4 sites, as well as the ATF site are essential for basal FIV 
promoter function (Sparger et al., 1992, Thompson et al., 1994).  The AP-1 site 
is also shown to be necessary for activation by PMA (Sparger et al., 1992).  
Sequencing of the LTR showed that while there is no sequence variation within 
the AP-1 site of both GL8 and PPR, single nucleotide variations occur around the 
AP-1 site and within the ATF site (Fig. 5-6).  However, as mentioned earlier the 
U3 region of the LTR in the chimeric viruses was unchanged, thus the sequence 
variation within U3 cannot account for the differences in viral production 
between strains.  The mechanism behind the different sensitivity to PKC activity 
demonstrated between FIV GL8 and PPR remains elusive.  The implication of 
these findings to viral pathogenesis is also unknown at this stage.  A complete 
profile of PKC-sensitivity for each FIV strain could be produced using knock-down 
experiments or employing other specific PKC inhibitors in infection assays.  The 
data generated from these experiments would be crucial to our understanding of 
this phenomenon. 
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Lastly, the data from these experiments showed that PMA and Prostratin 
activate novel and conventional PKC isoforms differently in MYA-1 CD4+ T cells.  
Phorbol esters bind to PKC at a hydrophilic cleft at the C1 domain (Ono et al., 
1989, Burns and Bell, 1991, Zhang et al., 1995).  This interaction results in the 
translocation of PKC to lipid membranes, which is essential for the activation of 
the enzyme (Zhang et al., 1995).  The molecular structures of the phorbol esters 
determine their lipophilicities and biological activities (Wang et al., 2000b).  The 
structural differences between PMA and Prostratin that mediate preferences for 
different PKC isoforms are outside the scope of this thesis, but it would be an 
important consideration in the rational design of PKC modulating compounds 
that target latency. 
In summary, the experiments described in this chapter show that ‘early’ and 
‘late’ strains of FIV have different replication dynamics under experimental 
manipulation of host cell signalling.  Attempts were made to map the viral 
genome sequence(s) responsible and found that both the env and 5’UTR may 
jointly mediate the differential responses between strains.  This finding, if 
confirmed, would illustrate a new relationship between the viral RNA secondary 
structure and host cell signalling which can affect virus replication and 
pathogenesis. 
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6 Concluding remarks 
Viruses fall within the twilight zone between living and non-living entities 
(Moreira and Lopez-Garcia, 2009).  All viruses, including the ‘quasi-autonomous’ 
Mimivirus, are obligate intracellular pathogens that are completely reliant on 
the host cell for replication (Claverie and Abergel, 2010).  This makes virus 
replication very sensitive to changes in cell signalling.  In this thesis I have 
explored the different ways in which cell signalling can affect FIV replication.  
Firstly, I have investigated the hypothesis that FIV Env triggers CD134-mediated 
cell signalling.  My results did not support this theory and I have discussed an 
alternative hypothesis in which FIV binds to the co-receptor CXCR4 and triggers 
signalling.  Next I investigated latent infection with FIV further, and showed that 
by depleting IL-2 from IL-2 dependent MYA-1 CD4+ T cells productive infection 
with FIV is almost completely stopped, mainly due to a block of virus spread 
among the uninfected resting T cells.  Moreover stimulation by the phorbol 
esters PMA or Prostratin induced the resting MYA-1 T cells to become conducive 
to productive infection.  Paradoxically in the presence of IL-2, productive 
infection with FIV can be inhibited by the same phorbol esters.  The dual-activity 
of PMA and Prostratin is dependent on PKC and is analogous to findings from HIV-
1 studies, illustrating a reliance on a similar cell signalling pathway for the 
replication of both HIV-1 and FIV.   However, the data indicated a post-entry 
mechanism mediates the anti-FIV effect of Prostratin, contrary to findings from 
HIV-1 studies.  Lastly I demonstrated measurable biological differences between 
‘early’ and ‘late’ isolates of FIV by the manipulation of host cell signalling and 
speculated on the significance of these differences to viral pathogenesis.  I also 
attempted to map locations on the viral genomes that are associated with the 
biological differences between strains.  The preliminary data showed the 
involvement of the env gene and the 5’ UTR of the virus in determining strain 
differences, and I speculated that the sequence differences between FIV GL8 
and PPR resulted in differences in the viral RNA secondary structures that 
translate into phenotypic variations between the two strains. 
The results presented in this thesis illustrate an important aspect of FIV host-
pathogen interactions; the almost complete dependency of viral replication on 
the activation status of the host cell.  This is not the case for other viruses such 
as influenza, which encodes the viral protein NS-1 to activate the PI3K pathway 
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in its target cells in order to enhance infection (Hale et al., 2006); or the human 
papillomavirus (HPV) which induces cell proliferation by targeting host cell cycle 
regulators p53 and retinoblastoma proteins for degradation using the viral 
proteins E6 and E7 (reviewed in (Moody and Laimins, 2010)).  The reliance of FIV 
replication on the activation of host cell signalling, in particular PKC, is a 
function of the cell tropism of the virus: in order for the host CD4+ T cell to 
function it must become activated, which also makes it conducive to infection 
by FIV.  In other words, there is no need for the virus to induce cellular 
activation.  Even in the instances when virus infection does not immediately lead 
to efficient viral replication, the long term fitness of the virus is not affected 
because latent infection of CD4+ T cells leads to viral persistence and increases 
the chance of transmission in the future.  However, FIV replication is inhibited 
when PKC is stimulated above an optimum level (Fig. 6-1).  Although the over-
stimulation of PKC by phorbol esters is an artificial scenario probably not 
encountered in nature, does this indicate a potential weakness, a therapeutic 
“Achilles heel” of the virus which we can exploit? 
 
Figure 6-1 – FIV replicates best at an optimum level of PKC activation.  
Results from this thesis have indicated that the activity of PKC is a central 
determinant between productive and latent FIV infection; when PKC activation 
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level is low, virus replication is impaired, whereas increasing the level of PKC 
activation past the optimum range an anti-viral response is triggered.    
The findings of this thesis also reflect the role host responses play in the 
pathogenesis of viral diseases: infection with HIV-1 and FIV leads to chronic 
activation and dysregulation of the host immune system, causing the selective 
destruction of the mucosal barrier and lymphoid tissues, which promote the 
translocation of microbes and chronic inflammation (See Chapter 1).  The host 
immune response plays a large part in its own destruction; other notable 
examples of host mediated pathogenesis include the highly lethal viral 
haemorrhagic fever caused by viruses such as Ebola, Marburg and the Crimean–
Congo hemorrhagic fever (CCHF) virus, as well as the recent outbreak of severe 
acute respiratory syndrome (SARS); haemorrhagic fever viruses target host 
endothelial cells as well as macrophages and dendritic cell, which damage host 
blood vessels directly and indirectly through the release of proinflammatory 
cytokines, coagulation factors and vasodilators. (Hoenen et al., 2006, Hensley et 
al., 2011, Whitehouse, 2004).  The result is massive damage to the host vascular 
system that triggers a devastating condition known as disseminated intravascular 
coagulation (DIC), leading to uncontrollable bleeding, shock and death (Hoenen 
et al., 2006, Hensley et al., 2011, Whitehouse, 2004).  SARS is caused by a novel 
coronavirus thought to originate from bats (Peiris et al., 2003) (Li et al., 2005).  
In severe cases the host interferon responses become dysregulated, impairing 
the switch from innate to adaptive response and triggering a destructive 
“cytokine storm” that causes potentially fatal lung damage (Huang et al., 2005, 
Cameron et al., 2007).    
The investigation of the molecular mechanisms behind lentiviral latency is vital 
to the discovery of a cure to HIV-AIDS, which remains a major public health 
concern across the world despite the advent of HAART (Richman et al., 2009).  
At the time of writing, a method that can potentially induce sterilising immunity 
against HIV-1 has just been announced (Balazs et al., 2011).  Instead of relying 
on the conventional adaptive immune response against a foreign antigen, this 
technique utilized an adeno-associated gene therapy viral vector to express high 
titres of a HIV-broadly neutralizing monoclonal antibody from muscle cells.  The 
expression of the antibody completely blocked HIV-1 infection in a humanized 
mouse model system (Balazs et al., 2011).  Even if an effective way to immunise 
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against HIV-1 is established and virus transmission is finally halted, there remain 
the millions of infected individuals who will have to rely on antiretroviral drugs 
for the rest of their lives unless a practical cure is developed.  A suitable small 
animal model of HIV-1 latency and reactivation is vital to unravel the complex 
networks of cell signalling involved in lentiviral latency and may lead to the 
development of therapeutic regimes with minimum side effects to reverse latent 
infection.  The research presented in this thesis has demonstrated similarities 
between HIV-1 and FIV, supporting the assertion that FIV infection of the 
domestic cat has potential as an animal model for HIV-1 infection of humans in 
terms of latency.  However, FIV is a different virus to HIV-1, and the data 
presented here revealed some of these differences.  Further research is required 
to identify which characteristics are common to both viruses to ensure that 
findings from any future feline model are comparable to HIV-1 infection in 
humans. 
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7 Appendices 
7.1 Appendix 1: Primers 
 
Name Sequence (5’ to 3’) 
(Detection of FIV DNA)  
LTR Forward 3 GCTTAACCGCAAAACCACAT 
Gag Reverse 3  CAAATCTCCTGGCTTGAAGG 
Env sense 1  GGCAATGTGGCATGTCTGAAAAAGAGGAGGAATGATG 
  
GAPDH Forward  CCTTCATTGACCTCA ACTACAT 
GAPDH Reverse CCAAAGTTGTCATGGATGACC 
  
(Mutagenesis)  
P-env Mlu 1 OLIGO1: 
GGAAATGCAGGTAAGTTTAGACGAGCAAGATTCTTGAGAT
ATTC  
 
OLIGO2: 
GAATATCTCAAGAATCTTGCTCGTCTAAACTTACCTGCATT
TCC  
 
P-env Mlu 2 
 
OLIGO1: 
GAAATGCAGGTAAGTTTAGACGCGCAAGATTCTTGAGATA
TTCTG  
 
OLIGO2: 
CAGAATATCTCAAGAATCTTGCGCGTCTAAACTTACCTGCA
TTTC  
 
P-env Mlu 3 
 
OLIGO1: 
GCAGGTAAGTTTAGACGCGTAAGATTCTTGAGATATTCTG
ATG 
 
OLIGO2: 
CATCAGAATATCTCAAGAATCTTACGCGTCTAAACTTACCT
GC 
  
(Quantitative PCR) 
 
(FIV gag) 
 
FIV1360F  GCA GAA GCA AGA TTT GCA CCA 
FIV1437R  TAT GGC GGC CAA TTT TCC T 
FIV1416P  
(Taqman probe) 
5’-FAM-TGC CTC AAG ATA CCA TGC TCT ACA CTG CA-
TAMRA-3’ 
 
(18S rRNA) 
 
343-Fwd CCA TTC GAA CGT CTG CCC TA 
409-Rev TCA CCC GTG GTC ACC ATG 
Taqman probe 5'-FAM-CGA TGG TAG TCG CCG TGC CTA-TAMRA-3' 
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7.2 Appendix 2: List of buffers 
 
Hirt buffer: 0.6% SDS, 10mM EDTA, pH 7.5 
LB: 10% Bacto-Tryptone w/v, 5% yeast extract w/v, 85 mM NaCl, pH 7.5 
PBAz wash buffer: 10 g BSA and 1 g sodium azide dissolved in 1 litre of PBS (See 
below) 
PBS: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM KH2PO4 
PBS-T wash buffer: PBS plus 0.1% Tween® 
Sample treatment solution (10x): 100mM Tris, 1.5M NaCl, 5% Triton, 5% 
deoxycholale, 1% SDS, 50mM EDTA and 0.1% azide 
TBE (10x): Tris base 890 mM, Boric acid 890 mM, EDTA 2 mM 
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